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ABSTRACT 
Each year 3500 people in Switzerland are diagnosed with colorectal cancer. 
Approximately 20 percent of all affected patients have two or more first or 
second-degree relatives with colorectal cancer (at-risk family members). 
About five percent of these are inherited in an autosomal dominant manner. 
This thesis has focused on genotype-phenotype correlations in two hereditary 
colorectal cancer syndromes, familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colorectal cancer (HNPCC). In addition, rare 
susceptibility genes were analyzed: MYH in FAP and PMS2 and MSH3 in 
HNPCC. The works encompassed investigations of a consecutive series of 
101 Swiss polyposis patients and establishment of genotype-phenotype 
correlations, delineation of somatic APC alterations in attenuated familial 
adenomatous polyposis (AFAP), genetic characterization of the MYH gene 
recently associated with a multiple colorectal adenoma and carcinoma 
phenotype, and finally, the assessment of the role of rarely mutated mismatch 
repair genes PMS2 and MSH3 in HNPCC. 
 
In the first part of the thesis, phenotypic differences between APC germline 
mutation carriers and APC/MYH mutation-negative individuals in a 
consecutive cohort of 101 FAP patients were characterized. Furthermore, we 
wanted to assess possible genotype-phenotype correlations in APC mutation 
carriers. In our study population, no genotype-phenotype correlations with 
regard to polyp number or extracolonic disease manifestations could be 
established. The data challenge the prevailing view on genotype-phenotype 
correlations and advise great caution when basing clinical management 
decisions for an individual patient on the site of the APC germline mutation. 
In the second part of the thesis 235 tumors from 35 AFAP patients out of 
16 families were screened for APC mutations to find out the somatic APC 
mutation spectrum, to determine phenotypic differences among AFAP 
families, and to delineate the pathways of somatic APC mutation in AFAP. It 
has been shown that colonic polyp number varies greatly among AFAP 
patients, but members of the same family tended to have more similar 
disease severity. 5’-mutants generally had more polyps than the other 
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patients. In some polyps bi-allelic changes (“third hits”) have been found, 
which probably initiated tumorigenesis. Taken together, AFAP is 
phenotypically and genetically heterogeneous and modifier genes may be 
acting on the AFAP phenotype.  
Biallelic changes in the MYH gene have been shown to predispose to a 
multiple adenoma and carcinoma phenotype. In the third part of the thesis, 79 
unrelated APC-negative Swiss polyposis patients were screened for germline 
mutations in MYH to assess the frequency of MYH mutations and to identify 
phenotypic differences between MYH mutation carriers and APC/MYH 
mutation-negative polyposis patients. Colorectal cancer was significantly more 
frequent in biallelic as compared to monoallelic mutation carriers or those 
without MYH alterations. With regard to other phenotypic properties (age of 
onset, extracolonic disease manifestations), it is virtually impossible to 
discriminate biallelic from monoallelic MYH mutation carriers and MYH 
mutation-negative polyposis patients. 
In HNPCC alterations in PMS2 have been documented only in extremely 
rare cases. In the fourth part of the thesis, DNAs of colorectal cancer patients 
with immunohistochemically proven loss of PMS2 in the tumor (n = 16) were 
screened for PMS2 germline mutations. It was possible to identify 
heterozygous PMS2 germline mutations in six patients. To detect germline 
mutations in the remaining 10 patients, additional mutation screening methods 
(cDNA sequencing and MLPA technique) have been applied. In conclusion it 
was shown that PMS2 defects account for a small but significant proportion of 
CRCs. 
In the fifth part of the thesis MSH3, a MMR gene, which has thus far not 
been implicated in HNPCC, has been investigated in a 46 years old colorectal 
cancer patient with immunohistochemical loss of MSH3 only. A MSH3 
missense mutation (c.2383C>T, p.Arg795Trp) was identified and the possible 
pathogenicity of the alteration was assessed. It was found that the mutation is 
present in a hemizygous state in the tumor. Furthermore, 100 healthy 
probands did not carry the alteration and sequence and amino acid alignment 
with vertebrates showed that it is located in a conserved region of the gene. 
Taken together, our findings indicate that the alteration in MSH3 may indeed 
be pathogenic.  
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INTRODUCTION 
 
This thesis aimed to investigate genotype-phenotype correlations and to 
assess the role of rare susceptibility genes in the two most common 
hereditary colorectal cancer predispositions, familial adenomatous polyposis 
(FAP) and hereditary nonpolyposis colorectal cancer (HNPCC).  
  
In the first study of this thesis genotype-phenotype correlations were 
investigated in a consecutive cohort of 101 Swiss FAP patients. Differences 
between adenomatous polyposis coli (APC) germline mutation carriers and 
APC/MYH mutation-negative individuals were characterized and possible 
genotype-phenotype correlations in APC mutation carriers were assessed. 
The manuscript will be submitted for publication.  
 The second study describes the analysis of somatic APC mutations in 
235 tumors from 35 AFAP patients (out of 16 families). The main goals of this 
study were to characterize the somatic APC mutation spectrum in AFAP 
patients with 3’-mutations, to compare this with other AFAP-associated 
regions of APC, and to delineate the pathways of somatic APC mutations in 
AFAP. It was found that disease severity and genetic pathways vary greatly 
but depend on the site of the germline mutation. This study was published in 
Gut, volume 55, no. 10, pages 1440 – 1448, 2006.  
 
Recently, another FAP susceptibility gene besides APC was identified. It was 
shown that biallelic germline mutations in the human homologue of the base 
excision repair gene MutY (MYH) cause a phenotype of multiple colorectal 
adenomas and carcinomas, thus describing for the first time an autosomal 
recessively inherited CRC predisposition. 
 This third part of this thesis aimed to assess the frequency of MYH 
mutation carriers within a Swiss cohort of 79 unrelated polyposis patients. In 
addition, comparisons have been made between MYH mutation carriers and 
APC mutation-negative individuals to establish genotype-phenotype 
correlations in this cohort of patients. The results of the study were published 
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in the International Journal of Cancer, Volume 118, No. 8, p.1937 – 1940, 
2006.  
 
In HNPCC the main susceptibility genes are MLH1 and MSH2. But it is known 
that also mutations in other MMR genes like MSH6 and PMS2 contribute to 
the disease. The role of MSH3, the heterodimeric partner of MSH2 in the 
MutSβ complex, in HNPCC is not known so far.  
 In the fourth study of this thesis, a collaborative study with G. Marra, 
Institute of Molecular Cancer Research Zurich, 1048 tumors from 5 Swiss 
hospitals were collected and immunohistochemically tested for loss of MLH1, 
MSH2, MSH6 and PMS2. Our part of the collaboration included the molecular 
genetic screening of patients with loss of MMR proteins, in particular the 
technically demanding screening for PMS2 germline mutations. The identified 
high frequency of patients affected by cancers with a primary defect of PMS2 
strengthens the role of PMS2 in CRC. This study was published in 
Gastroenterology, Volume 128, No. 5 p.1160 – 1171, 2005. 
 The addendum to this study describes further screening efforts for 
mutations using additional methods in patients with loss of PMS2 in their 
tumors but without identified PMS2 germline mutation. cDNA analysis was 
applied to identify mutations that were possibly masked by the presence of 
pseudogenes and multiplex ligation dependant probe amplification (MLPA) 
was used to detect large genomic insertions or deletions.  
The fifth study aimed to find out more about the role of the MMR repair 
gene MSH3 in HNPCC. It was possible to detect a germline missense 
mutation in MSH3 in a CRC patient with immunohistochemical exclusively 
loss of MSH3 in the tumor. The missense mutation (p.Arg795Trp) was present 
in a hemizygous state in the tumor of the patient and LOH analysis indicates 
loss of the wildtype allele. In addition, the missense mutation was not 
identified in 100 healthy control patients. Thus, there is good evidence that the 
identified missense mutation may actually have a pathogenic meaning. 
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1. GENERAL INTRODUCTION 
 
Colorectal cancer incidence 
Worldwide more than 10 million people develop cancer each year with 
approximately 1 million of them being diagnosed of colorectal cancer 
(www.krebshilfe.de). In industrialized countries colorectal cancer is the third 
most frequently observed cancer in men (after lung and prostate cancers) and 
the second most in women (after breast cancer). The lifetime risk in the 
general population for developing colorectal cancer is 5% but by the age of 70 
years almost half of the Western population will have developed an adenoma. 
In Switzerland, about 3500 people are diagnosed of colorectal cancer each 
year (Swiss Cancer Registries’ Association Database, 2003). 
 
Colorectal carcinogenesis 
Colorectal carcinogenesis is one of the best studied cancer models how 
normal cells become tumor cells due to two main reasons: 1) Most colorectal 
tumors develop within more than 10 years in histologically well-defined steps. 
2) The colon is well observable by colonoscopy and different cancer stages 
can be easily identified1.  
 
Different stages of colorectal tumorigenesis: 
1. Aberrant crypt foci (ACF) 
are clusters of abnormal tube-like glands in the colon and rectum and 
can be dysplastic or nondysplastic. Methylene blue staining or 
microscopic examination of the colonic mucosa can detect these 
lesions. ACFs are one of the earliest changes visible in the colon that 
may lead to cancer.  
2. Adenomas 
Adenomas are believed to develop from dysplastic aberrant crypt foci. 
They are often referred to as adenomatous polyps. There are different 
types of adenomas: tubular, tubular-villous, and villous adenomas. 
Most of carcinomas develop from villous adenomas. 
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3. Carcinomas 
Carcinomas are thought to develop from adenomas and are therefore 
called adenocarcinomas. These lesions are highly dysplastic and 
invade the surrounding tissue. The different stages of 
adenocarcinomas (Dukes stages, see appendix) are very important for 
the prognosis. Main factors for the classifications are the grade of 
infiltration into the tissue and the presence or absence of metastasis. 
 
During the development from a normal colonocyt to a cancer cell additional 
mutations in oncogenes and tumor suppressor genes give rise to clonal 
expansion (Figure 1). It is thought that at least 4 sequential genetic changes 
are necessary for colorectal cancer evolution. Primary targets for these 
genetic changes are KRAS, APC, SMAD4 and TP532,3. 
 
 
Figure 1:  Histopathology of colorectal cancer and accumulation of different 
mutations during cancerogenesis (from Fodde et al.4) 
 
Genetic basics of colorectal cancer 
In most of the colorectal cancer patients (approximately 80%) the disease 
appears to have occurred sporadically due to environmental or dietary factors. 
In the remaining 20% CRC seems to be attributed to a definable genetic 
component5. Evidence for a genetic factor in colorectal cancer is given in 
persons with a familial aggregation of colorectal cancer consistent with 
autosomal dominant inheritance. In addition, it has been demonstrated 
recently that biallelic germline mutations in the human homologue of the base 
excision repair gene MutY (MYH) cause colorectal carcinomas, thus 
describing an autosomal recessively inherited CRC predisposition6,7. 
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There are two well-defined autosomal dominant inherited colorectal cancer 
predisposition syndromes: familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colorectal cancer (HNPCC). FAP is estimated to 
account for less than 1%8 and HNPCC for 2 – 5%9 of all colorectal cancers in 
Western countries. Other colorectal cancer predispositions include e.g. the 
juvenile polyposis syndrome and the Peutz-Jeghers-syndrome. But there are 
still many familial aggregations of colon cancer remaining etiologically 
undefined.  
 In this thesis the main focus is on the assessment of genotype-
phenotype correlations in FAP and HNPCC and on the molecular analysis of 
rarely mutated genes in these colorectal cancer predispositions.  
 
Familial adenomatous polyposis (FAP) and attenuated familial 
adenomatous polyposis (AFAP) 
FAP is an autosomal dominantly inherited colorectal cancer predisposition, 
which accounts for ca. 1% of all colorectal cancers. The syndrome is caused 
by germline mutations in the adenomatous polyposis coli (APC) gene. APC 
mutation carriers typically develop hundreds to thousands of polyps 
throughout the rectum and the colon and, if left untreated, colorectal cancer in 
the third or fourth decade of life10. Patients frequently develop benign 
extracolonic lesions including polyps of the gastric fundus and duodenum, 
osteomas, dental anomalies, congenital hypertrophy of the retinal pigment 
epithelium (CHRPE), soft tissue tumors, and desmoid tumors. In addition, 
several extracolonic cancers occur with a higher incidence in FAP than in the 
general population11. These cancers include tumors of the upper 
gastrointestinal tract, liver, thyroid and adrenal gland, pancreas, and brain12-14. 
 Attenuated familial adenomatous polyposis (AFAP) is characterized by 
a significant risk of colorectal cancer but patients usually develop fewer than 
100 and more proximally located colonic polyps often detected at later age 
compared to classical FAP (reviewed in15). 
As mentioned above, most of FAP cases are attributed to germline mutations 
in the APC gene. It is located on chromosome 5q21 consisting of 15 exons 
which is part of the Wnt signaling pathway (see below). The tumor suppressor 
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gene or “gatekeeper” encodes a protein essential in cell adhesion, signal 
transduction and transcriptional activation, with c-myc and β-catenin having 
established as downstream targets16. The majority of APC germline mutations 
occur in the first half of the APC coding region17 and to date almost 700 
different alterations have been described according to the human genome 
mutation database (http://www.hgmd.cf.ac.uk/ac/index.php). About 95% of all 
detected alterations are insertions, deletions and nonsense mutations leading 
to a frameshift or a premature stop codon and result in the truncation of the 
APC protein18.  
 Much effort has been done into making genotype-phenotype 
correlations that link the site of the germline mutation with the severity of the 
disease. Profuse polyposis has been associated with APC germline mutations 
between codons 1240 and 146419. In contrast, patients present more often 
with attenuated FAP if they carry the mutation at the extreme 5’ end     
(codons 1 – 177)20-23, the alternatively spliced exon 9 (codons 312 – 412)24-26, 
and the 3’ end (codons >1580)23,27,28. In addition, certain extracolonic 
manifestations as desmoid tumors or CHRPE have been correlated with 
alterations between codons 1403 and 1578 or 463 and 1387, respectively29-31. 
However, even in patients with identical germline alterations there is a high 
inter- and intrafamilial phenotypic variability in the individual patients32,33. 
 
The canonical Wnt-pathway 
The Wnt signaling pathway is highly conserved and controls numerous 
decisions during animal development. In unstimulated cells, free β-catenin is 
destabilized after binding to axin, conductin, glycogen synthase kinase 3β 
(GSK3β) and APC34-37 (Figure 2). The main tumor suppressor function of APC 
resides in its capacity to properly regulate intracellular β-catenin levels38-40. As 
mentioned above, most APC mutations result in truncated proteins that lack 
all axin/conduction-binding motifs and a variable number of the 20-amino-acid 
repeats that are associated with the downregulation of intracellular β-catenin 
levels41,42. Therefore β-catenin is accumulated due to APC mutations, diffuse 
into the nucleus, where it acts as a co-activator for TCF-responsive genes.  
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Figure 2:  Model of the wnt-signaling pathway (from Fodde et al.4). a) in the 
absence of a Wnt signal β-catenin is degraded b) in the presence of a 
wnt signal β-catenin is accumulated. 
 
MYH associated polyposis (MAP) 
The phenotype of MAP is similar to FAP and AFAP, but the disorder is 
inherited in an autosomal recessive manner. MAP is caused by biallelic 
mutations in the human homolog of the E. coli base excision repair gene mutY 
(MYH)6 and has been shown to account for a substantial portion (10 – 30%) 
of APC mutation-negative polyposis patients24. The DNA glycosylase MYH is 
part of the base excision repair (BER) pathway and removes adenines from 
mispairs with 8-oxoguanine that occur during replication of oxidized DNA. 
Failure to correct these mispairs consequently leads to G:CT:A transversion  
mutations, a typical “footprint” of oxidative DNA damage43. 
 
Base Excision Repair (BER) 
BER is a pathway that corrects DNA modifications that arise either 
spontaneously or from attack by reactive chemicals, e.g. reactive oxygen 
species (superoxide, hydroxyl peroxide). One of the most stable products of 
oxidative DNA damage and also the most deleterious due to its mispairing 
capacity with adenine is 7.8-dihydro-8-oxo-guanine (8-oxoG). 
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 In the prevention of 8-oxoG induced mutagenesis, proteins from three 
genes of the BER pathway, hMTH1, hOGG1 and hMYH, interact together 
both within the nucleus and the mitochondria. hMTH1, with its nucleoside 
triphosphatase activity, is responsible for the hydrolysis of 8-oxo-dGTP, hence 
preventing the inclusion of the oxidized nucleotide during DNA replication. 
hOGG1 establishes and eliminates ring-opened purine lesions and mutagenic 
8-oxoG adducts, whilst hMYH, an adenine specific DNA gycosylase, removes 
adenines mismatched with 8-oxoG or guanines during DNA replication 
errors44. 
 
Figure 3:  Base excision repair pathways for oxidative DNA damage. hOgg1, 
hMYH, and hMTH and their respective repair function45. 
 
 
Hereditary nonpolyposis colorectal cancer (HNPCC) 
Hereditary nonpolyposis colorectal cancer (HNPCC) is characterized by an 
increased risk of colon cancer and other cancers that include cancers of the 
endometrium, ovary, stomach, small intestine, hepatobiliary tract, upper 
urinary tract, brain, and skin. Individuals with HNPCC have an approximately 
80% lifetime risk for colon cancer. Two-thirds of these cancers occur in the 
proximal colon. The average age of colorectal cancer diagnosis is 44 years.  
In 1990, the international collaborative group on hereditary nonpolyposis 
colorectal cancer established the Amsterdam criteria to identify HNPCC 
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families and to detect susceptibility genes for the disease. These criteria were 
thought to be too restrictive for clinical purposes and were later modified 
(Amsterdam criteria II) to include the other HNPCC-related cancers. To suit 
the Amsterdam criteria I or II (see appendix), all the criteria must be fulfilled. 
 To identify those individuals whose tumors are candidates for MSI 
testing, the Bethesda guidelines (see appendix) were developed in 199746 
and later updated to increase their sensitivity47. To fulfill the Bethesda 
guidelines, just one of the criteria need to be met. 
 HNPCC results from germline mutations in one of the four major 
HNPCC associated mismatch repair (MMR) genes: hMSH2 (human mutS 
homolog 2) on chromosome 2p1648, hMLH1 (human mutL homolog 1) on 
chromosome 3p2149, hMSH6 (human mutS homolog 6) on chromosome 
2p1650, and hPMS2 (human postmeiotic segregation 2) on chromosome 
7q1151. The majority of HNPCC-causing mutations are estimated to affect 
hMLH1 in 50% of the families, hMSH2 in 39%, hMSH6 in 7% and hPMS2 in 
occasional families52.  
 
Genetic testing for HNPCC 
1) Microsatellite instability 
Genes in the MMR pathway are responsible for identifying and repairing 
single nucleotide mismatches and insertion and/or deletion loops that occur 
due to DNA polymerase errors introduced to genomic DNA during replication. 
A defect in the MMR genes leads to multiple errors in repetitive DNA 
sequences (microsatellites) throughout the genome of tumors53. 
Microsatellites are stretches of DNA with a repetitive sequence of nucleotides 
(e.g. AAAAA or CGCGCGCG), and these regions of DNA are particularly 
susceptible to acquiring errors when mismatch repair gene function is 
impaired. This form of genomic instability is called microsatellite instability 
(MSI) and is the hallmark of HNPCC. In general, a panel of six microsatellite 
loci (BAT25, BAT26, BAT40, D5S346, D17S250 and D2S123) recommended 
by the national cancer institute (NCI) workshop is used to assess 
microsatellite instability47. Matched tumor and normal DNA extracted from 
formalin fixed tissue and blood, respectively, are analyzed for differences in 
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the length in the microsatellite motifs. A tumor is classified as MSI-high if at 
least 30% of the markers show MSI, as MSI-low if only one Marker shows 
MSI and as MS-stable (MSS) if no MSI can be detected54. Approximately 90% 
of colon cancer families matching Amsterdam criteria carry MSI-high 
tumors55,56. Therefore identifying MSI in a tumor has been found to be a good 
predictor of an underlying germline mismatch repair mutation57 and any case 
with any tumor showing MSI is referred for further testing.  
 
2) Immunohistochemistry 
Immunohistochemistry (IHC) is a simple and effective method to screen the 
loss of one or more protein of the mismatch repair system in the tumor. This 
loss occurs due to two events. First the germline mutation of a MMR gene on 
one allele followed by a second somatic event on the remaining wildtype allele 
(second mutation or loss of heterozygosity). Normal mucosa and tumor tissue 
from patients suspicious for HNPCC are investigated for loss of hMLH1, 
hMSH2, hMSH6 and hPMS2. The loss of expression of one of these proteins 
suggests which MMR gene should be investigated for a germline     
mutation58-60. 
 
3) Mutation screening 
After IHC analysis the respective gene will be screened for a germline 
mutation using direct sequencing of exons and exon/intron boundaries to 
detect point mutations and small insertions or deletions. Large genomic 
deletions or insertions can be detected by using the recently introduced 
multiplex ligation-dependant probe amplification (MLPA) assay.  
 
Mismatch repair 
DNA mismatch repair (MMR) is responsible for the recognition and repair of 
mispaired nucleotides. Mispaired bases in DNA can occur as a result of 
chemical or physical DNA damage, polymerase errors during DNA replication, 
or recombination between non-homologous parental DNA sequences. The 
single steps of MMR have been conserved throughout evolution of eukaryotes 
and have been most extensively studied in E. coli.  
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 The first step is the recognition of the mismatch mediated primarily of 
the MutSα complex consisting of the heterodimer hMSH2 and hMSH6 (Figure 
4A). This protein complex efficiently recognizes and binds to base/base 
mispairs, but its affinity for loops of more than one extrahelical nucleotide is 
relatively low50. A third MutS homologue, hMSH3, is also able to form a 
heterodimer with hMSH2, the MutSβ complex. This complex efficiently 
recognizes small insertion and deletion loops61. Recognition of mismatched 
nucleotides provokes ADP for ATP exchange by MutS that defines it as a 
Molecular Switch. ATP binding by MutS results in the formation of a 
hydrolysis-independent sliding clamp that is capable of diffusion for at least 
1kb along the DNA adjacent to the mismatch. Following the 
dissociation/diffusion of one ATP-bound MutS sliding clamp the mismatch site 
is exposed to iterative lading of multiple MutS sliding clamps (Figure 4B). The 
mismatch bound MutSα complex then recruits another protein heterodimer, 
the MutLα complex consisting of hMLH1 and hPMS2. Fishel et al. found that 
the MutL protein only interacts with ATP-bound MutS sliding clamps (Figure 
4C). The resulting sliding clamp complex of 4 proteins (hMSH2, hMSH6, 
hMLH1 and hPMS2) diffuses along the DNA backbone until it encounters a 
“downstream effector” that drives ATP-binding by the MutL protein. In 
eukaryotes, the first downstream effector is likely to be the PCNA-polymerase 
complex on the leading strand (Figure 4D). The goal of these interactions is to 
identify and/or to introduce a strand scission on the newly replicated DNA 
strand. The next downstream effector in MMR is likely to be a helicase that 
recognizes and begins to displace the incised DNA strand (Figure 4E). This 
would require a protein displacement event on the leading strand. Concerted 
displacement of the newly replicated strand provides a ssDNA substrate for 
an exonuclase (hEXO1) responsible for degradation of the error-containing 
strand until the mismatch has been removed (Figure 4F). The combined 
actions of MSH-MLH-(Helicase)-Exonuclease results in excision of the newly-
replicated strand (Figure 4G). A new error-free DNA strand can then made by 
DNA polymerase with the help of other proteins (Figure 4H)62. 
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Figure 4:  Molecular Switch Model for MMR by Fishel and Schmutte (from 
http://mmr.med.ohio-state.edu/rfishel/RF2.html and Fishel, 199862) 
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ABSTRACT 
In about 20-50% of familial adenomatous polyposis (FAP) patients worldwide 
no germline mutation in the adenomatous polyposis coli (APC) gene can be 
identified. In patients carrying a pathogenic APC mutation the position of the 
alteration has been associated with polyp burden and/or extracolonic disease. 
By screening a consecutive series of 101 unrelated polyposis patients for 
APC/MUTYH mutations the study aimed i) to compare the phenotypic 
properties of APC mutation carriers with those of APC/MUTYH mutation-
negative polyposis patients and ii) to assess possible genotype-phenotype 
correlations in APC mutation carriers. Patients were screened for mutations in 
APC, applying the protein truncation test, DNA sequencing and gene copy 
number analysis. APC alterations were identified in 56 (63%) polyposis 
patients (76% with classical and 54% with attenuated polyposis), with 30% of 
them representing novel mutations. Compared to APC/MUTYH mutation-
negative polyposis patients (51.0 years), APC mutation carriers displayed a 
significantly younger median age at diagnosis (40.0 years; p=0.0002). 
Twenty-two (48%) patients with an APC mutation within the “classical 
polyposis region” actually displayed an attenuated phenotype (AFAP), 
independent of age and family history. Similarly, four (40%) out of 10 patients 
with an “AFAP region” mutation presented with profuse polyposis. In 
summary, APC mutation carriers significantly differ from APC/MUTYH 
mutation-negative polyposis patients with regard to age at diagnosis and 
polyp number. The fact that no evidence for genotype-phenotype correlations 
could be observed in this cohort of APC mutation carriers advises caution 
when basing clinical management in an individual patient on the site of the 
APC germline mutation. 
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INTRODUCTION 
Familial adenomatous polyposis (FAP, MIM #175100) is an autosomal 
dominantly inherited colorectal cancer predisposition caused by germline 
mutations in the adenomatous polyposis coli (APC) gene. In classical FAP, 
APC mutation carriers develop hundreds to thousands of colorectal polyps 
which if left untreated will progress to colorectal cancer in the third or forth 
decade of life10. Attenuated FAP (AFAP), also referred to “multiple” polyps, is 
characterized by the presence of 5 to 99 colorectal adenomas and later age at 
diagnosis compared to classical FAP (reviewed in15,63).  
The APC gene is located on chromosome 5q21, consists of 8,535 base 
pairs organised in 15 exons and encodes a protein of 2,843 amino acids 
(GenBank accession number NM_000038.3). APC is an essential component 
of the Wnt signaling pathway involved in ß-catenin down-regulation. 
Furthermore, it has been implicated in cell adhesion, migration as well as in 
chromosomal stability, and cell cycle progression64. Exon 15 encodes the 
largest part of the protein (>75%) including the region responsible for binding 
ß-catenin. The majority of APC germline mutations occur in the first half of the 
APC coding region17,64 whereas most somatic mutations are found between 
codons 1286 and 1513 – the so-called mutation cluster region65. About 95% 
of all APC germline mutations result in a truncated protein product16,18.  
Genotype-phenotype correlations, linking the site of the germline 
mutation with the severity of the disease, have been reported by several 
research groups: Severe polyposis with thousands of colorectal polyps has 
been associated with APC germline mutations between codons 1240 and 
146419. In contrast, patients carrying mutations at the extreme 5’ end (codons 
1 – 177)20-23, the alternatively spliced exon 9 (codons 312 – 412)24-26 and the 
3’ end (codons >1580)23,27,28 were found to present more often with 
attenuated polyposis at diagnosis. In addition, certain extracolonic disease 
manifestations have been correlated with the site of the germline mutation, 
e.g. alterations between codons 1403 and 1578 with desmoid tumours29,30.  
Despite extensive genetic testing, in about 20% of FAP and almost 70% 
of AFAP patients worldwide no germline APC mutation can be identified18,66. 
The etiology of the AFAP phenotype is largely unknown and likely to be 
heterogeneous on the molecular genetic level. Recently, biallelic mutations in 
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the human homologue of the E. coli base excision repair gene mutY (MYH) 
have been shown to predispose to the autosomal recessively inherited MYH 
associated polyposis (MAP, MIM #608456)6. MAP has been shown to account 
for a substantial portion (10 – 30%)24 of APC mutation-negative polyposis 
patients67. 
Screening a consecutive series of 101 unrelated polyposis patients, 
this study aimed (i) to compare the phenotypic properties of APC mutation 
carriers with those of APC/MYH mutation-negative polyposis patients and (ii) 
to assess potential genotype-phenotype correlations in APC mutation carriers. 
 
PATIENTS AND METHODS 
For this study a consecutive series of 101 unrelated polyposis index patients 
referred because of either classical (>100 polyps) or attenuated (5 - 99 
polyps) polyposis coli were investigated. Written informed consent was 
obtained from all patients. Detailed clinical information was gathered from 
interviews and reports from physicians, pathologists and/or patients.  
The family history (FH) was considered positive if a first-degree relative 
has been reported to have developed either gastrointestinal polyposis or 
colorectal cancer. Extracolonic disease manifestations included: polyps of the 
stomach and/or the small bowel, osteomas, desmoid tumours, benign 
cutaneous lesions (e.g. epidermoid cysts, fibromas), adrenal masses (mostly 
adrenocortical adenomas without endocrinopathy or hypertension) as well as 
a defined spectrum of extracolonic cancers (stomach, duodenum, pancreas, 
CNS, bile duct, adrenal gland, thyroid gland and liver)11-14. 
 
Mutation analysis  
Mutation analysis of the APC gene was performed using a combination of 
screening methods, i.e. the protein truncation test (PTT) and direct DNA 
sequencing of PTT fragments displaying band shifts. These methods were 
applied according to published protocols63,68. DNA sequencing of exon 15g 
was carried out in all patients to screen for the common missense mutations 
p.Ile1307Lys and p.Glu1317Gln. The entire coding sequence as well as the 
promoter and the 3’ untranslated region had been previously sequenced in 9 
patients (Patient IDs: 1749, 1762, 1767, 1775, 1803, 1821, 1828, 1842, 
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1859)18. The recently introduced multiplex ligation-dependent probe 
amplification (MLPA) technique was used to screen APC for the presence of 
large genomic rearrangements (MRC Holland, Amsterdam, the Netherlands). 
In addition, RT-PCR analysis was carried out to characterize the two donor 
splice site mutations in intron 4 using primers located at the APC exon 
boundary 2/3 and 7/8 (primers and conditions available from authors upon 
request). 
Patients in whom no pathogenic APC germline alteration could be 
identified were subsequently investigated for germline mutations in MYH 
(GenBank accession number NM_012222.1) by denaturing high performance 
liquid chromatography (dHPLC) and direct sequencing of exons 7 and 13 for 
the most frequent pathogenic mutations (p.Tyr176Cys and p.Gly393Asp)67. 
Bi- and monoallelic MYH mutation carriers were excluded from further 
phenotypic analysis. 
 
Statistical analysis 
Statistical comparison of patients’ features, encompassing phenotypic 
characteristics (gender, age at diagnosis, polyp number, colorectal cancer, 
extracolonic disease, family history) and mutational status (APC mutation-
positive vs. mutation-negative) was performed using Chi square or Fisher’s 
exact test for categorical variables or Student’s t-test for continuous variables, 
considering a p-value <0.05 to be statistically significant. 
 
RESULTS 
In this study a consecutive series of 101 unrelated polyposis patients were 
investigated for the germline mutations in the APC gene and, if no pathogenic 
mutation was detected, the MYH gene (Figure 1). Patients with mono- or 
biallelic germline mutations in MYH (n=12) were excluded from subsequent 
phenotypic analysis. 
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Figure 1:  Screening results for APC and MYH mutations in a consecutive series 
of 101 polyposis patients split according to polyp number at diagnosis 
 
 
APC germline alterations 
Overall, 56 out of 89 (63%) index patients were found to carry pathogenic 
mutations in APC. The mutation detection rate was 76% (28 out of 37) in 
patients with classical polyposis (>100 polyps) and 54% (28 out of 52) in 
patients with attenuated polyposis (5 to 99 polyps). Subdivision of polyposis 
patients according to age at diagnosis into those <40 and those >40 years 
resulted in similar, statistically significantly different APC mutation detection 
rates of 81% (30 out of 37) and 50% (26 out of 52; p= 0.007), respectively. 
Importantly, the percentage of APC mutation carriers with classical polyposis 
was very similar (53% (n=16) and 46% (n=12), respectively) in both groups 
(p=0.59). 
Forty-six (82%) APC germline mutations were located within the 
“classical FAP region” (encompassing codons 178 – 1580, except exon 9) 
with the remainder occurring within the “AFAP regions” (codons 1 – 177, exon 
9 and beyond codon 1580).  
Overall, 33 frameshifts, 17 nonsense mutations, 3 splice site alterations 
(c.531+2-531+8delTAAGTAAinsACTTACATTTT, c.531+3insT, c.1547A>G), 2 
genomic deletions as well as the missense mutation p.Glu1317Gln, 
associated with multiple colorectal adenomas, were identified69. 
Seventeen (30%) APC mutations represent novel alterations, which, 
according to the human gene mutation database [Cardiff, 
http://www.hgmd.cf.ac.uk/] have not yet been reported (Table 1).  
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Table 1:  Novel pathogenic APC germline alterations identified in this study  
Mutation Consequence Patient 
ID 
c.512_3insG p.Ser171fs175X 1869 
c.531+2-531+8delTAAGTAA 
   insACTTACATTTT p.Ser142_Asn177del 2366 
c.1262G>A p.Trp421X 1907 
c.1374delT p.Phe458fs465X 1761 
c.1547A>G p.Lys516Arg 2353 
c.1726delG p.Ala576fs577X 1769 
c.1960C>T p.Gln654X 1819 
c.2335_6delTT p.Leu779fs786X 1766 
c.2383_4delCT p.Leu795fs797X   2175 
c.2787_8delTA p.His929fs938X 2097 
c.2925_6delAA p.Lys975fs983X       2074 
c.3285delG p.Gln1095fs1125X 2156 
c.3565delT p.Ser1189fs1264X 1923 
c.3767insC p.Gln1256fs1275X 2132 
c.4773delA p.Ala1591fs1649X 2193 
c.36_7delTC p.Ser246fs249X 1818 
c.1312-?_10285del p.654Gln_283Xdel 1749 
 
Among these we were able to characterize by RT-PCR and cDNA sequencing 
the nature of two donor splice site alterations in intron 4, c.531+3insT (patient 
ID 2197) and c.531+2-531+8delTAAGTAA insACTTACATTTT (patient ID 
2366). Both were found to result in skipping of exon 4, corresponding to loss 
of 109 bp, and, consequently, leading to a shift in the reading frame and a first 
stop codon at amino acid position 148 (p.Leu148X; Figure 2). In index patient 
1749 Sieber et al.70 had previously identified the presence of a large deletion 
by means of a real-time quantitative multiplex PCR assay coupled with 
microsatellite marker analysis but without further delineating the extent of the 
deletion. Applying the MLPA technique the deletion could now be shown to 
actually encompass exons 10 to 15.  
Based on the detailed family history available from 53 out of 56 APC 
mutation carriers, 42% (22 out of 53) of the index patients did not have an 
affected first-degree relative (parent and/or siblings) at the time of diagnosis 
which would indicate an unusual high proportion of de novo APC alterations in 
our cohort. Based on the median age at diagnosis of the index patients (39.5 
years (IQR 20.0) parents can be assumed to be at least 20 years older (e.g. 
about 60 years), an age at which about 93% of cases are expected to display 
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typical symptoms16. Importantly, there was no difference with regard to age at 
diagnosis of index patients with or without a positive family history (40.0 years 
(IQR 14.5) vs. 39.5 years (IQR 20.0), respectively) and the proportion of de 
novo mutations was similar in both subgroups, those with classical and those 
with attenuated polyposis (41% vs. 42% respectively). 
 
 
Figure 2: RT-PCR analysis of APC intron 4 donor splice site mutations 
c.531+3insT (patient ID 2197) and c.531+2-531+8delTAAGTAA 
insACTTACATTTT (patient ID 2366). The mutant allele corresponds to a 
loss of approximately 100 bp resulting in complete skipping of exon 4 
as shown by cDNA sequencing of the mutant band. (M=DNA molecular 
weight markers; C=Control-cDNA from a healthy person; wt=wildtype 
allele; mut=mutated allele) 
 
 
Phenotypic properties of APC mutation-positive and APC/MUTYH–
negative polyposis patients 
The phenotypic properties of APC mutation-positive and mutation-negative 
polyposis patients are depicted in Table 2.  
APC mutation-positive patients displayed a significantly younger 
median age at diagnosis (40.0 years (IQR 18.0) vs. 51.0 years (IQR 18.3); 
p=0.0002). This could, in theory, be explained by the fact that APC mutation 
carriers presented significantly more often with classical polyposis (50% vs. 
27%; p=0.03). The difference in age at diagnosis, however, remained 
statistically significant when patients were further subdivided according to 
polyp number count: 40.0 years (IQR 18.0) vs. 50.0 years (IQR 19.5; 
p=0.0002) in patients with classical polyposis (n=39), and 40.5 years (IQR 
17.0) vs. 51.0 years (IQR 17.0; p=0.005) in those with attenuated polyposis 
(n=52). This age difference could not be explained by either a positive family 
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history (55% vs. 39%, p=0.38) or by colorectal cancer being present at the 
time of diagnosis (30% vs. 36%, p=0.56). 
Extracolonic disease manifestations were reported in 25 (28%) 
polyposis patients and encompassed polyps of the upper gastrointestinal tract 
(n=15), desmoids (n=4), fundic gland polyps (n=2), osteomas (n=1), cancer of 
the stomach, the thyroid and adrenal gland (one each). The mean age of 
index patients displaying extracolonic manifestations was 38.5 years (IQR 
21.0). Overall, APC/MYH mutation-negative patients tended to present with 
less extracolonic disease manifestations (15%) compared to APC mutation 
carriers (30%), but this difference was not statistically significant (p=0.11) 
(Table 2). 
 
Table 2:  Phenotypic properties of APC mutation-positive (n=56) and APC/MYH–
negative (n=33) polyposis patients 
 APC mutation carriers APC/MYH mutation-negative  
  overall <100 polyps >100 polyps overall <100 polyps >100 polyps  
  n=56  n=28  n=28  n=33  n=24  n=9  p-value 
Sex         
male 32 (57%) 16 (57%) 16 (57%) 21 (64%) 14 (58%) 7 (78%)  
female 24 (43%) 12 (43%) 12 (43%) 12 (36%) 10 (42%) 2 (23%) p=0.55 
Family history         
positive 31 (58%) 15 (58%) 16 (59%) 13 (48%) 9 (38%) 4 (57%)  
negative 22 (42%) 11 (42%) 11 (41%) 14 (52%) 11 (62%) 3 (43%) p=0.38 
no information 3  2  1  6  4  2   
Age (years)         
median (IQR) 40 (18) 40.5 (17) 40 (18) 51 (18.3) 51 (17) 50 (18) p=0.0002 
Polyp number         
<100 28 (50%)   34 (76%)    
>100 28 (50%)   11 (24%)   p=0.008 
Colorectal cancer         
present 17 (30%) 6 (21%) 11 (39%) 12 (36%) 10 (42%) 2 (22%)  
absent 39 (70%) 22 (79%) 17 (61%) 21 (64%) 14 (58%) 7 (78%) p=0.56 
Extracolonic 
disease         
present 17 (30%) 11 (39%) 6 (21%) 5 (15%) 3 (13%) 2 (22%)  
absent 39 (70%) 17 (61%) 22 (79%) 28 (85%) 21 (87%) 7 (78%) p=0.11 
 
Genotype-phenotype correlations 
To assess possible genotype-phenotype correlations the APC mutation-
positive index patients were grouped according to the site of the APC 
mutation: group 1 (n=46) encompassing patients carrying a germline mutation 
within the “classical FAP region” (codons 178 – 1579, except exon 9) and 
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group 2 (n=10) containing those with a mutation within one of the “AFAP 
regions” (codons 1 – 177, exon 9 and codons >1580). 
Nearly half (n=22, 48%) of group 1 patients presented with an AFAP 
phenotype (<100 polyps) at the time of diagnosis (Figure 3). Attenuated and 
classical polyposis patients from this group, however, did not significantly 
differ with regard to median age at diagnosis (41.5 years (IQR 17.0) vs. 38.5 
years (IQR 16.5), p=0.79) or any other phenotypic property. Moreover, two 
out of five index patients (30 and 42 years old, respectively) carrying the 
c.3927_3931delAAAGA mutation at codon 1309, commonly associated with 
severe polyposis71, actually displayed a multiple adenoma phenotype   
(Figure 3).  
In group 2, six (60%) out of 10 index patients displayed an attenuated 
phenotype. Four (57%) out of seven patients carrying APC mutations at the 5’ 
end or in exon 9 presented with a severe phenotype at diagnosis with 
hundreds to thousands of colorectal adenomas (Figure 3). All group 2 patients 
harbouring a mutation at the 3’ end of the gene (n=3) displayed an attenuated 
polyposis phenotype. Extracolonic disease was equally frequent in both 
groups (30% each).  
 
 
 
Figure 3: Schematic representation of the APC protein indicating polyp number 
and extracolonic disease in 56 APC mutation carriers according to the 
site of the respective germline mutation. White lines delineate 15-amino 
acid repeats for β-catenin binding. Light grey lines indicate 20-amino 
acid repeats for β-catenin binding and degradation and for GSK 3β  
phosphorylation. Dotted squares indicate the “AFAP regions. 
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DISCUSSION 
This study on a consecutive series of 101 unrelated polyposis patients aimed 
to i) compare the phenotypic properties of APC mutation carriers with those of 
APC/MUTYH mutation-negative polyposis patients and ii) assess potential 
genotype-phenotype correlations in APC mutation carriers. 
Overall, two thirds of the patients were found to harbour pathogenic 
germline mutations in APC, which is similar to observations by others (48 – 
62%66,72-75). In accordance with results by Friedl et al.66, the mutation 
detection rate in patients with classical polyposis was considerably higher 
(76%) compared to those with an attenuated phenotype (54%) with most of 
the APC germline mutations being located within the 5’ half of the gene 
(codons 1 – 1309). Interestingly, the mutation detection rate in polyposis 
patients <40 years at diagnosis was significantly higher than in patients >40 
years (81% vs. 50%, p= 0.007) and, importantly, was independent from polyp 
number.  
One third of APC germline alterations represented novel mutations, 
consistent with previous reports (35% in average;66,76-79). This finding 
highlights the importance of screening the entire coding sequence of the APC 
gene for mutations. 
 Ten to 25% of APC germline mutations are estimated to occur de 
novo72,80,81. The high frequency observed in our study (42%), although 
independent from either age at diagnosis or polyp number, may actually 
reflect incomplete family history assessment and/or variable disease 
penetrance within families and consequently result in an overestimation. To 
clarify this issue, molecular genetic analysis of the parents would be needed. 
APC mutation carriers differed statistically significantly from APC/MYH 
mutation–negative polyposis patients with regard to age at diagnosis (median 
age of 40 vs. 51 years, respectively) which is similar to previous 
observations77,82,83. This finding could not be explained by differences in polyp 
number, family history or colorectal cancer occurrence between the groups. 
Furthermore, although not statistically significant, extracolonic disease 
manifestations were twice as frequent in APC mutation carriers. 
 Several research groups have reported on genotype-phenotype 
correlations in APC mutation carriers correlating the site of the mutation with 
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polyp number and/or extracolonic disease19,20,84. Severe or classical polyposis 
(>100 adenomas) has been mainly observed in patients carrying APC 
mutations within the “classical FAP region” (codons 177 to 1580, except exon 
9). In our study however, nearly half of our APC mutation carriers with 
alterations in the classical region actually displayed an attenuated polyposis 
phenotype.  
Patients carrying an APC germline mutation in the “AFAP regions” 
(codon 1-177, exon 9 and codons >1580) have been reported to present with 
attenuated polyposis at diagnosis15,23,26. In contrast to these findings, four 
(57%) out of seven 5’ APC mutation carriers in our consecutive series actually 
presented with severe polyposis coli displaying hundreds to thousands of 
colorectal polyps, similar to a report by Sieber et al.85. Despite the small 
number of patients with “AFAP region” mutations, precluding any meaningful 
statistical analysis, these observations clearly illustrate the considerable 
phenotypic variability in this group of mutation carriers. 
 Occurrence of desmoid tumours, upper gastrointestinal polyps and 
osteomas in polyposis patients has previously been correlated with APC 
alterations at codons 976 – 1067 and beyond codon 130986 as well as 
between codons 1403 and 157829. In our study, extracolonic disease 
manifestations were evenly distributed among patients with mutations in the 
“classical FAP” or the “AFAP region”. With regard to the above mentioned, 
specific extracolonic manifestations, 59% (10 out of 17) of patients actually 
carried mutations outside these regions. 
A possible limitation of the current study may concern polyp count 
assessment in the index patients. Despite the fact that all referring medical 
centres and practices performed colonoscopy according to well-accepted 
international guidelines, use of imprecise terms like “multiple” may result in 
incorrect group assignment (i.e. < vs. >100 polyps).  
In conclusion, our study on a consecutive series of 101 polyposis 
patients showed that i) APC mutation carriers significantly differed from 
APC/MYH mutation-negative polyposis patients with regard to age at 
diagnosis (40 vs. 51 years) and polyp number and that ii) no evidence for 
possible genotype-phenotype correlations was observed in our set of APC 
mutation carriers. Our finding that the individual phenotype could not be 
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predicted with certainty from the genotype has also been reported recently by 
A.L. Knudsen et al. (1st conference of InSiGHT, Newcastle upon Tyne, June 
2005). Taken together, these data challenge the prevailing view on genotype-
phenotype correlations and advise great caution when basing clinical 
management decisions for an individual patient on the site of the APC 
germline mutation. 
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ABSTRACT     
Background: Attenuated familial adenomatous polyposis (AFAP) is associated 
with germline mutations in the 5’, 3’ and exon 9 of APC. These mutations 
probably encode a limited amount of functional APC protein. Methods and 
Results: We found that colonic polyp number varies greatly among AFAP 
patients, but members of the same family tended to have more similar 
disease severity. 5’-mutants generally had more polyps than the other 
patients. We analysed somatic APC mutations/LOH in 235 tumours from 35 
patients (16 families) with a variety of AFAP-associated germline mutations. 
Like two previous studies of individual kindreds, we found bi-allelic changes 
(‘third hits’) in some polyps. We found that the ‘third hit’ probably initiated 
tumorigenesis. Somatic mutation spectra were similar in 5’- and 3’-mutant 
patients, often resembling classical FAP. In exon 9-mutants, by contrast, ‘third 
hits’ were more common. Most ‘third hits’ left three 20-amino acid repeats 
(20AARs) on the germline mutant APC allele, with LOH (or proximal somatic 
mutation) of the wild-type allele; but some polyps had loss of the germline 
mutant, with mutation leaving one 20AAR on the wild-type allele. Conclusions: 
We propose that mutations, such as nt4661insA, that leave three 20AARs are 
preferentially selected in cis with some AFAP mutations, because the residual 
protein function is near-optimal for tumorigenesis. Not all AFAP polyps appear 
to need ‘three hits’, however. AFAP is phenotypically and genetically 
heterogeneous. In addition to effects of different germline mutations, modifier 
genes may be acting on the AFAP phenotype, perhaps influencing the 
quantity of functional protein produced by the germline mutant allele. 
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INTRODUCTION 
Classical familial adenomatous polyposis (FAP) is caused by germline 
mutations in the adenomatous polyposis coli (APC) gene between codons 
178 and 1580. FAP patients typically develop hundreds to thousands of 
adenomatous polyps in the colon and rectum by the third decade of life. If left 
untreated, one or more adenomas progress to carcinoma by 45 years of age. 
Extracolonic features, such as polyps of the upper gastrointestinal tract, 
desmoid tumours and osteomas, are also common. Attenuated FAP (AFAP or 
AAPC) patients generally present with a lower number (<100) of colorectal 
adenomas by their fourth decade and have a later age of onset of colorectal 
cancer (mean age 55 years)15,87,88. In some AFAP patients, extracolonic 
features have been reported to be infrequent24, although other AFAP patients 
– such as those with hereditary desmoid disease – have severe extra-colonic 
disease89,90. AFAP is associated with germline mutations in specific regions of 
the APC gene (Figure 1): the 5’-end (codons 1-177, exons 1-4); the 3’-end 
(distal to codon 1580); and the alternatively spliced region of exon 9 (codons 
311-408)15,23,26. The molecular mechanism(s) underlying these genotype-
phenotype associations for APC remains largely unknown. 
 
 
 
 
 
 
 
 
 
Figure 1 Representation of the adenomatous polyposis coli protein comprising 
important functional domains and showing regions of the protein 
germline mutation, which are associated with attenuated familial 
adenomatous polyposis (FAP). 
 
APC is a tumour suppressor gene and almost all mutations truncate the 
protein or take the form of allelic loss (loss of heterozygosity, LOH). Several 
genetic studies of colorectal adenomas from FAP patients have shown that 
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somatic APC mutations are dependent on the position of the germline APC 
mutation (Figure 1)91-93. The APC protein contains seven 20-amino acid 
repeats (20AARs), which are involved in degrading the transcriptional cofactor 
beta-catenin and hence negatively regulate Wnt signalling. In colorectal 
polyps, germline mutations between codons 1285 and 1378 leave only one 
20AAR intact and are strongly associated with somatic loss of the wild-type 
APC allele. LOH usually occurs through mitotic recombination, thus leaving 
two identical alleles and a total of two 20AARs in the tumour cell94. FAP 
patients who carry germline mutations before codon 1285 (no 20AARs) tend 
to have somatic mutations which leave one or, more commonly, two 20AARs 
in the protein. Finally, patients with germline mutations after codon 1398 (two 
or three 20AARs) tend to have somatic mutations before codon 1285. The 
same associations are also found in sporadic colorectal tumours95. This 
interdependence of  ‘first’ and ‘second hits’ shows that selective constraints 
on APC mutations are active and that an optimum level of beta-catenin 
mediated signalling must be achieved for the tumour cell to grow92. There is 
no reason to expect that AFAP polyps are not subject to the same selection 
for optimal Wnt signalling as other colorectal adenomas.      
The ‘first hit-second hit’ associations can explain why FAP patients with 
germline APC mutations between codons 1285 and 1378 have particularly 
severe colorectal disease, because the associated allelic loss occurs at a 
higher spontaneous frequency than the somatic truncating mutations selected 
in other FAP patients91. Conversely, the milder disease in AFAP patients may 
be explained if the mutations required to give the polyp cell a strong selective 
advantage are difficult to acquire. Spirio et al.87 studied colorectal tumours 
from a single AFAP family with a germline APC mutation in the 5’-end of the 
gene (codon 142FS). About 12% of their polyps showed loss of the germline 
mutant allele, implying that this was a ‘third hit’ subsequent to a mutation on 
the germline wild-type allele. Furthermore, a large proportion (36%) of the 
truncating somatic mutations detected were 1bp insertions at an A6-tract 
between nucleotides 4661-4666 (codons 1554-1556). Spirio et al.87 concluded 
that germline mutations in the 5’ region of APC encode proteins that retain 
residual activity, owing to alternative splicing or initiation of translation. 
Somatic mutations would be required not only to inactivate the wild-type 
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allele, but also to reduce the residual activity of the mutant germline allele. Su 
et al.96 studied 9 adenomas from an AFAP family with a germline mutation 
(R332X) in exon 9. They found ‘third hits’, including loss of the germline 
mutant allele and 4661insA, and showed the latter to occur on the germline 
mutant chromosome. The APC isoprotein lacking exon 9 retained at least 
partial ability to downregulate beta-catenin-mediated transcription, providing a 
reason for the ‘three hits’ and thus attenuation of the phenotype. Su et al.96 
suggested that exon 9-mutant AFAP patients develop more tumours than the 
general population because the germline mutant APC allele could be 
inactivated by a broad spectrum of somatic mutations, including some, such 
as nt4661insA, that would not normally affect a wild-type APC allele.     
The existing studies only analysed single families, but established the 
important principle that ‘third hits’ can occur in AFAP. These ‘third hits’ could 
be LOH or mutation at codon 4661. In this study, we analysed a larger 
number of AFAP families with the following aims   
•  to search for phenotypic differences among AFAP families, both between 
and within kindreds with mutations in each of the three AFAP-associated 
regions of APC   
•  to determine whether the two families reported were typical of AFAP   
•  to find out the somatic APC mutation spectrum in AFAP patients with 3’-
mutations and to compare this with the other AFAP-associated regions of 
APC   
•  to find out why 4661insA is such a common ‘third hit’   
•  to delineate the pathways of somatic APC mutation in AFAP, with emphasis 
on whether polyps end up with the optimal genotype as predicted by studies 
of classical FAP   
•  to determine whether ‘three hits’ are always needed in AFAP. 
 
MATERIALS AND METHODS 
Study population and samples   
We contacted Polyposis Registries in the United Kingdom, Switzerland, 
Germany and Denmark with a request to study colorectal tumours from AFAP 
patients with characterised germline APC mutations in the 5’- or 3’-regions of 
the gene (codons 1-177 and 1580-2843) or in the alternatively spliced region 
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of exon 9 (codons 311-408). In total, 235 fresh-frozen or formalin-fixed, 
paraffin-embedded colorectal tumours were obtained from 35 individuals in 16 
families. All patients gave written informed consent. 231 of the tumours were 
colorectal adenomas, almost all of tubular morphology and with a median 
diameter of 3mm (range=117mm); four tumours were colorectal carcinomas 
(median diameter=5mm, range=2-20mm). 30 tumours were from 6 AFAP 
patients from 5 families with germline APC mutations in the 5’-region of the 
gene (G126X, 141FS, Q163X, 170FS, 173FS). 79 tumours were from 10 
AFAP patients from 5 families, each of which carried the relatively common 
R332X nonsense mutation in the alternatively spliced region of APC exon 9. 
126 tumours were from 19 AFAP patients from 6 families with germline APC 
mutations in the 3’-region of the gene (1597FS, 1738FS, 1919FS, 1943FS, 
1982FS, 2078FS). Clinical details (APC germline mutation, gender, age at 
presentation, polyp count) were obtained and are being analysed as part of a 
larger study of phenotype in AFAP (A.L.Knudsen, in preparation); numbers of 
polyps analysed per patient are summarised in Table 1. Paired normal tissue 
was available for all patients. H&E-stained sections were prepared from each 
tumour to confirm the presence of at least 60% neoplastic tissue. DNA was 
extracted from tumour and normal tissue using standard methods. 
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Table 1  Characteristics of the 35 patients with germline adenomatous polyposis 
  coli (APC) mutations in the three attenuated familial adenomatous 
polyposis (AFAP) associated regions (5', exon 9, and 3'; codons 1–177, 
 311–408, and >1580) 
Patient ID 
Germline APC 
mutation Sex 
Age at presentation 
(y) Polyp count Polyps analysed 
AFXMK G126X M 36 834 6 
DFAP48 141FS F 56 2 1 
AVC.III.2 Q163X M 51 2100 4 
55.iv.2/1112 170FS F 32 1357 11 
554.iii.2 170FS M 50 1077 5 
1464/1 173FS M 39 "multiple" 3 
673.iii.3/1132 R332X F 49 200-300 6 
1571.ii.2 R332X F 68 5 5 
578.AA R332X F n/a n/a 4 
578.FPL R332X F 27 20 6 
578.iii.9 R332X M 41 n/a 17 
578.iv.1 R332X F 43 130 14 
578,uv,4 R332X F 27 n/a 9 
578.iv.7 R332X M n/a n/a 15 
DFAP16 R332X M 52 "multiple" 1 
DFAP81 R332X M 32 <100 2 
344-40 1597FS M 47 99 4 
344-44 1597FS M 43 50 3 
01/266 1738FS F 53 29 19 
2233/3 1919FS n/a n/a n/a 15 
MD2976 1919FS F 43 >100 21 
77-11 1943FS M 66 500 24 
77-12 1943FS M 56 500 2 
77-40 1943FS M 39 500 2 
1460/28 1982FS F 65 >100 5 
1460/42 1982FS F 33 8 1 
1460/88 1982FS M 48 <100 1 
1489/10 1982FS F 29 n/a 1 
1624/04 1982FS F 40 <100 3 
S73119 2078FS F 52 <100 1 
DW20284 2078FS F n/a n/a 1 
J42424 2078FS F n/a n/a 3 
L12562 2078FS F 60 "numerous" 3 
110.2.vi 2078FS F n/a 33 14 
FS, frameshift; n/a, not available. 
 
Mutation screening   
All samples were screened for somatic APC mutations using fluorescence 
single strand conformational polymorphism (SSCP) analysis on the ABI3100 
sequencer (details available from authors upon request). Fresh-frozen 
samples were screened between codons 1 and 1779. Owing to the limiting 
quantity of DNA, formalin-fixed, paraffin-embedded samples were screened 
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between codons 1220 and 1603, an area encompassing the somatic mutation 
cluster region16 and extending beyond the first SAMP repeat involved in axin 
binding. Samples with bandshifts on SSCP analysis were sequenced in both 
forward and reverse orientations from a new PCR product.      
 
Cloning   
We wished to determine the phase of somatic APC mutations with respect to 
the germline wildtype or mutant allele, but the quality of DNA available from 
archival tumours was insufficient to allow long-range PCR amplification. We 
therefore identified a SNP (nt4479A>G) within APC which was close enough 
to most somatic mutations of interest to be PCR-amplified, and which was 
informative and linked to the disease-causing mutation. After amplification of a 
region encompassing the somatic APC mutation and the SNP, the PCR 
product was cloned and multiple clones were sequenced using the pGEM-T 
Easy Vector System II (Promega). 
 
Loss of heterozygosity analysis   
In the case of germline nonsense mutations in APC, loss of heterozygosity 
(LOH, allelic loss) analysis was performed using three microsatellite markers, 
D5S346, D5S421 and D5S656, which map close to APC. Where linkage 
information was available for the microsatellites studied, the allele targeted by 
the allelic loss was assigned as germline mutant or wild type. Where no 
linkage information was available, the allele targeted was determined by 
inspection of the sequencing electropherogram in constitutional and tumour 
DNA for the region containing the mutation. In the case of germline (and 
somatic) frameshift mutations, LOH analysis was performed using 
oligonucleotide primers, which encompassed the germline insertion/deletion, 
which was then used as a pseudo-polymorphism for assessing loss. Standard 
methods of fluorescence-based genotyping on the ABI3100 sequencer were 
used. Allelic loss was scored at any informative marker if the area under one 
allelic peak in the tumour was reduced by more than 50% relative to the other 
allele, after correction for the relative peak areas of the alleles found in 
constitutional DNA of the same patient.     
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Multiplex ligation-dependent probe amplification (MLPA) analysis and 
real-time quantitative multiplex (RQM-)PCR   
MLPA analysis to determine the copy number of the APC promoter and 
individual exons was performed on polyps with allelic loss at APC using the 
Salsa MLPA kit P043 APC (MRCHolland) according to manufacturer’s 
instructions. RQM-PCR to determine the copy number of APC exon 14 
(normalised against human serum albumin (Alb) exon 12) was performed as 
previously described70. The assay has previously been shown to be sensitive 
for tumour samples containing less than 30% contaminating normal tissue93. 
 
RESULTS 
Overall phenotypic assessment     
We have previously shown that disease severity (number of colorectal 
adenomas) in classical FAP patients varies considerably independent of the 
germline mutation, but that family members tend to have similar severities of 
disease97. In order to test for the same tendency in AFAP, we searched the 
published literature (details available from authors) for all patients who had 
germline mutations in the AFAP-associated regions of APC and with precisely 
reported colorectal polyp counts at presentation. We then combined these 
data with our own. Patient age had no significant effect on polyp number. We 
then tested for familial aggregation of disease severity and found good 
evidence for this, both when all families were considered together 
(p<0.00001, Kruskal-Wallis test) and when families with germline mutations in 
the three AFAP-associated regions of APC were analysed separately 
(p=0.0002, p=0.045, p=0.0005 respectively for 5’-, exon 9- and 3’mutants, 
Kruskal-Wallis test). Whilst some effects of local clinical practice are possible, 
such strong associations are unlikely to result from systematic errors in polyp 
counting. We then calculated the median polyp count for each family 
irrespective of size, and tested whether this varied among the three groups 
with mutations in different regions of the APC gene. The 33 families with 5’ 
mutations had significantly more severe disease (median of medians=69 
polyps, IQR=45475; p=0.047, Kruskal-Wallis test) than the 16 exon 9-mutant 
and 26 3’mutant families, who had similar disease severities (median of 
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medians=16, IQR=8-130 for exon 9; median of medians=15, IQR=4-150 for 
3’).       
 
Somatic mutations in tumours of patients with AFAP-associated 
germline APC mutations     
Given that our data showed aggregation of disease severity within families, it 
became more likely that the individual kindreds analysed by previous 
studies87,96 had provided only a partial description of the genetic pathways of 
tumorigenesis in AFAP. We first screened colorectal tumours from 5’-mutant 
patients for somatic APC changes (Supplementary Table 1). We found 
truncating somatic mutations in 9 of 30 (30%) adenomas. Similar to 
adenomas from classical FAP patients with germline mutations before codon 
128591-93, all of the truncating mutations left either one or two 20AARs in the 
protein. Just two of the adenomas (7%) harboured a detected ‘third hit’, each 
in the form of loss of the germline mutant allele  (Supplementary Table 1). Our 
results were consistent with those reported by Albuquerque et al.92 on the 
polyps of a single 5’ mutant-patient, but differed from those of Spirio et al.87 in 
that we found no mutations at nucleotides 4661-6 or at any other site after the 
third 20AAR. It was notable that while most of the patients of Spirio et al.87 
had presented with attenuated polyposis, the patient of Albuquerque et al. 
had been reported to have about 100 adenomas and most of our 5’-mutant 
patients had presented with a classical FAP phenotype (Table 1). The family 
of Spirio et al.87 cannot therefore be considered representative of all patients 
with mutations in the AFAP-associated 5’ region of APC.       
For patients with exon 9 germline mutations, we found truncating somatic 
mutations in 47/79 (59%) adenomas (Table 2, Supplementary Table 2). Of the 
total of 50 truncating mutations, 33 (66%) were nt4661insA at codon 1554, 
and this change was always present on the germline mutant allele where 
assignment was possible. (An uncharacterised defect in DNA mismatch repair 
as a cause for this observation was excluded by analysing the microsatellite 
marker BAT26.) Three other mutations leaving three 20AARs (at codons 
1518, 1530 and 1537) were found. LOH was found in 13/79 (16%) adenomas; 
this affected the wildtype allele in 9 cases and the mutant allele in 4 cases. 
Thirty-one (39%) adenomas had evidence of ‘thirds hits’, either two detected 
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somatic changes or a single identified somatic change on the germline mutant 
allele. The data allowed three main genetic pathways to be identified in the 
exon 9-mutant patients’ polyps with evidence of ‘third hits’ (Table 2):  
(i) mutation leaving three 20AARs on germline mutant allele, plus loss 
of the wildtype allele;  
(ii) mutation leaving three 20AARs on germline mutant allele, with 
undetectable mutation of the wildtype allele (most likely towards the 
5’ end of the gene, which could not be screened in all polyps, and 
leaving zero 20AARs);   
(iii) mutation leaving one 20AAR on the wildtype allele plus loss of the 
germline mutant allele 
 
Table 2 Numbers of tumours with evidence of "third hits" (somatic mutation of 
  germline mutant allele) at the adenomatous polyposis coli (APC) gene 
  in exon 9 and 3' mutant patients’ polyps 
Somatic mutation on 
germline wild-type 
allele ("second hit") 
Somatic mutation 
on germline 
mutant allele 
("third hit") 
No of 5' 
mutant 
patients 
No of exon 9 
mutant patients 
No of 3' 
mutant 
patients 
LOH 20AAR3 0 6 0 
LOH 20AAR2 0 0 2 
20AAR0 20AAR3 0 2 1 
20AAR1 20AAR3 0 2 0 
20AAR0 LOH 0 0 1 
20AAR1 LOH 2 4 3 
20AAR2 LOH 0 0 2 
Not found 20AAR3 0 20 0 
Not found 20AAR2 0 2 2 
Not found LOH 0 0 9 
LOH, loss of heterozygosity 
 
20AAR1, truncating mutation before first 20 amino acid beta-catenin binding 
and degradation repeats (20AAR), etc. Note that these are minimum 
estimates of the true frequency, not only because we could not screen the 
entire gene for mutations in small archival polyps but also because it was not 
possible to assign all mutations to the germline mutant or wild-type allele. 
For patients with 3’ germline mutations, we found truncating somatic 
mutations in 35/126 (28%) adenomas (Table 2, Supplementary Table 3). Of 
the total of 36 truncating mutations, only 2 (6%) were nt4661insA. Three other 
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mutations leaving three 20AARs (at codons 1537, 1576 and 1570) were 
found. LOH was found in 30/126 (23%) adenomas, equally affecting the 
wildtype and mutant alleles. Twenty (16%) adenomas had either two detected 
somatic changes or an identified somatic change of the germline mutant 
allele. There was no clear tendency for different families to acquire different 
somatic mutations (Supplementary Table 3). The data only allowed one 
consistent genetic pathway to be identified in the 3’-mutant patients’ polyps 
with evidence of ‘third hits’, namely a mutation leaving one (or two) 20AARs 
on the germline wildtype allele, plus loss of the mutant allele (Table 2). 
 
Comparison between somatic mutations in the three groups of patients     
The somatic mutation spectra of the 5’- and 3’-mutant patients’ tumours did 
not differ significantly from each other as regards: (i) proportion of mutations 
leaving one, two or three 20AARs (p=0.074, χ2 test); (ii) overall LOH 
frequency (2/9 versus 30/126, p=0.64); and (iii) proportion of tumours with 
detected ‘third hits’ or an identified somatic change on the germline mutant 
allele (2/9 versus 20/126, p=0.45). However, whilst exon 9-mutant patients 
had a similar frequency of LOH (13/79, 22%, p=0.14) to the other patients, 
germline exon 9 mutants had a higher frequency of mutations that left three 
20AARs (36/50 versus 5/45, p<0.001, χ2 test) and a higher frequency of 
tumours with detected ‘third hits’ (31/79 versus 22/156, p<0.0012, χ2 test). In 
large part, these associations reflected the fact that nt4661insA was 
particularly common in the exon 9-mutant patients’ tumours and exclusively 
targeted the mutant germline allele. Overall, our data were consistent with a 
large proportion of polyps in the 5’- and 3’-mutant patients developing along 
the ‘classical’ FAP pathway, their polyps showing similar somatic mutations to 
individuals with germline mutations which leave zero 20AARs91. Exon 9-
mutant patients were, however, significantly different from the other two 
groups of patients. Although not all nt4661insA mutations could be assigned 
to a germline allele, if we made the reasonable assumption that all of these 
mutations were on the germline mutant allele, over half of all tumours from 
exon 9-mutant patients had ‘third hits’ (Supplementary Table 2). These 
differences could not readily be explained by features such as the size or 
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dysplasia of the tumours analysed, which did not differ significantly among the 
three patient groups (details not shown).       
 
Mechanism of LOH     
We tested the possibility that different LOH events (for example, those 
involving the germline wild type and mutant alleles) were caused by different 
mechanisms, such as mitotic recombination and deletion, which resulted in 
different gene dosages and functional consequences. However, none of 17 
tumours with allelic loss (10 with mutant LOH and 7 with wild-type LOH) 
showed copy number changes in the APC promoter region or exons using 
MLPA analysis. We selected for RQM-PCR analysis 10 further tumours (2 
with mutant LOH and 8 with wild-type LOH) with mean LOH ratios below 0.3 
(indicating that contamination with normal tissue was low enough not to 
confound the detection of deletion93), but, all adenomas showed copy number 
values between 0.79 and 0.97, consistent with diploid APC copy number and 
LOH by mitotic recombination.       
 
Early pathways of tumorigenesis in AFAP polyps with ‘three hits’     
Our data, combined with previous findings87,96, showed that a substantial 
proportion of AFAP adenomas have acquired two somatic APC changes, one 
targeting the germline wildtype and one the germline mutant allele. 
Consideration of the order in which these somatic changes occur and their 
respective effects on tumour growth has important implications for 
determining the molecular genetic mechanism underlying AFAP. In AFAP 
adenomas, initiation of tumour growth might require all ‘three hits’ to be 
present in the tumour cell of origin (‘kick-start’ model). In this case, the two 
somatic mutations could occur in either order without functional consequence. 
The ‘kick-start’ model implies that a mechanism exists which results in an 
increase of the intrinsic or effective mutation rate in order to explain the 
relatively high frequency of such tumours as compared to the general 
population.   
Alternatively, the ‘second hit’ - necessarily involving the germline wild-type 
allele - might be sufficient for early adenoma growth, with the ‘third hit’ 
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(involving the germline mutant allele) being required for subsequent 
tumorigenesis prior to clinical presentation. This ‘stepwise’ model postulates 
that mutation of the germline wild-type allele induces limited clonal expansion 
(thereby increasing the effective mutation rate), and is followed by mutation of 
the germline mutant allele to give an optimal APC genotype. 
APC mutation data from individual adenomas can be used to distinguish 
between these possibilities, because the ‘kick-start’ and ‘stepwise’ models are 
expected to leave distinct footprints as regards the proportion(s) of somatic 
mutant allele(s), since these proportions depend on the order in which the 
somatic changes have occurred and some residual adenoma with ‘two hits’ is 
expected in the ‘stepwise’ case (Figure 2).     
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Figure 2 Pathways of tumorigenesis in attenuated familial adenomatous 
polyposis (AFAP) polyps with "three hits", illustrating the possible 
sequences in which somatic mutations/allelic loss may occur in AFAP 
polyps with "three hits" as well as the possible functional effects of 
these changes. Loss of the germline wild-type allele and truncating 
somatic mutation are shown. In a "kick-start" model, these changes can 
occur in either order (i) or (ii) and tumour growth ensues once both 
somatic changes have occurred; in a "step wise" model (iii), loss of the 
germline wild-type allele leads to limited clonal expansion and is 
followed by the truncating somatic mutation which promotes further 
tumour growth. The expected proportions of ßsom and gl are shown. 
ßsom = proportion of somatic mutant allele in polyp; gl = proportion of 
germline wild-type allele in polyp. LOH, loss of heterozygosity by 
mitotic recombination. For each model, the expected proportion of the 
somatic mutant allele (ßsom) in the polyp can be determined from the 
proportions of the germline wild-type (gl) allele as shown. gl can be 
estimated from the LOH ratio. 
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Figure 3 Pathways of tumorigenesis in attenuated familial adenomatous 
polyposis (AFAP) polyps with "three hits", illustrating the possible 
sequences in which somatic mutations/allelic loss may occur in AFAP 
polyps with "three hits" as well as the possible functional effects of 
these changes. Loss of the germline mutant allele and truncating 
somatic mutation are shown. In both the "kick-start" (i) and "step wise" 
(ii) models, the truncating somatic mutation precedes loss of the 
germline mutant allele but in the "kick-start" model, both changes are 
required for tumour growth. The expected proportions of ßgl and ßsom 
are shown. ßsom = proportion of somatic mutant allele in polyp; ßgl = 
proportion of germline mutant allele in polyp. LOH, loss of 
heterozygosity by mitotic recombination. For each model, the expected 
proportion of the somatic mutant allele (ßsom) in the polyp can be 
determined from the proportions of the germline mutant (ßgl) allele as 
shown. ßgl can be estimated from the LOH ratio. 
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Figure 4 Pathways of tumorigenesis in attenuated familial adenomatous 
polyposis (AFAP) polyps with "three hits", illustrating the possible 
sequences in which somatic mutations/allelic loss may occur in AFAP 
polyps with "three hits" as well as the possible functional effects of 
these changes. Two truncating somatic mutations are shown. In a 
"kick-start" model (i), these changes can occur in either order and 
tumour growth ensues once both somatic changes have occurred; in a 
"step wise" model (ii), somatic mutation of the germline wild-type allele 
causes limited clonal expansion and is followed by somatic mutation of 
the germline mutant allele, which promotes further tumour growth. The 
expected ratio of the two somatic alleles is 1:1 for the "kick-start model" 
but lies between 1:4 and 1:1 for the "step wise" model with the 
minimum estimate (*) assuming a mutation detection sensitivity of 20%. 
 
 
Consider, for example, polyps with loss of the germline wild-type allele and a 
somatic insertion/deletion mutation on the germline mutant allele. We can 
measure two ratios of relative allelic dosage, one for the germline mutation 
and the other for the truncating somatic mutation, and use these to estimate 
the proportion of each allelotype in the tumour. Furthermore, we can calculate 
the expected values of these ratios by predicting the proportion of somatic 
mutant allele expected in the tumour under different models of tumorigenesis 
(Figure 2). By comparing the observed proportion of the somatic mutant allele 
with that expected, we can determined whether the ‘stepwise’ or ‘kickstart’ 
model fits better (see Figure 2 for details). Similarly, observed and expected 
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allele proportions can be determined for adenomas with one somatic 
insertion/deletion mutation on the germline wildtype allele and loss of the 
germline mutant allele (Figure 2). For tumours with two truncating somatic 
mutations, the expected ratio of the two mutant alleles under each model can 
be compared to the ratio measured directly by cloning a PCR product 
encompassing both changes, sequencing multiple clones and counting how 
many times each allele is represented (Figure 2).     
For seven tumours with loss of the germline wild-type allele and a 
somatic insertion/deletion mutation, the observed and expected proportions of 
the somatic mutant allele were very similar to those expected under the ‘kick-
start’ model, assuming that the ‘second hit’ was the insertion/deletion (on the 
somatic mutant allele) and the ‘third hit’ was the allelic loss (Table 3). Similar 
results in favour of a ‘kick-start’ model were obtained for three adenomas with 
one somatic insertion/deletion and loss of the germline mutant allele, and for 
one adenoma with two truncating somatic mutations (Table 3). 
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Table 3   Observed and expected frequencies of somatic mutant APC alleles in 
  attenuated familial adenomatous polyposis (AFAP) polyps with "three 
  hits" for "kick-start" and "step wise" models of tumorigenesis. Polyp 
  with one somatic insertion/deletion and loss of the germline wild-type 
  allele 
 
A. Polyp with one somatic insertion/deletion and loss of the germline wild-type allele. 
Model 
Allele 
frequencies Polyp 1  Polyp 2 Polyp 3 Polyp 4 Polyp 5 Polyp 6 Polyp 7  χ2 
 Observed αgl 0.21 0.27 0.21 0.29 0.3 0.26 0.28  
 Observed βsom 0.64 0.52 0.49 0.52 0.33 0.4 0.27  
"Kick-start", 
LOH first 
Expected βsom 
= [(1-2αgl)/2] 0.29 0.23 0.29 0.21 0.2 0.24 0.22 1.59 
"Kick-start", 
LOH second 
Expected βsom 
= (1-2αgl) 0.58 0.46 0.58 0.42 0.4 0.48 0.44 0.14 
"Step wise" 
Expected 
minimum βsom* 0.2 0.2 0.2 0.2 0.2 0.2 0.2 2.72 
  
Expected 
maximum βsom 
=[(1-2αgl)/2] 0.29 0.23 0.29 0.21 0.2 0.24 0.22 1.59 
*Assuming that the somatic insertion/deletion can be detected if it comprises >20% of all alleles in the polyp. 
 
B Polyp with one somatic insertion/deletion and loss of the germline mutant allele. 
Model 
Allele 
frequencies Polyp 8  Polyp 9 Polyp 10   χ2 
 Observed βgl 0.33 0.1 0.24  
 Observed βsom 0.41 0.83 0.61  
"Kick-start" (LOH 
must be second) 
Expected βsom 
= (1-2βgl) 0.34 0.8 0.52 0.03 
"Step wise" 
Expected 
minimum som = 
(1-2βgl) 0.34 0.8 0.52 0.03 
  
Expected 
maximum som 
= (1-2βgl) 0.67 0.9 0.76 0.14 
 
C Two truncating somatic mutations. 
Model 
"Third" to "second 
hit" ratios* Polyp 11    χ2 
 Observed  27:31  
"Kick-start"  Expected  1:1 0.03 
"Step wise" Expected minimum  1:4 14.4 
  
Expected 
maximum 1:1 0.03 
* Assuming a detection sensitivity of 20% for the somatic ‘third hit’. 
αgl = proportion of germline wild-type allele in polyp; ßsom = proportion of somatic mutant allele in polyp. 
Observed αgl frequency was determined from the loss of heterozygosity (LOH) ratios. Observed ßsom frequencies 
were similarly determined from LOH ratios generated by polymerase chain reaction amplification of a region 
encompassing the somatic insertion/deletion and subsequent Genescan analysis (using constitutional DNA from 
patients with germline mutations identical to the somatic change for normalisation). The observed "third" to 
"second hit" ratio for polyp 3 was determined by sequencing 58 clones of a polymerase chain reaction product 
encompassing both somatic changes. 
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DISCUSSION 
Our analysis of a relatively large set of AFAP families has shown complexity 
in the phenotype and early genetic pathways of tumorigenesis. The two 
previous analyses of somatic APC mutations in AFAP each focussed on 
single families, one with a germline mutation in the 5’ region of the gene87 and 
the other with a mutation in exon 996. These two studies unequivocally 
provided the important and original finding that ‘three hits’ - that is, two 
somatic mutations, including loss or mutation of the germline mutant allele - 
can occur in AFAP tumours. The restricted size of the two studies meant, 
however, that they were unable to provide further conclusions.      
We have found that patients with germline APC mutations in the 5’ and 3’ 
regions of the gene or the alternatively spliced region of exon 9 have a highly 
variable large-bowel phenotype, in that the number of colorectal adenomas 
varies from almost none to the hundreds or thousands of lesions found in 
classical FAP15. Although assessment methods necessarily differ among 
clinical centres, our analysis shows that patients with 5’ APC mutations 
(codons 1-177) are likely to have a more severe phenotype than those with 
mutations in exon 9 or the 3’ end of the gene (>codon 1580). Phenotypic 
severity also tends to be similar within families, suggesting that restricting 
analyses to single kindreds may not provide accurate assessment of AFAP 
patients.        
Our study has confirmed that ‘three hits’ at APC often occur in AFAP 
adenomas. In such polyps, the ‘third hit’ appears to be required for the 
initiation of tumorigenesis. Although ‘third hits’ might occur at loci other than 
APC, we have previously found no mutations at beta-catenin in AFAP polyps 
(unpubl. data). In polyps with ‘three hits’ from exon 9-mutant and 3’-mutant 
patients, we have been able to identify specific combinations of APC 
mutations, which tend to occur. Exon 9 is alternatively spliced in all normal 
and neoplastic tissues, which we have examined (not shown). The 
combinations of APC mutations almost certainly produce a near-optimal level 
of Wnt signalling, comparable with those found in classical FAP91. Some of 
the combinations – such as R332X-nt4661insA/LOH – strongly suggest that 
the tumour has developed as a result of the functional effects of the germline 
mutant allele, but other combinations of mutations – such as truncating 
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mutation leaving one 20AAR on the wildtype with LOH of the germline mutant 
– might simply be indicative of a ‘sporadic’ tumour occurring on the 
background of AFAP.      
In our families, ‘third hits’ were much rarer in 5’- and 3’-mutant patients 
than in the exon 9 mutants. These former families’ somatic mutations usually - 
but not always - resembled those of classical FAP patients who have germline 
mutations before the first 20AAR of the APC protein. In many ways, this is the 
result which would be predicted were the 5’ or 3’ mutations simply to cause 
absent or non-functional protein. 5’ APC mutations probably produce a small 
amount of partially functional APC through use of an internal ribosome entry 
site (IRES) at codon 18498. 3’-mutant proteins have been reported as being 
unstable27, although the reasons for this are unknown. It is entirely plausible 
that the levels of functional APC protein vary among individuals with both 5’ 
and 3’ mutations, for example as a result of modifier alleles. Thus, for an 
adenoma to form, some patients would tend to require ‘third hits’ and others 
would not. The family of Spirio et al.87, for example, may have been relatively 
efficient at use of the IRES. Formal testing of this hypothesis in vivo would 
require an exceptionally large, unselected series of tumours and patients.       
Our analysis of exon 9-mutant cases further provides further evidence to 
show that not all AFAP patients are the same. ‘Third hits’ were common in 
these patients’ tumours. There was a markedly increased frequency of 
mutations which left three 20AARs on the germline mutant allele, particularly 
– but not exclusively - at nt4661, which appears to be a relatively 
hypermutable site. Our view differs somewhat from that of Su et al.96, who 
proposed that insAnt4661 mutations were over-represented in AFAP polyps 
because both ‘strong’ and ‘weak’ mutations were sufficient to severely reduce 
function of the exon 9-mutant allele. We suggest that mutations leaving three 
20AARs on the germline mutant allele are common because the resulting 
allelotype R332X-4661insA gives a near-optimal genotype, taking into 
account loss of the germline wildtype allele and alternative splicing of exon 9. 
Variation in splicing efficiency – again through modifier allele action - could 
explain phenotypic variability in exon 9-mutant AFAP, but it appears that 
many of these patients produce sufficient functional protein by splicing out 
exon 9 that ‘third hits’ are necessary in most polyps.     
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The reason why AFAP patients develop fewer polyps than classical FAP 
patients is evident, in that ‘three hits’ are often needed to produce the near-
optimal genotype. We do not, however, claim that all polyps from patients with 
AFAP-associated APC mutations require ‘three hits’. Even allowing for the 
imperfections of mutation screening and LOH analysis in archival specimens, 
we were able to analyse the fresh-frozen adenomas comprehensively and 
found many without ‘three hits’. Moreover, several polyps from our patients 
had somatic mutations which would have been predicted from a ‘two hit’ 
model of optimal Wnt signalling. Currently, we cannot explain why in a single 
patient, some polyps seem to require ‘three hits’ and others do not, but it is 
possible that ‘third hits’ at other loci can substitute for APC mutation. Another 
possibility is that selective constraints on the diminished APC function needed 
for tumorigenesis are ‘just right’87,92 at some times, but weaker at others, for 
example during development or when tissue is undergoing repair.        
The genetic analysis of colorectal tumours from patients with germline 
mutations in AFAP-associated regions of APC, by this study and others, has 
revealed a novel mechanism underlying the genotype-phenotype association 
in this tumour syndrome, namely a requirement for ‘three hits’ in at least some 
AFAP adenomas. This finding must be viewed in the framework of the model 
of optimal combinations of APC mutations, rather than simple loss of protein 
function. More than one different combination of APC mutations can provide 
near-optimal Wnt signalling in AFAP. However, not all AFAP patients are the 
same. Given that assembling a very large series of AFAP patients is 
extremely difficult, it is not easy to decide on what is the ‘typical’ AFAP 
phenotype or somatic genotype. In the seven families with 5’ APC mutations 
studied to date87,92 and this study), about 15-20% of polyps seem to acquire 
‘three hits’, but only Spirio et al.87 found a high frequency of nt4661insA. In the 
six 3’-mutant families studied (all from this study), the frequency of ‘third hits’ 
seems similar to that of the 5’-mutants. Six exon 9-mutant families have been 
studied (96 and this study) and almost all of these show evidence of a high 
frequency of ‘third hits’ – we estimate a minimum of 50% in our study. In 
addition, there appear to be genetic factors apart from the germline APC 
mutation that influence disease severity, as evidenced by the tendency for 
polyp numbers to be similar within families. The phenotypic and somatic 
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molecular heterogeneity in AFAP means that clinical management of patients 
with AFAPassociated mutations must be empirical. Accurate prediction of 
phenotype may only be possible when factors, such as modifier genes, that 
influence genetic pathways and disease severity are identified. 
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ABSTRACT 
In 10–30% of patients with classical familial adenomatous polyposis (FAP) 
and up to 90% of those with attenuated (<100 colorectal adenomas; AFAP) 
polyposis, no pathogenic germline mutation in the adenomatous polyposis coli 
(APC) gene can be identified (APC mutation-negative). Recently, biallelic 
mutations in the base excision repair gene MYH have been shown to 
predispose to a multiple adenoma and carcinoma phenotype. This study 
aimed to (i) assess the MYH mutation carrier frequency among Swiss APC 
mutation-negative patients and (ii) identify phenotypic differences between 
MYH mutation carriers and APC/MYH mutation-negative polyposis patients. 
Seventy-nine unrelated APC mutation-negative Swiss patients with either 
classical (n = 18) or attenuated (n = 61) polyposis were screened for germline 
mutations in MYH by dHPLC and direct genomic DNA sequencing. Overall, 7 
(8.9%) biallelic and 9 (11.4%) monoallelic MYH germline mutation carriers 
were identified. Among patients with a family history compatible with 
autosomal recessive inheritance (n = 45), 1 (10.0%) out of 10 classical 
polyposis and 6 (17.1%) out of 35 attenuated polyposis patients carried 
biallelic MYH alterations, 2 of which represent novel gene variants (p.R171Q 
and p.R231H). Colorectal cancer was significantly (p < 0.007) more frequent 
in biallelic mutation carriers (71.4%) compared with that of monoallelic and 
MYH mutation-negative polyposis patients (0 and 13.8%, respectively). On 
the basis of our findings and earlier reports, MYH mutation screening should 
be considered if all of the following criteria are fulfilled: (i) presence of 
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classical or attenuated polyposis coli, (ii) absence of a pathogenic APC 
mutation, and (iii) a family history compatible with an autosomal recessive 
mode of inheritance.  
 
 
INTRODUCTION 
Familial adenomatous polyposis (FAP; OMIM entry no.175100) is an 
autosomal dominantly inherited colorectal cancer (CRC) predisposition 
caused by germline mutations in the adenomatous polyposis coli (APC) gene 
and characterized by the development of hundreds to thousands of 
adenomatous polyps throughout the intestinal tract16. Attenuated FAP (AFAP) 
represents a clinical variant of classical FAP, associated with multiple (<100) 
colorectal adenomas and caused by mutations in the most 5’ or 3’ regions of 
APC or in the alternatively spliced region of exon 916,87,96. With routine 
screening techniques failing to detect pathogenic APC germline mutations in 
10–30% of classical FAP patients and in up to 90% of AFAP patients99, 
investigations about the role of other polyposis predisposition genes are 
topical.  
Recently, Al Tassan et al. demonstrated that biallelic germline 
mutations in the human homologue of the base excision repair gene MutY 
(MYH) cause a phenotype of multiple colorectal adenomas and carcinomas, 
thus, describing for the first time an autosomal recessively inherited CRC 
predisposition6,7. The DNA glycosylase MYH removes adenines from mispairs 
with 8-oxoguanine that occur during replication of oxidized DNA. Failure to 
correct these mispairs consequently leads to G:C→T:A transversion 
mutations, a typical ‘‘footprint’’ of oxidative DNA damage43. The observation of 
an excess of transversion mutations in tumors eventually led to the discovery 
of MYH-associated polyposis (MAP). A number of studies have already been 
conducted in attempts establish the extent to which germline mutations in the 
MYH gene may contribute to individuals with an AFAP phenotype7,100,101. As a 
result, biallelic MYH germline mutations have been attributed to ~1–3% of all 
unselected CRC patients. This nation-wide study aimed to (i) assess the 
frequency of MYH mutation carriers in 79 unrelated Swiss patients presenting 
with either classical or attenuated polyposis and in whom no pathogenic APC 
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germline mutation could be identified and (ii) to identify phenotypic differences 
between biallelic mutation carriers, monoallelic mutation carriers and 
APC/MYH mutation-negative patients. 
 
PATIENTS AND METHODS  
This nation-wide study investigated 79 ostensibly unrelated Swiss index 
patients referred between 1994 and 2004 to either the Research Group 
Human Genetics, Division of Medical Genetics, Basel, or the Unit of Genetics, 
Institut Central des Hôpitaux Valaisans, Sion, Switzerland, because of 
classical (>100 polyps, n = 18) or multiple adenomas/attenuated                     
(5 – 99 polyps) FAP (AFAP; n = 61). In all patients, no germline APC mutation 
could be identified by means of the protein truncation test, single strand 
conformation polymorphism or direct DNA sequencing (patients thereafter 
referred to as APC mutation-negative)18. Forty-five patients displayed a family 
history compatible with autosomal recessive inheritance; in the remainder 
there was either evidence for vertical transmission or no detailed family 
history available. In addition, 100 control Swiss individuals were enrolled so 
as to establish the carrier frequency of previously reported MYH variants as 
well as novel mutations of unknown pathogenic significance in unaffected 
individuals. Informed consent for the study was obtained from all individuals 
investigated. Patients were considered as anonymous to cases, and the 
results of the various genetic analyses were independently checked by at 
least 2 assessors.  
 
DNA extraction  
Genomic DNA was isolated from EDTA blood, using methods previously 
described by Miller et al.102. Briefly, 10ml blood was mixed with 30ml of EL 
buffer (155mM NH4Cl, 10mM KHCO3, 1mM EDTA, pH 7.4) and left on ice for 
15 min. The lysate was centrifuged at 2000g for 10 min, washed twice with EL 
buffer and the intact leukocyte pellet resuspended in NL buffer (10mM 
Tris.HCl, pH 8.2, 400mM NaCl, 2mM Na2EDTA, 1%SDS and 200µg/ml 
proteinase K) and incubated overnight at 37°C. The next day, 1ml of 6M NaCl 
was added and vigorously shaken, followed by centrifugation to remove 
cellular proteins. The supernatant containing the DNA was placed in a fresh 
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tube and the DNA precipitated with ethanol. The resulting DNA pellet was 
washed with 70% ethanol, dried briefly and then suspended in 1ml of TE 
buffer (10 mM Tris.HCl, pH 7.5, 0.1 M EDTA).  
 
MYH mutation analysis  
In 57 (72%) patients (15 FAP and 42 AFAP), the entire MYH coding sequence 
was analyzed by direct DNA sequencing. An additional 22 patients (3 FAP 
and 19 AFAP) were exclusively screened for mutations in exons 7 and 13 in 
which the most common pathogenic mutations in the Caucasian population, 
p.Y165C and p.G382D, occur. Each time a heterozygous MYH mutation was 
identified, the entire gene was subsequently analyzed by direct DNA 
sequencing (exons 2, 5, 8 and 12) and dHPLC (exons 1, 3, 4, 6, 9, 10, 11, 14, 
15, 16) to identify/exclude the presence of a second germline mutation.  
Exon specific primer pairs were used to amplify the 16 exons of MYH 
(HUGO ID: MUTYH; Genbank accession no. NM_012222), including the 
respective exon–intron boundaries (primer sequences and PCR conditions 
available from the authors upon request). Twenty-five microliters of PCR 
reaction mixture contained 50ng of genomic DNA, 10pmol of each primer and 
a PCR mastermix at 1.5mM MgCl2, according to the manufacturer’s 
instructions (Invitrogen, Basel, Switzerland). All PCR reactions were done on 
a Hybaid OmnE thermocycler (Catalys AG, Wallisellen, Switzerland).  
As a prescreening method to detect DNA sequence changes, dHPLC 
was performed using the 3500HT WAVE nucleic acid fragment analysis 
system (Transgenomic, Crewe, UK). Melting temperatures for dHPLC were 
predicted by the Wavemaker software version 4.1.42 (Transgenomic) (dHPLC 
melting temperatures available from the authors upon request). Where 
different elution profiles were observed in comparison with the control 
samples run in parallel, direct DNA sequencing was performed to characterize 
the nature of the sequence alteration.  
For DNA sequencing, PCR products were purified using the QIAquick 
PCR Purification kit (Qiagen, Basel, Switzerland). The sequencing reaction 
was performed using the Big Dye Teminator Cycle Sequencing kit (Applied 
Biosystems, Rotkreuz, Switzerland), according to the manufacturers’ 
guidelines. Following purification using the DyeEx 2.0 Spin Kit (Qiagen, Basel, 
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Switzerland), sequencing products were analyzed on an ABI PRISM 310 
Genetic Analyser (Applied Biosystems). Germline mutations identified in MYH 
were confirmed by sequencing in both, forward and reverse, directions, and 
from at least 2 independent PCR products. Germline mutations p.Y165C and 
p.G382D were independently confirmed by restriction enzyme digests, using 
IlaI and BglII, respectively.  
 
Statistical analysis  
Statistical comparison of patients’ features, encompassing phenotypic 
characteristics (gender, age at diagnosis, polyp number, extracolonic 
manifestations, family history) and mutational status was performed using the 
χ2 and Fisher’s exact test for categorical variables, or Student’s t-test for 
continuous variables, with all of the probabilities reported as two-tailed ps, 
considering a p value of <0.05 to be statistically significant.  
 
 
RESULTS 
Seventy-nine APC mutation-negative Swiss polyposis patients from the Basel 
(n = 58) and Sion (n = 21) medical genetic centers were investigated for the 
presence of MYH germline alterations. Twenty-three percent of the individuals 
were referred because of suspected classical FAP (n =18), whilst the majority 
exhibited an attenuated or multiple adenoma phenotype (n = 61).  
 
MYH mutation analysis  
The complete coding sequence of the MYH gene was investigated in 57 index 
patients. In addition, 22 patients were screened for alterations in exons 7 and 
13, which harbor the most common pathogenic mutations, p.Y165C and 
p.G382D. Overall, 7 (8.9%) biallelic and 9 (11.4%) monoallelic MYH germline 
mutation carriers were identified. According to the clinical classification,          
1 (5.6%) out of 18 FAP and 6 (9.8%) out of 61 AFAP patients harbored a 
biallelic MYH mutation. If only individuals with a family history compatible with 
autosomal recessive inheritance were considered (n = 45), 10.0% (1/10) of 
patients with classical polyposis and 17.1% (6/35) of AFAP patients harbored 
biallelic MYH germline mutations. 
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Table 1  Phenotypic Features and germline mutations identified in MYH mutation 
carriers1 
            MYH 
Patient ID Sex Age  Polyp No. CRC Extracolonic 
disease 
1st Mutation 2nd Mutation 
Biallelic MYH mutation carriers     
1775/01 M 38 <100 Yes Yes p.G84fs p.W138_M139insIW 
1828/01 F 42 <100 Yes No p.Y165C P.Y165C 
1859/01 M 33 <100 No No p.Y165C P.Y165C 
2013/01 M 50 <100 Yes No p.G382D p.G382D 
2073/01 F 60 50 No No p.Y165C p.R171Q 
2184/01 M 48 >100 Yes No p.G382D p.G382D 
2185/01 M 48 74 Yes No p.Y165C P.R231H 
        
Monoallelic MYH mutation carriers     
1384/01 F 20 Multiple No Yes p.G382D None detected 
1665/01 F 54 >100 No No p.I209V None detected 
2145/01 M 40 70 No No p.Y165C None detected 
2243/01 M 49 50 No No p.Y165C None detected 
2261/01 F 69 >100 No No p.Y165C None detected 
DFAP 17 F 34 20 No Yes p.G382D None detected 
DFAP 82 M 58 >100 No No p.G382D None detected 
DFAP 99 F 63 43 No No p.G382D None detected 
SA453 M 41 5 No No p.G382D None detected 
CRC Colorectal Cancer 
1 Patient 1775/01 has previously been reported by Sieber et al.100 
 
In addition to the mutations p.Y165C and p.G382D, which accounted for 43% 
and 29% of mutant alleles in the biallelic patients, respectively, 2 novel 
alterations were detected in AFAP patients compound heterozygote for 
p.Y165C/p.R171Q and p.Y165C/ p.R231H (Figs. 1a and 1b). One FAP 
patient, who was found to be a compound heterozygote with a 
p.G84fs/p.W138_M139insIW mutation, has been previously reported by 
Sieber et al.100 The healthy parents of this individual were available for 
investigation and were found to be heterozygous carriers of the p. 
W138_M139insIW and the p.G84fs alteration, respectively. Although the 
pathogenicity of p.R171Q and p.R231H remains to be established by 
functional studies, such gene alterations were not observed in 200 
chromosomes from Swiss control samples. Furthermore, the amino acid 
positions are evolutionary highly conserved across distantly related species 
(E. coli, S. pombe, mouse, rat and human).  
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Figure 1  Sequencing chromatograms displaying the 2 novel MYH germline 
variants marked by an asterisk (*). (a) c.512G>A, p.R171Q 
(heterozygote); (b) c.693G>A, p.R231H (heterozygote) 
 
Nine patients were identified as monoallelic MYH mutation carriers, with the 
p.G382D mutation present in 5 (56%) of them (Table I). In the remaining 63 
(80%) patients, no pathogenic MYH mutations could be identified. The 
previously described polymorphisms in exon 2 (c.64G > A; p.V22M) and exon 
12 (c.972G > C; p.Q324H) were detected with allele frequencies of 6% and 
17%, respectively, similar to that of a Swiss control sample population (200 
chromosomes) assessed in parallel (2% p.V22M and 12% p.Q324H).  
 
Genotype–phenotype comparisons  
The phenotypic features of the 7 biallelic MYH mutation carriers are depicted 
in Table I, with one of them displaying classical FAP. In 5 (71%) patients, 
CRC had been diagnosed at a median age of 48 years (IQR 10.5, range 33–
60 years), with 3 of them located proximal to the splenic flexure. The family 
history in all biallelic mutation carriers corresponded to an autosomal 
recessive mode of inheritance. Remarkably, in 3 out of 11 siblings of patient 
2073/01 (p.Y165C/p.R171Q) a CRC had been diagnosed at a median age of 
51 years (range 49–54). Except for patient 1775, in whom duodenal 
adenomas had been detected, no apparent extracolonic disease 
manifestations were observed in the other biallelic mutation carriers.  
Among the 9 monoallelic MYH mutation carriers (Tables 1 and 2), 4 
patients (no. 1384/01, 2243, DFAP17 and DFAP 82) had siblings with either 
CRC or polyps reported. With respect to extracolonic disease manifestations, 
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a facial lipoma was observed in patient DFAP17 and a duodenal 
adenocarcinoma at age 20 in patient 1384/01.  
 
Table 2 Phenotypic characteristics of biallelic MYH mutation carriers, 
monoallelic mutation carriers and APC/MYH mutation-negative patients 
with a family history compatible with autosomal recessive inheritance 
 
Biallelic MYH 
mutation 
carriers (n=7) 
Monoallelic 
MYH mutation 
carriers (n=9) 
MYH mutation 
negative 
patients (n=29) 
Sex    
    Male 5 (71)1 5 (56) 18 (62) 
    Female 2 (29) 4 (44) 11 (38) 
Clinical classification    
    FAP (>100 polyps) 1 (14) 3 (33) 6 (21) 
    AFAP (<100 polyps) 6(86) 6 (67) 23 (79) 
Age at diagnosis (y)    
    Median 48 49 48 
    IQR 10.5 20.8 20 
    Range 33-60 20-69 22-77 
Colorectal cancer    
    Present 5 (71) 0 4 (14) 
    Absent 2 (29) 9 (100) 25 (86) 
Extracolonic disease    
    Present 1 (14) 2 (22) 4 (14) 
    Absent 6(86) 7 (78) 25 (86) 
    FAP, Familial Adenomatous Polyposis; AFAP, attenuated FAP. 
      1 Values given in parentheses indicate percentages. 
 
Twenty-nine (46%) out of 63 MYH mutation-negative patients had a family 
history of CRC and/or multiple polyps/polyposis compatible with an autosomal 
recessive mode of inheritance and could, therefore, be included in the 
genotype–phenotype analysis (Table II). Comparing the phenotypic properties 
of biallelic MYH mutation carriers, monoallelic mutation carriers and 
APC/MYH mutation-negative polyposis patients, colorectal cancer was 
significantly more frequent in biallelic mutation carriers than in the other 
subgroups (71% vs. 0% and 14%, respectively; χ2 14.5, p < 0.001). Median 
age at diagnosis was similar between the 3 subgroups (48, 49 and 48 years, 
respectively). No further statistically significant phenotypic differences with 
respect to polyp number, age at diagnosis or extracolonic disease were 
observed.  
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DISCUSSION  
In this nation-wide survey on 79 Swiss APC mutation-negative polyposis 
patients, 9% were found to harbor biallelic (n = 7) and 11% monoallelic (n = 9) 
germline mutations in the base excision repair gene MYH. Considering only 
patients with a family history compatible with autosomal recessive inheritance, 
biallelic MYH mutation carriers were observed in 10% (1/10) of patients with 
classical and in 17% (6/35) of those with attenuated polyposis, respectively. 
No MYH alterations were identified in patients exhibiting a family history 
suggestive of an autosomal dominant inheritance pattern. In addition to the 
most common pathogenic missense mutations, p.Y165C and p.G382D 
6,7,100,103, 2 novel alterations in the MYH gene p.R171Q and p.R231H were 
detected. Two hundred control chromosomes, assessed in parallel, did not 
harbor these missense changes, which proved to be target amino acids highly 
conserved across 5 distantly related species. Furthermore, whilst p.R171 
constitutes part of a 6 helix barrel domain that contains the Helix–Hairpin–
Helix motif, p.R231 lies within the alpha-8 helix making up the cluster domain. 
Together they form part of a DNA binding complex, where 9 lysines and 5 
arginines form an electrostatically positive DNA interaction surface104. Clearly, 
functional studies are needed to ascertain the pathogenicity of these novel 
mutations. Moreover, since the parents of the individuals harboring these 
gene alterations were not available for screening, we cannot exclude the 
possibility that the mutations in the compound heterozygotes may lie on the 
same allele. In our study population, the overall allele frequency of the 
missense variants p.Y165C and p.G382D amounted to 5.7% (9/158) and 
5.1% (8/158), respectively; if only patients with a family history compatible 
with an autosomal recessive mode of inheritance were considered, the allele 
frequencies raised to 10% (9/90) and 8.9% (8/90). In contrast, these 
alterations were not present in Swiss control samples (0/100), similar to 
reports on Finnish blood donors (0/424) and healthy British controls 
(2/100)6,103. This further substantiates the view that the frequency of the 
p.Y165C and p.G382D mutations in the general population is too low to justify 
large-scale mutation screening43.  
The overall frequencies of biallelic mutation carriers did not significantly 
differ between patients displaying a classical (5.6%) and those displaying an 
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attenuated (9.8%) FAP phenotype, which is similar to reports by Sieber et al. 
who identified biallelic mutations in 7.5% and 5% of patients, respectively100. 
The frequency of monoallelic mutation carriers, however, was significantly 
higher in our study group (11.4% compared with that of 3.9% as reported by 
Sieber et al.100) which may reflect ethnic and geographic differences between 
the populations studied. Six (86%) out of 7 biallelic MYH mutation carriers 
were found to have less than 100 polyps at the time of diagnosis and 5 (71%) 
had developed colorectal cancer. Thus, in contrast to initial studies reporting 
classical disease (>100 adenomas) in all biallelic mutation carriers7, the MYH 
associated-polyposis phenotype in our patients is predominantly an 
attenuated one, which is in accordance with recent data from Enholm et al.103, 
who investigated a population-based series of Finnish CRC patients.  
On the basis of clinicopathological features, it is virtually impossible to 
discriminate biallelic from monoallelic MYH mutation carriers and MYH 
mutation-negative polyposis patients who have a family history compatible 
with autosomal recessive inheritance. In all groups, median age at diagnosis 
did not differ significantly, and the occurrence of extracolonic disease was 
similar. Colorectal adenocarcinomas, however, were significantly (p < 0.001) 
more frequent among biallelic as compared to that of monoallelic MYH 
mutation carriers and MYH mutation-negative polyposis patients.  
In conclusion, biallelic MYH germline alterations were identified in 
15.5% of Swiss APC mutation-negative patients with a family history 
compatible with autosomal recessive inheritance. Biallelic mutation carriers 
were more frequently observed in AFAP patients compared to those with 
classical FAP (17% vs. 10%). Colorectal cancer was significantly more 
frequent in biallelic as compared to monoallelic mutation carriers or those 
without MYH alterations. Based on our experience and earlier reports, we 
suggest that MYH mutation screening should be offered to individuals who 
fulfill all of the following criteria: (i) presence of classical or attenuated 
polyposis, (ii) absence of an APC germline mutation and (iii) a family history 
compatible with an autosomal recessive mode of inheritance. It remains to be 
determined within the framework of international collaborative studies if 
monoallelic MYH mutation carriers, compared to the general population, may 
actually be at an increased risk for developing colorectal cancer105.
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ABSTRACT 
Background & Aims: Germline mutations in the DNA mismatch repair (MMR) 
genes MSH2, MSH6 or MLH1 predispose to colorectal cancer (CRC) with an 
autosomal dominant inheritance pattern. The protein encoded by PMS2 is 
also essential for MMR; however, alterations in this gene have been 
documented only in extremely rare cases. We addressed this unexpected 
finding by analyzing a large series of CRCs. Methods: Expression of MSH2, 
MSH6, MLH1, and PMS2 was studied by immunohistochemistry in 1048 
unselected, consecutive CRCs. Where absence of MMR proteins was 
detected, microsatellite instability and cytosine methylation of the respective 
gene promoter were analyzed. The DNA of patients presenting with PMS2-
deficient cancers was examined for germline and somatic alterations in the 
PMS2 gene. Results: An aberrant pattern of MMR protein expression was 
detected in 13.2% of CRCs. Loss of expression of MSH2, MSH6, or MLH1 
was found in 1.4%, 0.5%, and 9.8%, respectively. PMS2 deficiency 
accompanied by microsatellite instability was found in 16 cases (1.5%) with a 
weak family history of cancer. The PMS2 promoter was not hypermethylated 
in these cases. Despite interference of the PMS2 pseudogenes, we identified 
several heterozygous germline mutations in the PMS2 gene. Conclusions: 
PMS2 defects account for a small but significant proportion of CRCs and for a 
substantial fraction of tumors with microsatellite instability. However, the 
penetrance of heterozygous germline mutations in PMS2 is considerably 
lower than that of mutations in other MMR genes. The possible underlying 
causes of this unorthodox inheritance pattern are discussed.  
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INTRODUCTION 
Repair of mismatches, non-Watson-Crick base pairs arising during DNA 
replication or recombination, requires the mismatch repair (MMR) proteins 
MSH2, MSH3, MSH6, MLH1, and PMS2 and several factors involved in DNA 
replication106. Most base-base mismatches (G/T, G/G, and so on) are 
recognized by the MSH2/MSH6 heterodimer, whereas small insertion/deletion 
loops arising in mononucleotide and dinucleotide repeats (the so-called 
microsatellites) through strand misalignments can be bound either by the 
MSH2/MSH6 or the MSH2/MSH3 heterodimer. The partial redundancy of 
MSH3 and MSH6 in the repair of insertion/ deletion loops has a profound 
effect on microsatellite instability (MSI), one of the key phenotypic traits of 
MMR-deficient tumors107,108. Thus, whereas MSH2-deficient tumors invariably 
display MSI because both heterodimers are defective, the degree of MSI in 
MSH6deficient tumors can vary109-111 because the MSH2/MSH3 heterodimer 
partially compensates for the loss of MSH2/ MSH6 in insertion/deletion loop 
repair112,113. The converse is not true, however, because the MSH2/MSH6 
heterodimer compensates for the absence of MSH2/MSH3 in 
insertion/deletion loop repair. Correspondingly, primary alterations in the 
MSH3 gene have not been found in tumors with MSI. Like their biological 
roles, the biochemical characteristics of the 3 MSH polypeptides also differ, 
inasmuch as MSH2 deficiency leads to the proteolytic degradation of both 
MSH3 and MSH6, whereas MSH2 is largely stable in the absence of one of its 
cognate partners106. This means that cells with destabilized MSH2 will also 
appear as MSH3 and MSH6 negative in immunohistochemistry, whereas cells 
with mutated MSH3 or MSH6 will be seen to lack solely the affected 
polypeptide.  
The MLH1/PMS2 heterodimer was suggested to act as a matchmaker 
between the mismatch recognition complex and the downstream MMR 
factors106. Interestingly, as in the case of the MSH proteins, the stabilities of 
the MLH1 and PMS2 polypeptides are different. Thus, when MLH1 is not 
expressed or when it is mutated such that it is either destabilized or it cannot 
interact with PMS2, the latter protein is degraded. In contrast, MLH1 remains 
stable in the absence of PMS2113,114, possibly through interactions with other 
MutL homologues such as PMS1 or MLH3.  
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MSI analyses of tumor DNA suggested that 10%– 20% of colorectal cancers 
(CRC) may be associated with MMR system malfunctions115. In sporadic (i.e., 
nonfamilial) CRCs, the MMR defect is associated with the silencing of MLH1 
transcription by cytosine methylation116. In families affected by hereditary 
nonpolyposis colon cancer (HNPCC, also called Lynch syndrome), MMR 
malfunction has been linked primarily with heterozygous germline mutations in 
MSH2 or MLH1. Due to the partial functional redundancy of MSH3 and 
MSH6, germline alterations in MSH6 are less frequent and are associated 
with colon and endometrial cancers in families that often do not fulfill 
Amsterdam criteria for diagnosis of HNPCC117,118 (sometimes referred to as 
“HNPCC-like” or “attenuated HNPCC”). Nevertheless, the inheritance pattern 
in families carrying MSH6 germline mutations is autosomal dominant, as in 
families with germline alterations in MSH2 or MLH1. Germline mutations in 
the PMS2 gene have been reported in 6 subjects presenting with a severe 
childhood cancer syndrome characterized by CRC and brain tumors in the 
first 2 decades of life (3 cases were diagnosed as Turcot’s syndrome)51,119-123. 
A careful mutational analysis in these cases showed that the germline 
alterations were biallelic, suggesting a recessive inheritance pattern 
reminiscent of similar syndromes observed in children found to be compound 
heterozygotes or true homozygotes for mutations in MSH2 or MLH1124-128. To 
date, heterozygous germline mutations in PMS2 have not been reported in 
HNPCC families as defined by Amsterdam criteria. This finding is contrary to 
expectations, because PMS2 is essential for MMR. MLH1 can interact with 
other partners, notably PMS1114 and MLH3129 (Cannavó et al., manuscript in 
preparation); however, neither heterodimer could be shown to play a major 
role in human MMR. Correspondingly, cell lines not expressing PMS2 display 
MSI and their extracts are MMR deficient to an extent similar to that observed 
in cells mutated in MLH1 or MSH2114,130,131. It might therefore be anticipated 
that, similarly to MSH2, MLH1, and MSH6, germline mutations in a single 
PMS2 allele would predispose to CRC. We addressed this curious finding by 
analyzing the expression of PMS2 along with that of its heterodimeric partner 
MLH1 and with that of MSH2 and MSH6 in a large series of unselected CRCs. 
This approach, supported by the analysis of the PMS2 gene, allowed us to 
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identify patients affected by cancers with a primary defect of PMS2 (i.e., not 
secondary to an MLH1 defect) and to describe their phenotype.  
 
PATIENTS AND METHODS  
Patients  
Between January 2000 and June 2002, 1048 consecutive CRCs were 
collected from patients who underwent surgery at 5 Swiss hospitals: Triemli 
Hospital Zurich (F.B.), University Hospital Zurich (H.-M.R.), Cantonal Hospital 
of Lucerne (J.-O.G.), Cantonal Hospital of Aarau (H.Y.), and Cantonal 
Hospital of St Gallen (J.N.). No tumors were excluded from this study. In the 
first instance, the expression of MSH2, MSH6, MLH1, and PMS2 was 
investigated by immunohistochemistry. In tumors with aberrant patterns of 
MMR protein expression, MSI analysis was performed using the 
mononucleotide marker BAT26. We then analyzed the methylation status of 
the MLH1 or PMS2 gene promoters in tumors not expressing MLH1 or PMS2, 
respectively. Finally, for patients presenting with PMS2-deficient tumors, 
blood and tumor DNA were analyzed for the presence of germline and 
somatic mutations and for the loss of heterozygosity (LOH) at the PMS2 
locus.  
Information about the family history of cancer was obtained from a 
questionnaire sent to the family doctors and to the patients. In our study, 
cases fulfilling the Amsterdam criteria II (or revised Amsterdam criteria)117 for 
diagnosis of HNPCC are designated “AC,” whereas cases not complying with 
AC but fulfilling the revised Bethesda guidelines for MSI testing (Table 2 of 
Umar et al.47; guidelines for the identification of tumors that should be tested 
for MSI) are designated “BG.” Cases fulfilling neither AC nor BG are termed 
“sporadic.”  
The study protocol was approved by the institutional review boards.  
 
Immunohistochemistry  
Tumors were fixed in buffered formalin and embedded in paraffin. Four-
micrometer sections were mounted on glass slides coated with organosilane 
(DakoCytomation, Glostrup, Denmark), deparaffinized, and rehydrated. 
Antigen retrieval was accomplished by heating the sections in a pressure 
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cooker at 120°C for 2 minutes in 10mmol/L citrate-buffered solution (pH 6.0). 
DakoCytomation peroxidase blocking reagent and goat serum were 
sequentially used to suppress nonspecific staining due to endogenous 
peroxidase activity and unspecific binding of antibodies, respectively. 
Incubations with primary monoclonal antibodies were performed as follows: 
antihMSH2, 24 hours at 4°C with 1µg/mL antibody NA26 (Oncogene 
Research, Darmstadt, Germany); anti-hMSH6, 2 hours at room temperature 
with 4µg/mL antibody G70220 (Transduction Laboratories, Basel, 
Switzerland); anti-hMLH1, 1 hour at room temperature with 1.2µg/mL antibody 
13271A (PharMingen, Basel, Switzerland); anti-hPMS2, 24 hours at 4°C with 
3µg/mL antibody 65861A (PharMingen, Basel, Switzerland). After washing, 
anti-mouse secondary antibodies conjugated to peroxidase-labeled polymer 
(Dako EnVision+ kit) were applied for 30 minutes at room temperature, and 
the peroxidase activity was developed by incubation with 3,3’-
diaminobenzidine chromogen solution (Dako). The sections were then 
counterstained with hematoxylin. Lack of protein expression was clearly 
evident as absence of nuclear staining in tumor cells despite nuclear staining 
in proliferating cells in normal crypts and stroma.  
 
MSI, LOH, and PMS2 Sequencing  
DNA was extracted from histologic sections and blood with QIAamp DNA and 
DNeasy, whereas RNeasy and Omniscript/Sensiscript RT kits (Qiagen, Basel, 
Switzerland) were used for RNA isolation and complementary DNA synthesis. 
MSI analysis was performed by analyzing the mononucleotide repeat BAT26 
and, for PMS2-deficient tumors, several dinucleotide repeats on chromosome 
7p22. LOH analysis was performed using 8 microsatellite markers flanking 
PMS2 on chromosome 7p22. LOH was scored at any informative marker if 
the area under one allelic peak in tumor DNA was reduced by >50% relative 
to the other allele after correcting for the relative peak areas in DNA from 
normal tissue. Search for germline mutations was performed on genomic DNA 
and complementary DNA by sequencing all 15 PMS2 exons and their intron-
exon boundaries. Primers described by Nicolaides et al.132 were used except 
for exons 1, 3, 5, and 10–14, for which new primers were designed to allow a 
more specific amplification and to avoid coamplification of PMS2 
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pseudogenes. All primers and reaction conditions are reported in 
supplementary table 1 (see appendix).  
 
Promoter Methylation Status  
Genomic DNA was subjected to sodium bisulfite conversion. Briefly, 2 µg of 
DNA was denatured in 0.3N NaOH at 37°C for 20 minutes and then incubated 
in 3mol/L sodium bisulfite and 500 µmol/L hydroquinone at 50°C for 16–18 
hours. After desalting with Wizard DNA Clean-Up System (Promega, 
Walliselen, Switzerland), the bisulfite-treated DNA was desulfonated with 0.3N 
NaOH for 20 minutes at 37°C, neutralized with ammonium acetate, ethanol 
precipitated, and resuspended in 20 µL of water. The methylation status of 2 
overlapping regions in the PMS2 promoter rich in CpG sites (although not 
fulfilling the classic CpG island definition133) and of an MLH1-promoter region 
critical for gene silencing was evaluated by a real-time polymerase chain 
reaction (PCR) approach and confirmed by methylation-specific PCR (see 
supplementary table 1 in the appendix). The analysis of melting curves after 
real-time PCR and of specific bands in agarose gel electrophoresis after 
methylation-specific PCR permitted a reliable differentiation between 
methylated and unmethylated alleles.  
 
Statistical Analysis  
Descriptive statistical analysis used analysis of variance, χ2 tests, t tests, and 
Fisher exact tests. Logistic regression was used to analyze the variables 
associated with MMR-deficient tumors and to evaluate their independent 
effects. 
 
RESULTS 
The clinical characteristics of the study population are listed in Table 1. Based 
on the absence of MMR proteins, as judged by immunohistochemistry, 139 
CRCs (13.2%) were classified as MMR deficient. These tumors occurred 
significantly more frequently in women (P < .001) and in the proximal colon (P 
< .001) and showed lower frequency of lymph node involvement (P < .001) 
and degree of cell differentiation (P < .001) than MMR-proficient CRCs. 
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Logistic regression of MMR status on these variables confirmed their 
independent effects (footnote in Table 1).  
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Table 1  Characteristics of Patients and CRCs in Relation to Tumor MMR Status 
MMR-
proficient 
Difference Characteristics All cases 
CRC 
MMR-
deficient 
CRC (95% Cl) 
pa 
Patients no. (%) 1048 (100) 909 (86.7) 139 (13.2)   
Age at presentation, y      
 Mean (+SD) 69.7 (11.9) 69.7 (11.4) 69.9 (14.9)  0.82 
 Median  71 71 74  
 Range 23 – 94 23 – 93 27 – 94   
Sex, no. (%)      
 Male 609 (58.1) 547 (60.2) 62 (44.6) 15.6 (6.8 – 24.3) < .001 
 Female 439 (41.9) 362 (39.8) 77 (55.4)   
Site of Tumor, no. (%)      
 Cecum 127 (12.1) 92 (10.1) 35 (25.2)  <.00005 
 Ascending colon 134 (12.8) 84 (9.2) 50 (36.0)   
 Hepatic flexure 34 (3.2) 25 (2.8) 9 (6.5)   
 Transverse colon 48 (4.6) 40 (4.4) 8 (5.8)   
 Splenic flexure 21 (2.0) 19 (2.1) 2 (1.4)   
 Descending colon 36 (3.4) 29 (3.2) 7 (5.0)   
 Sigmoid colon 343 (32.7) 329 (36.2) 14 (10.1)   
 Rectum 305 (29.1) 291 (32.0) 14 (10.1)   
 Proximal to splenic flexure 343 (32.7) 241 (26.5) 102 (73.4) 46.9 (39.0 – 54.8) <.00005 
 Distal to splenic flexure 705 (67.3) 668 (73.5) 37 (26.6)   
Pathologic classification of the 
primary tumor, no. (%)b 
     
 T1 70 (6.7) 63 (6.9) 7 (5.0)   
 T2 163 (15.6) 146 (16.1) 17 (12.2)   
 T3 636 (60.7) 544 (59.8) 92 (66.2)   
 T4 179 (17.1) 156 (17.2) 23 (16.5)   
Pathologic classification of the 
regional lymph nodes, no. (%)b 
     
 N0 573 (54.7) 479 (52.7) 94 (67.6)  0.003 
 N1 266 (25.4) 244 (26.8) 22 (15.8)   
 N2 209 (19.9) 186 (20.5) 23 (16.5)   
No lymph node involvement 573 (54.7) 479 (52.7) 94 (67.6) 14.9 (6.1 – 23.8) <.001 
Lymph node involvement 475 (45.3) 430 (47.3) 45 (32.3)   
Tumor grade, no. (%)      
 Well differentiated (G1) 27 (2.6) 25 (2.8) 2 (1.4) 23.6 (16.5 – 30.7) <.00005c 
 Moderately differentiated (G2) 806 (76.9) 726 (79.9) 80 (57.5)   
 Poorly differentiated (G3) 215 (20.5) 158 (17.4) 57 (41.0)     
CI, confidence interval. 
a Comparison between MMR-proficient and -deficient CRCs (t and χ2 tests). Logistic regression: the 
odds ratio was 1.6 (95%CI, 1.1 – 2.4) for women versus men, 7.1 (95%CI, 4.7 – 10.9 for proximal 
versus distal colon, 3.1 (95%CI, 2.0 – 4.8) for no lymph node involvement and 3.4 (95% CI, 2.2 – 5.2) 
for poorly versus well plus moderately differentiated tumors 
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b TNM and tumor grade classification according to Sobin LH, Wittekin DH, TNM claffication of malignant 
tumors, 6th ed. New York,: WiIley-Liss, 2002. Only T and N stages are reported because they are 
histologically confirmed in all cases. 
c Comparison between well plus moderately differentiated and poorly differentiated tumors 
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 Table 2  Characteristics of Patients With MMR-Deficient Tumors 
    CRCs not expressing 
  MLH1  PMS2  MSH2  MSH6 
  All cases Total AC or BGa Sporadica   Total AC or BGa Sporadica   Total AC or BGa Sporadica   Total AC or BGa Sporadica 
Patients, no.(%) 139 103 (74) 28 (29) 68 (71)  16 (11.5) 12 (75) 4 (25)  15 (10.8) 9 (82) 2 (18)  5 (3.6) 3 (75) 1 (25) 
Age at presentation, y                 
    Mean (+SD) 69.9 (14.9) 72.6 (14.1) 57.9 (15.7) 78.5 (8.2)  62.8 (14.7) 59.4 (15.4) 73.0 (5.0)  62.5 (17.2) 52 (12.7) 69.0 (7.1)  60.4 (5.1) 62.3 (6.1) 58 
    Median 74 76 57 78  61.5 57 74.5  64 53 69  58 61  
    Range 27-94 27-94 27-91 52-94  42-82 42-82 66-77  34-87 34-71 64-74  57-69 57-69  
Sex, no.(%)                 
    Male 62 (45) 39 (38) 13 (46) 25 (37)  14 (88) 10 (83) 4 (100)  7 (47) 5 (56) 1 (50)  2 (40) 0 1 (100) 
    Female 77 (55) 64 (62) 15 (54) 43 (63)  2 (12) 2 (17) 0  8 (53) 4 (44) 1 (50)  3 (60) 3 (100) 0 
Site of tumor, no.(%)                 
    Cecum 35 (25) 31 (30) 6 (21) 23 (34)  1 (6) 1 (8) 0  3 (20) 1 (11) 1 (50)  0 0 0 
    Ascending colon 50 (36) 35 (34) 6 (21) 28 (41)  7 (44) 3 (25) 4 (100)  6 (40) 4 (44) 0  2 (40) 2 (67) 0 
    Hepatic flexure 9 (6) 8 (8) 2 (7) 6 (9)  1 (6) 1 (8) 0  0 0 0  0 0 0 
    Transverse colon 8 (6) 7 (7) 1 (4) 6 (9)  1 (6) 1 (8) 0  0 0 0  0 0 0 
    Splenic flexure 2 (1) 0 0 0  2 (13) 2 (17) 0  0 0 0  0 0 0 
    Descending colon 7 (5) 4 (4) 3 (11) 0  2 (13) 2 (17) 0  1 (7) 1 (11) 0  0 0 0 
    Sigmoid colon 14 (10) 11 (11) 5 (18) 3 (4)  1 (6) 1 (8) 0  1 (7) 1 (11) 0  1 (20) 1 (33) 0 
    Rectum 14 (10) 7 (7) 5 (18) 2 (3)  1 (6) 1 (8) 0  4 (27) 2 (22) 1 (50)  2 (40) 0 1 (100) 
    Proximal to splenic flexure 102 (73) 81 (79) 15 (54) 63 (93)  10 (63) 6 (50) 4 (100)  9 (60) 5 (56) 1 (50)  2 (40) 2 (67) 0 
    Distal to splenic flexure 37 (27) 22 (21) 13 (46) 5 (7)  6 (37) 6 (50) 0  6 (40) 4 (44) 1 (50)  3 (60) 1 (33) 1 (100) 
Pathological classification of the primary tumor, no. (%)b                
    T1 7 (5) 5 (5) 3 (11) 1 (2)  2 (13) 1 (8) 1 (25)  0 0 0  0 0 0 
    T2 17 (12) 13 (13) 3 (11) 9 (13)  1 (6) 1 (8) 0  3 (20) 2 (22) 0  0 0 0 
    T3 92 (66) 68 (66) 18 (64) 45 (66)  10 (63) 8 (67) 2 (50)  10 (67) 6 (67) 2 (100)  4 (80) 2 (67) 1 (100) 
    T4 23 (17) 17 (16) 4 (14) 13 (19)  3 (19) 2 (17) 1 (25)  2 (13) 1 (11) 0  1 (20) 1 (33) 0 
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    CRCs not expressing 
  MLH1  PMS2  MSH2  MSH6 
  All cases Total AC or BGa Sporadica   Total AC or BGa Sporadica   Total AC or BGa Sporadica   Total AC or BGa Sporadica 
Pathological classification of the regional lymph nodes, no. (%)b              
    N0 94 (68) 67 (65) 18 (64) 44 (65)  14 (88) 10 (83) 4 (100)  11 (73) 6 (67) 2 (100)  2 (40) 1 (33) 1 (100) 
    N1 22 (16) 20 (19) 5 (18) 13 (19)  1 (6) 1 (8) 0  0 0 0  1 (20) 0 0 
    N2 23 (17) 16 (15) 5 (18) 11 (16)  1 (6) 1 (8) 0  4 (27) 3 (33) 0  2 (40) 2 (67) 0 
No lymph node involvement 94 (68) 67 (65) 18 (64) 44 (65)  14 (88) 10 (83) 4 (100)  11 (73) 6 (67) 2 (100)  2 (40) 1 (33) 1 (100) 
Lymph node involvement 45 (32) 36 (35) 10 (36) 24 (36)  2 (12) 2 (17) 0  4 (27) 3 (33) 0  3 (60) 2 (67) 0 
Tumor grade, no. (%)                 
    Well differentiated (G1) 2 (1) 2 (2) 1 (4) 1 (1)  0 0 0  0 0 0  0 0 0 
    Moderately differentiated (G2) 80 (56) 55 (53) 22 (79) 29 (43)  12 (75) 8 (67) 4 (100)  9 (60) 6 (67) 2 (100)  4 (80) 2 (67) 1 (100) 
    Poorly differentiated (G3) 57 (41) 46 (45) 5 (18) 38 (56)  4 (25) 4 (33) 0  6 (40) 3 (33) 0  1 (20) 1 (33) 0 
MSIc                 
    Unstable 127 (92)d 99 (96) 27 (96) 66 (97)  15 (100) d 11 (100) 4 (100)  12 (80) 7 (78) 2 (100)  1 (20) 1 (33) 0 
    Stable 11 (8) 4 (4) 1 (4) 2 (3)  0 0 0  3 (20) 2 (22) 0  4 (80) 2 (67) 1 (100) 
Promotor methylatione                 
    Present 84 (82) 14 (50) 65 (96) 0  0 0          
    Absent 19 (18) 14 (50) 3 (4) 15 (100)d   11 (100) 4 (100)                   
 
a Percentage refers to the number of patients whose family pedigree was available (MSH2, 11; MSH6, 4; MLH1, 96; PMS2, 16; for details see 
supplementary Table 2). Sporadic CRCs were separated from those fulfilling the AC for HNPCC diagnosis or BG for MSI testing (for definitions, see 
Patients and Methods). 
b TNM and tumor grade classification according to Sobin LH, Wittekind CH. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss, 
2002. Only T and N stages are reported because they are histologically confirmed in all cases. 
c MSI as detected by BAT26 analysis, except for PMS2 cases where dinucleotide repeats flanking PMS2 on chromosome 7 were also investigated. 
d In one case, DNA was not suitable for analysis 
e Only MLH1 or PMS2 promoter were analyzed in MLH1-deficient or PMS2-deficient CRCs, respectively 
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Figure 1 Immunohistochemical staining of colorectal tumors for MMR proteins.   
(A) MLH1 is absent from tumor tissue, but normal crypts (upper part of the 
picture) and proliferating stromal cells express this protein normally.  
(B) The same tumor does not express PMS2, because this protein is unstable in 
the absence of MLH1. However, other MMR proteins are expressed normally, as 
shown for MSH2 (inset). (C) The dysplastic crypts on the right side of this 
tumor express MLH1 levels similar to the normal crypts on the left; (D) 
however, the dysplastic crypts are deficient in PMS2. 
 
Table 2 lists the characteristics of patients presenting with MMR-deficient tumors. A 
total of 103 of the MMR-deficient CRCs (74%) lacked MLH1 expression and 
consequently also PMS2 (see the introduction). These tumors are referred to as 
“MLH1 deficient.” PMS2 was lacking in 16 MMR-deficient CRCs (11.5%) in which 
MLH1 was expressed normally (Figure 1). The latter tumor category is referred to as 
“PMS2 deficient.” MSH2 was not detected in the 15 tumors (10.8%) in which MSH6 
was also undetectable (“MSH2-deficient” category), whereas MSH6 was lacking in 5 
tumors (3.6%) that expressed MSH2 normally (“MSH6-deficient” tumors). For the 
sake of consistency, cases not fulfilling the AC or BG were designated as sporadic in 
this table (see Patients and Methods for definition of AC and BG; as reported in the 
footnote to Table 2, 127 of the 139 pedigrees were available). The vast majority of 
sporadic tumors were deficient in MLH1. These tumors represented about half of the 
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entire group of MMR-deficient tumors. MLH1-deficient CRCs appear to have a 
higher average age of onset as compared with the other 3 groups (P=.004). 
However, this is due to the very late onset of sporadic MLH1-deficient tumors 
(P<.001, as compared with nonsporadic MLH1-deficient tumors). In contrast to 
CRCs not expressing MSH2, MSH6, and MLH1, the majority of PMS2-deficient 
tumors occurred in men (P=.003). The preferential occurrence of MMR-deficient 
tumors in the right colon was evident in all 4 groups, particularly in sporadic, MLH1-
deficient CRCs (P<.001, as compared with the nonsporadic counterpart). No 
relevant differences among the 4 groups were found with regard to other variables; 
however, sporadic, MLH1-deficient CRCs were more often poorly differentiated than 
nonsporadic ones (P<.001). A detailed list of the MMR-deficient cases is reported in 
Supplementary Table 2 (see appendix). The clinical and genetic evaluation of  
MLH1-, MSH2-, and MSH6-deficient cases is under way. Few of the MMR-deficient 
tumors identified in this study were shown to originate from patients whose families 
are already on the Swiss Familial CRC Registry and in which the germline mutations 
are known. The results of this study will be the subject of another report.  
As shown in table 2, 92% (127 of 138; in one case, the DNA was not suitable 
for analysis) of MMR-deficient tumors displayed MSI at the BAT26 locus, which is 
generally considered one of the most sensitive and reliable markers of MSI. The fact 
that the BAT26 marker was stable in 4 of 5 MSH6-deficient CRCs was not surprising 
due to the functional redundancy between MSH6 and MSH3 (see the introduction). 
The latter protein was indeed expressed in all 5 MSH6-negative cases (data not 
shown). Eighty-four of 103 MLH1-deficient tumors (82%) showed MLH1 promoter 
hypermethylation (Table 2), which was more frequent in sporadic cancers (P < .001), 
as anticipated (see the introduction). However, promoter hypermethylation was also 
present in half of the MLH1-deficient cases fulfilling AC or BG (4 and 10 patients, 
respectively; details in supplementary table 2, see appendix). This could represent 
either a mechanism of somatic inactivation of the wild-type allele in a tumor carrying 
a germline mutation or a germline epimutation134. It is noteworthy that analysis of 
MLH1-promoter methylation by real-time PCR proved to be as reliable as 
methylation-specific PCR (Supplementary Table 1; see appendix).  
The immunohistochemical screening identified 16 PMS2-deficient tumors 
(Table 3). As shown in figure 2 (top panels), inactivation of both PMS2 alleles in the 
tumor appeared to be a very early event, occurring already in small benign 
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adenomas. Because PMS2 was invariably expressed in normal tissues of the 
affected individuals, the presence of biallelic germline PMS2 alterations could be 
excluded. In 5 patients, the tumors presented before the age of 50 years; in 3 
patients, the tumors presented between 50 and 60 years of age. Two additional 
patients with CRC in their late 70s had had a previous CRC ∼20 years earlier. 
Previous or synchronous adenomatous polyps were a common finding, and              
4 patients were also affected with prostate, brain, or skin cancers. Fourteen patients 
(87.5%) were men. Ten tumors (62.5%) were located in the proximal colon, and only 
2 (12.5%) showed lymph node involvement. Some of the previous or synchronous 
tumors of the index patients were available for immunohistochemistry and were also 
found to be lacking PMS2 expression (Table 3 and Figure 2). The cancer spectrum 
in relatives included CRCs (mean age, 48 years; range, 31–60 years) and cancers of 
other organs, often at earlier-than-average age of onset. Finally, BG were fulfilled in 
12 of 16 cases. PMS2-deficient tumors showed MSI at BAT26 and at the 
dinucleotide markers used for LOH evaluation at the PMS2 locus (Table 3). The 
same markers were stable in leukocyte-derived DNA. The LOH analysis was heavily 
affected by widespread MSI; however, it was clearly present in 6 tumors and neither 
excluded nor proven in the remaining cases. The PMS2 promoter was unmethylated 
in all cases (Table 2). Using the approach described in Patients and Methods, we 
have been able to identify PMS2 germline mutations in 6 patients (Table 3). All 6 are 
highly likely to be linked to CRC predisposition, because they lead to premature 
termination of PMS2 synthesis either as a result of frameshifts (4 insertions and one 
deletion) or a point mutation (Gln → stop). Because all of the truncated proteins 
would lack the MLH1-interacting domain, which is required for PMS2 stabilization, 
they would be rapidly degraded. Moreover, it is possible that the mutant messenger 
RNA will be degraded by nonsense-mediated decay. No germline mutations have to 
date been identified in the remaining cases, but mutations in MLH1 were not found, 
thus excluding categorically the possibility that PMS2 deficiency might be secondary 
to defects of MLH1. 
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Table 3 Characteristics of Patients With CRCs Not Expressing PMS2 
                  Other tumors   Tumors in family members     
Patient 
no. 
Age 
(y) Sex Site  Stage a Grade a MSIb LOH 
PMS2 Germline 
Mutationc f Organ Histology 
Age 
(y)   Relative Organ 
Age 
(y)   
AC 
and 
BG 
64501 79 M D T3N0M0 2 P NVd NVe Colon Carcinoma 57      BG2 
         Colon Adenomaf 79       
53072 57 M A T3N0M0 2 P LP NF     Sister Colon 31  BG4 
             Sister Pancreas 60   
             Brother Lymphoma 47   
61263 73 M A T3N0M0 2 P LP NF          
66543 77 F T T4N0M0 2 P NVd Exon 11: Colon Adenomaf 77  Sister Breast 35  BG4 
            1828insA     Sister Liver 77   
             Daughter Uterus 42   
66732 46 M D T3N0M0 2 P NVd Exon 11: Colon Adenomaf 46      BG1 
            1828insA          
52557 77 M A T1N0M0 2 P NVd NF Colon Adenomag 76       
54832 42 M A T3N0M0 2 P LP Exon 11:         BG1 
            1828insA          
53989 57 M SF T2N0M0 2 P NVd Exon 10: Prostate Carcinomaf 55  Brother Pancreas 39  BG4 
            1018delA          
61162 82 M C T3N0M0 3 P NVd NF Skin 
Squamos cell 
carcinomaf 75  Father Stomach 50  BG4 
65950 43 M R T3N0M0 3 P LP NF     Mother Brain 58  BG1 
             Uncle Bladder 54   
             Uncle Lung 68   
59519 78 M SF T3N0M0 3 P NVd NF Colon Carcinomaf 59      BG2 
         Colon Adenomag 78       
11318 46 F S T3N0M0 2 P NVd NF     Aunt Colon 60  BG1 
20498 76 M A T3N0M0 2 P LP NF Prostate Carcinomaf 68  Father Prostate 64   
             Mother Breast 40   
16655 66 M A T4N0M0 2 P NVd Exon 11: Colon Adenomag 66  Brother Lung 70   
            1828insA     Brother Stomach 65   
5194 57 M HF T4N2M1 3 P LP NVe Colon Adenomaf 57  
Grandfathe
r Colon 55  BG3 
27499 49 M A T1N0M0 2 ND ND Exon 6: Brain i 9  Sister Colon 41   
                703C>T Colon Adenomag 49  
Grandfathe
r Colon 55   
                    (Q235X)                   
M, male; F, female; D, descending colon; A, ascending; T, transversum; SF, splenic flexure; C, cecum; R, rectum; S, 
sigmoid colon; HF, hepatic flexure; P, present: in all cases MSI was present in both BAT26 and in dinucleotides 
except for tumors 52557 and 11318, where only the latter repeats were found unstable; ND, DNA extracted from 
microdissection was not suitable for MSI and LOH analyses; NV, not verifiable; LP, likely present; NF, not found with 
this approach. 
aTNM and tumor grade classification according to Sobin LH, Wittekind CH. TNM classification of malignant tumors. 
6th ed. New York: Wiley-Liss, 2002.  
bMSI at BAT26 and dinucleotide repeats on chromosome 7p22.  
cAfter sequencing all exons and intron-exon boundaries.  
dBecause of widespread MSI.  
eBecause blood was not available (patients deceased).  
fThis tumor does not express PMS2.  
gThis tumor expresses PMS2. The only case in which the lack of PMS2 expression did not affect the entire tumor.  
iHistology was not available, because the tumor was treated with radiotherapy. 
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Figure 2 Immunohistochemical staining of a colon adenoma and extracolonic cancers 
for the MMR proteins MLH1 and PMS2. PMS2 is not expressed in the 2 mildly 
dysplastic crypts of a 2-mm benign colon adenoma (upper panels, asterisks; 
higher magnification is shown in the right panel; case 66732 of Table 3), in a 
prostate carcinoma (middle panels; case 20498), and in a squamous cell 
carcinoma (lower panels; case 61162). Note that, in the latter 2 samples, PMS2 
is expressed in nonneoplastic tissues and MLH1 is expressed in both normal 
tissue and tumor tissue. 
 
 
 
 
 
 
 
PMS2 study 
 
 75 
DISCUSSION 
Immunohistochemical analysis of a large, consecutive series of unselected CRCs 
revealed that 13.2% were MMR deficient. Due to the biochemical properties of the 
MMR proteins (see the introduction), the use of antibodies against all 4 polypeptides 
of the 2 principal MMR heterodimeric complexes not only increased the accuracy of 
the immunostaining in detecting MMR-deficient cancers but also permitted the 
identification of tumors with a primary alteration of PMS2 (Figure 1). In this respect, 
our work differs from the other screening studies described to date, which used 
selection procedures that enriched for subjects with a clear family history of CRC or 
omitted PMS2 analysis111,135-140. 
Although immunohistochemistry is an extremely reliable tool for the detection 
of mutations that result in truncation and/or degradation of the antigen, it cannot 
distinguish between cells expressing variants of proteins carrying missense 
mutations that inactivate, but do not destabilize, the protein and cells expressing 
wild-type polypeptides. Correspondingly, we cannot exclude the possibility that a 
finite number of the analyzed CRCs harbored such MMR gene mutations. However, 
this number is expected to be very low, because all AC- or BG-fulfilling CRCs with 
MSI were accounted for by the lack of one of the 4 MMR proteins. In addition, in the 
Swiss Familial CRC Registry, most of the disease-associated MSH2 and MLH1 
germline missense mutations were characterized either by the lack of protein 
staining in tumor cells or, more rarely, by a weak and diffuse (cytoplasmic and 
nuclear) antigen staining (manuscript in preparation). This does not apply to sporadic 
tumors, where silencing of MLH1 expression and subsequent degradation of PMS2 
make the immunohistochemical analysis straightforward.  
Thus, immunohistochemical analysis of MMR protein expression in CRCs 
should be encouraged, especially considering the implications of such screening for 
the follow-up and treatment of MMR-deficient tumors141. The frequency of MLH1-
deficient sporadic CRCs is expected to increase worldwide because of population 
aging in developed and developing countries. In familial CRCs, 
immunohistochemistry helps identify the mutated gene and encourages the use of 
alternative procedures of mutational analysis142-144 in cases in which standard 
methods fail.  
The most striking finding of our study concerns the unexpectedly high 
frequency of PMS2-deficient CRCs (1.5%), which was similar to that of tumors 
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lacking MSH2 (1.4%). The fact that our patients did not belong to HNPCC families as 
defined by AC and were not believed by the physicians to be individuals at risk for 
CRC seemed to argue against their carrying germline PMS2 mutations. However, 
several findings suggested that these cases differed from sporadic CRCs (Table 3). 
Many were diagnosed in patients in their fifth or sixth decade of life, some patients 
were also affected with extracolonic PMS2-deficient tumors, and several relatives 
were identified with CRCs or cancers in other organs at earlier-than-average age of 
onset. The preponderance of PMS2 alterations in men is peculiar but needs 
confirmation in a larger series of patients. In contrast, the prevalent location in the 
proximal colon and the low frequency of lymph node involvement are characteristics 
of all MMR-deficient CRCs. Most importantly, our data suggest that most PMS2-
deficient CRCs can be identified, at least as MMR-deficient tumors, if the revised BG 
were applied regularly. We also excluded methylation of the PMS2 promoter that 
represents an epigenetic mechanism of gene inactivation generally associated with 
sporadic cancers, such as those deficient in MLH1. Taken together, this evidence 
points to germline PMS2 defects. Indeed, a detailed analysis of the PMS2 gene 
identified germline mutations in leukocyte DNA of 6 patients and somatic LOH in 
several tumors despite the genetic “noise” caused by the numerous PMS2 
pseudogenes on chromosome 7121,145 and by MSI (see Patients and Methods). We 
are currently implementing modified protocols for the identification of germline 
mutations or deletions, with the hope of uncovering other genetic alterations. 
Interestingly, we identified 4 subjects carrying the same germline alteration. Although 
the individuals are unrelated, we wanted to find out whether we might be dealing 
with a founder mutation. Unfortunately, the haplotype analysis results were 
inconclusive to date (data not shown). Even if there is a founder effect, this should 
not affect the overall frequency of PMS2-deficient CRCs relative to that of other 
MMR-deficient tumors, because founder mutations have also been reported in 
MSH2 and MLH1146-148.  
Our immunohistochemical data show that PMS2 and MSH2 deficiencies 
occur with similar frequencies and that both defects are linked with germline 
mutations. How is it possible then that mutations in MSH2 cause HNPCC as defined 
by AC, whereas those in PMS2 apparently do not? One possible explanation is that 
MLH1/PMS1 and/or MLH1/MLH3 heterodimers partially compensate for the loss of 
MLH1/PMS2, similar to the partial functional redundancy of MSH2/MSH3 and 
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MSH2/MSH6 (see the introduction). However, we have found that MLH1/PMS1 
heterodimer does not contribute to MMR in vitro114, whereas the contribution of 
MLH1/MLH3 to MMR in vitro is only marginal (Cannavó et al., manuscript in 
preparation). Furthermore, MSI was not detected in the intestinal mucosa of Pms1-/- 
mice149 and in fibroblasts of Mlh3-/- mice150, which were found to be free of morbid 
cancers in the first 14 and 9 months of life, respectively.  
A second explanation might lie in the role of MMR proteins in the response of 
mammalian cells to DNA-damaging agents151. Functional MMR seems to be 
necessary for activating cell cycle checkpoints and cell death on exposure to 
methylating agents and cisplatin, and it might be anticipated that absence of DNA 
damage signaling might favor the survival and thus also transformation of MMR-
deficient cells. If PMS2 involvement in this process were to be smaller than that of 
MSH2 and MLH1, PMS2-deficient cells might not have the same growth advantage 
as those mutated in MSH2 or MLH1. However, this hypothesis is not supported by 
experimental evidence showing that PMS2-deficient cells are as tolerant to killing by 
the methylating agent N-methylN’-nitro-N-nitrosoguanidine as cells deficient in 
MLH1131. 
An alternative, third explanation lies in the finding that chromosome 7, which 
houses the PMS2 gene, accommodates also numerous PMS2 
pseudogenes121,132,145,152-154. The existence of these pseudogenes has been 
documented to interfere with sequence analysis of the PMS2 locus121,145. However, 
they might also serve as a homologous sequence pool for recombination. Thus, 
assuming that the initial frequency of PMS2 germline mutations might be similar to 
that of MLH1, gene conversion events between PMS2 and its pseudogenes might 
result in the reversion of some mutations155, such that the overall mutation frequency 
might decline and resemble that seen at the MSH2 gene. Were such events to occur 
in the germline, this might help explain why germline mutations in PMS2 are 
apparently not inherited in an autosomal dominant manner, like the other MMR gene 
aberrations. In somatic cells, gene conversion might mitigate the severity of the 
PMS2 defects compared with MSH2 or MLH1.  
Our data suggest that PMS2-deficient CRCs associated with heterozygous 
germline alterations in the PMS2 gene will not be found in HNPCC families as 
defined by AC. However, clinical and pathologic data clearly differentiated this group 
of patients from those with sporadic CRCs. We believe that the main reasons why 
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PMS2-deficient tumors went undetected for so long are the following: (1) the 
screening focused on subjects belonging to families with an obvious history of CRC, 
(2) PMS2 staining was not included in many screening studies based on the 
unfounded credence in a minor role of PMS2 in MMR, and (3) mutation detection 
was complicated by the presence of PMS2 pseudogenes. We have noticed, 
however, that immunostaining for PMS2 has been recently included in the screening 
of selected populations111,137,139,140,145. In support of our data, Nakagawa et al.145 
identified 6 PMS2-deficient CRCs, all in patients without a clear family history of 
cancer but presenting with tumors with MSI in which mutations in MSH2, MSH6, and 
MLH1 were previously excluded. Heterozygous germline alterations were detected in 
2 of these patients only after using diploid-to-haploid conversion technique142.  
In conclusion, our study shows that about 1.5% of CRCs, the second most 
frequent cancer in humans, are associated with a genetic defect of the MMR gene 
PMS2. This translates to about 2200 newly diagnosed cases of CRC per year in the 
United States. Thus, many apparently sporadic CRCs with MSI, in which alterations 
in other MMR genes are not detected, might be associated with genetic alterations in 
PMS2. It should be remembered that PMS2 defects could also be found in tumors 
from other organs that display MSI. The characterization of the genetic mechanisms 
underlying PMS2 defects and the phenotypes of this subset of tumors are currently 
the subject of intense study.  
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Addendum: 
cDNA analysis and MLPA investigation of colorectal cancer 
patients with PMS2 deficiency in their tumors 
 
INTRODUCTION 
In the previous part of this thesis the mutation analysis in a cohort of 1048 colorectal 
cancers with immunohistochemical loss of a MMR protein has been described. In 
this study we were able to identify six patients with germline mutations in the PMS2 
gene, but there are still 10 patients with loss of PMS2 in the tumor but without any 
detectable germline mutation.  
 One problem in analyzing genes located on chromosome 7 is the presence of 
pseudogenes, which complicate mutation analysis. Hillier showed that about 45% of 
all genes on chromosome 7 are actually pseudogenes156. The PMS2 gene is located 
on chromosome 7 and 15 pseudogenes have been described of the 5’ part of PMS2 
and 1 nearly 100% homologous pseudogene of the 3’ part121. Only exon 6 – 8 and 
exon 10 of the PMS2 gene represent pseudogene free regions.  
 Another possibility why mutations could not have been detected is the 
presence of large genomic rearrangements like large deletions or duplications. The 
recently introduced MLPA technique allows the identification of such gene copy 
number variations.  
 In order to identify germline mutations in PMS2 in the remaining 10 patients, 
cDNA analysis and the MLPA technique have been applied.  
 
PATIENTS AND METHODS 
Patients 
Out of 1048 tumors collected from patients who underwent surgery in five Swiss 
hospitals, sixteen showed immunohistochemically loss of PMS2 (described in the 
PMS2 study). Using conventional DNA screening methods germline mutations in the 
PMS2 gene have been detected in six patients. In order to detect the reason of the 
loss of PMS2 in the remaining ten patients additional methods as cDNA analysis and 
MLPA investigation were applied. 
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Mutation analysis using mRNA 
To avoid co-amplification of pseudogenes cDNA of PMS2 was analyzed in two 
overlapping segments. The reverse primer of segment 1 and the forward primer of 
segment 2 is located in the pseudogene-free region of exon 10 with subsegments 
amplified in nested PCRs (S1n, S1A, S1B, S2A, S2B, S2C) (Figure 1). The primers 
for the nested PCRs are located at crossovers from one exon to the other. All 
primers and reaction conditions are reported in the appendix. 
 
Figure 1: Schematic delineation of different primers used for PMS2 cDNA analysis  
 
MLPA analysis 
For the detection of aberrant copy numbers in the PMS2 gene in constitutional, 
leukocyte-derived DNA, the SALSA P008 MSH6/PMS2 test MLPA kit (MRC Holland, 
Amsterdam, the Netherlands) was used157. The kit contains probes for the 15 exons 
of PMS2 as well as several probes located on different chromosomes as controls 
(see appendix for probemix). DNA samples from ten healthy probands were used to 
confirm the sensitivity and specificity of the method. All reactions were carried out 
according to the manufacturer’s protocol. Fragment analysis was done on an ABI 
310 capillary sequencer and results were analyzed using the Genescan and 
Genotyper software (Applied Biosystems) to identify the specific amplicons 
representing the respective exons and control loci. Peak areas and heights were 
then exported to a Microsoft Excel spreadsheet and calculations were done 
according to the method described by Taylor et al.158. An average dosage quotient 
close to 0.01 is expected for individuals with two copies, whereas values close to -
0.50 indicate loss and close to 0.50 duplication of one copy.  
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RESULTS 
cDNA analysis 
The cDNA of ten patients with loss of PMS2 in their tumors was screened for 
mutations in two overlapping segments to avoid co-amplification of the pseudogenes 
present for PMS2. The result of the screening is depicted in Table 1.  
After sequencing a frameshift was detected in segment 1 in six patients 
(Patients No. 5, 6, 8, 11, 12, 13). This frameshift is due to a deletion of 54 basepairs 
at the end of exon 4 (c.301_353del53) (Figure 2), which leads to a stop codon after 
120 amino acids (p.Gln100fs120X). To confirm this frameshift, mutation-specific 
primers were designed comprising the respective location. The forward primer was 
located at the exon2/3 and the reverse primer at the exon 5/6 crossover. Using these 
primers the PCR product was smaller and thus, sequencing reaction revealed easier 
and better results (for primer sequences and PCR conditions see appendix).  
In addition to this frameshift three SNPs in Segment 2 were detected: 
c.1621A>G (rs41534544) in all patients except of patient no. 4, c.2324A>G 
(rs17420802) in patient no. 4, and c.1408C>T (rs1805321) in patients no. 1, 9, 10, 
13 and 14.  
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Table 1  Summary of sequencing results of different cDNA segments of PMS2 
  cDNA Segment 1 cDNA Segment 2 
Patient 
No. S1 A S1 B S2 A S2 B S2 C 
1 n.a. n.a. 
SNP 
c.1408C>T; 
p.Pro469Ser 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
2 no cDNA         
3 no cDNA          
4 wildtype wildtype wildtype wildtype 
SNP c.2324A>G; 
p.Lys775Ser 
5 c.301_353del53 n.a. wildtype 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
6 c.301_353del53 n.a. wildtype 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
7 no cDNA         
8 c.301_353del53 wildtype wildtype 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
9 n.a. n.a. 
SNP 
c.1408C>T; 
p.Pro469Ser 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
10 n.a. n.a. 
SNP 
c.1408C>T; 
p.Pro469Ser 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
11 c.301_353del53 n.a. wildtype 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
12 c.301_353del53 n.a. wildtype 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
13 c.301_353del53 wildtype 
SNP 
c.1408C>T; 
p.Pro469Ser 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
14 wildtype n.a. 
SNP 
c.1408C>T; 
p.Pro469Ser 
SNP 
c.1621A>G; 
p.Lys540Glu wildtype 
n.a. not amplified 
 
 
 
 
Figure 2 Chromatogram of cDNA sequencing of Segment 1A from patient no. 8 
displaying mutation c.301_353del53 compared to a wildtype control. 
 
 
 
Patient No. 8 
 
 
 
 
 
wildtype control 
Addendum 
 
 83 
MLPA analysis 
Ten patients without identified pathogenic germline mutation in PMS2 were screened 
for large genomic rearrangements like large deletions or insertions using the MLPA 
assay. The results of this investigation are depicted in table 2. One problem applying 
the MLPA assay was the relatively high standard deviation. Results with standard 
deviation values of more than 0.20 should be interpreted carefully (e.g. patient no. 3 
and patient no. 12). In patient no. 4 a mean value of -0.68 indicated the loss of exon 
15. In patient no. 9 a similar result was observed with possible additional loss of 
exon 13 (mean value -0.44). The mean value of -0.54 pointed to deletion of exon 8 in 
patient no. 10. Exon 8 seemed also to be deleted in patient no. 11 as well as exons 
13 and 15 (mean values -0.55, -0.54 and -0.76 respectively).  
 Using the MLPA kit it was not possible to detect deletions in positive controls 
from Hendriks et al. (data not shown). 
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Table 2 MLPA results of 10 patients showing the mean dosage quotient and the 
standard deviation (SD) 
 
Patient No. 3  Patient No. 4  Patient No. 7 
PMS2 Exon  Mean SD  PMS2 Exon  Mean SD  PMS2 Exon  Mean SD 
1 0.35 0.33  1 -0.06 0.14  1 -0.02 0.19 
2 0.28 0.33  2 0.07 0.14  2 -0.16 0.19 
5 0.28 0.33  5 0.05 0.14  5 -0.14 0.19 
6 0.23 0.33  6 -0.16 0.14  6 -0.09 0.19 
7 0.21 0.33  7 -0.02 0.14  7 0.23 0.19 
8 -0.30 0.33  8 -0.09 0.14  8 0.19 0.19 
9 -0.19 0.33  9 -0.05 0.14  9 0.12 0.19 
10 -0.11 0.33  10 -0.06 0.14  10 -0.14 0.19 
11 -0.03 0.33  11 -0.03 0.14  11 -0.30 0.19 
12 -0.12 0.33  12 0.09 0.14  12 0.23 0.19 
13 -0.22 0.33  13 -0.37 0.14  13 -0.10 0.19 
14 -0.28 0.33  14 -0.29 0.14  14 -0.27 0.19 
15 -0.41 0.33  15 -0.68 0.14  15 -0.32 0.19 
           Patient No.8  Patient No.9  Patient No.10 
PMS2 Exon  Mean SD  PMS2 Exon  Mean SD  PMS2 Exon  Mean SD 
1 -0.02 0.14  1 0.12 0.10  1 0.15 0.17 
2 0.28 0.14  2 0.13 0.10  2 0.23 0.17 
5 0.20 0.14  5 0.16 0.10  5 0.13 0.17 
6 -0.04 0.14  6 -0.02 0.10  6 -0.03 0.17 
7 -0.14 0.14  7 -0.08 0.10  7 -0.08 0.17 
8 -0.50 0.14  8 -0.004 0.10  8 -0.55 0.17 
9 0.002 0.14  9 -0.0002 0.10  9 -0.09 0.17 
10 -0.15 0.14  10 -0.15 0.10  10 -0.08 0.17 
11 -0.11 0.14  11 -0.11 0.10  11 -0.21 0.17 
12 0.08 0.14  12 0.03 0.10  12 -0.17 0.17 
13 -0.16 0.14  13 -0.44 0.10  13 -0.18 0.17 
14 0.26 0.14  14 -0.08 0.10  14 -0.16 0.17 
15 0.04 0.14  15 -0.69 0.10  15 -0.14 0.17 
       
 
 
Patient No.11  Patient No.12     
PMS2 Exon  Mean SD  PMS2 Exon  Mean SD     
1 0.22 0.18  1 0.25 0.23     
2 0.36 0.18  2 0.33 0.23     
5 0.29 0.18  5 0.28 0.23     
6 0.04 0.18  6 0.11 0.23     
7 -0.15 0.18  7 -0.11 0.23     
8 -0.55 0.18  8 -0.08 0.23     
9 -0.08 0.18  9 -0.13 0.23     
10 -0.27 0.18  10 -0.18 0.23     
11 -0.24 0.18  11 -0.33 0.23     
12 -0.29 0.18  12 -0.37 0.23     
13 -0.54 0.18  13 -0.35 0.23     
14 -0.28 0.18  14 -0.06 0.23     
15 -0.76 0.18  15 -0.52 0.23     
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DISCUSSION 
In ten patients without identifiable germline PMS2 mutations described in Chapter 4 
of this thesis, cDNA analysis and MLPA investigation were carried out to detect 
additional PMS2 germline mutations.  
Analysis of PMS2 is complicated by the presence of several pseudogenes. 
De Vos et al. have described the pseudogene of PMS2 in detail: There are 15 
pseudogenes of the 5’ part (exon 1 – 5) and one nearly 100% homologous 
pseudogene of the 3’ part of the gene (exon 9, 11 – 15)121. This means that only 
exons 6, 7, 8 and 10 are of the PMS2 gene are free of pseudogenes. To avoid co-
amplification of pseudogenes cDNA of PMS2 was analyzed in two overlapping 
segments using primers located in peudogene-free exons. Amplification of the two 
segments turned out to be quite difficult and conditions had to be optimized carefully. 
In addition, it was necessary to reamplify both segments in nested PCRs and in 
“subsegments” (S1A, S1B, S2A, S2B and S2C). A frameshift was detected in 
segment 1 (c.301_353del53) which leads to a stop codon after 120 amino acids 
(p.Gln100fs120X). Surprisingly the same mutation occurs in six patients (patients no. 
5, 6, 8, 11, 12, 13) which raises the question for pathogenicity of the alteration. In 
general, mutations leading to a premature stop codon and therefore to truncation of 
the protein can be regarded as pathogenic. Another point why the detected mutation 
can be regarded as pathogenic is the fact that it occurs only in CRC patients and not 
in tested healthy persons. But it is very uncommon that the same mutation is 
detected in six unrelated patients. In addition, we find it in the cDNA of two patients 
carrying germline mutations in PMS2 (patients no. 6 and 13). Patient no. 6 carries 
the “first” germline mutation in the pseudogene-free exon 6, whereas patient no. 13 
displays an exon 11 alteration.  
So the question for pathogenicity of p.Gln100fs120X remains open. Possibly, 
an alternative spliced region of the gene has been detected. The control of splicing 
requires precise recognitions of cis-regulatory elements in exons and their 
surrounding introns by the splicing machinery. Either mutations of these cis-
regulatory elements, or differential expression or activation of trans-acting factors 
that recognize these elements can change the default splicing pattern of a gene, 
leading to alternative splicing159. Using an alternative splice site predictor160 showed 
a putative splice site at the detected frameshift start. Thus, we detected a possible 
alternative spliced region, which is not described until date.  
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Another possibility is that mutations in PMS2 are inherited in a recessive 
manner. So, both mutations in patients no. 6 and 13 are detected whereas the 
second mutation in the remaining 4 patients has to be identified. 
To clarify the question regarding pathogenicity of p.Gln100fs120X additional 
cDNAs of healthy persons should be analyzed. The possible pathogenic meaning of 
the alteration would be strengthened although it is present in six patients if it doesn’t 
occur in healthy persons. Another possibility to analyze the PMS2 gene avoiding co-
amplification of pseudogenes is the application of long-range PCR161.  
 
For the detection of aberrant copy numbers in the PMS2 gene, the recently 
introduced MLPA technique from MRC Holland was applied. The first problem in 
using the SALSA P008 MSH6/PMS2 kit was the appearance of high standard 
deviation values. Using DNA obtained by the salting out method revealed better 
results than DNA purified with a DNA purification kit. Possibly, reagents in the 
applied DNA cleaning kit interfere with reagents in the MLPA kit and lead to a high 
standard deviation. But although unpurified DNA was used in two patients (patients 
no. 3 and 12) the standard deviation was still too high (0.33 and 0.23, respectively), 
so the MLPA results could not be interpreted reliably. Looking at the results, mostly 
the same exons appeared to be deleted (exons 8, 13 and 15). It is very unlikely, 
however, that these exons are lost separately in the same patients (no. 9 and 11).  
To test the reliability of the MLPA kit, we checked DNA samples of Hendriks 
et al.110 for the presence of deletions. They identified large genomic deletions by 
Southern blot and provided us their samples to have positive controls. But the MLPA 
kit did not detect the deletions (data not shown), which advises great caution in using 
this kit for PMS2. Although the annealing points for the probes are selected carefully 
pseudogenes may interfere and complicate MLPA analysis. And indeed, the 
following warning is part of the probemix description: "PMS2 exon 13-14-15 probes 
have been reported to provide variable results by two users. Many sequences 
related to this exon 13-15 region are present in the genome. Results obtained with 
these probes should be treated with caution or be disregarded.”
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6. MSH3 - a novel susceptibility gene for  
hereditary nonpolyposis colorectal cancer (HNPCC)? 
 
INTRODUCTION  
The autosomal dominantly inherited colorectal cancer predisposition HNPCC 
(hereditary nonpolyposis colorectal cancer) accounts for approximately 5% of all 
colorectal cancers162. The disease is caused by germline mutations in DNA 
mismatch repair (MMR) genes, predominantly MLH1 and MSH2. The primary 
function of the MMR system is to eliminate single-base mismatches and insertion-
deletion loops that may arise during DNA replication163,164. At least six different MMR 
proteins are required. MSH2 protein forms a heterodimer with either MSH6 or MSH3 
to recognize the mismatch and recruits a second protein-heterodimer consisting of 
MLH1 and PMS2 coordinating the interplay between the mismatch recognition 
complex and other proteins necessary for MMR165. While the MSH2 and MSH6 
dimer (the hMutSα complex) recognizes base-base mismatches and single base 
loops, the MSH2 and MSH3 dimer (the hMutSβ complex) recognizes 
insertion/deletion loops of more than one base166. It has been shown that MSH3 and 
MSH6 are partially redundant in MSH2-dependent mismatch repair, whereby the 
substrate specificity of the repair process may be dictated by interaction of MSH2 
with either MSH3 or MSH6167. 
The majority of MMR germline mutations have been identified in MLH1 and 
MSH2 (ca. 90%) and a small fraction accounts for mutations in MSH6 (ca. 10%) and 
PMS2 (less than 5%) (International Collaborative Group on HNPCC,      
http://www.n-fdht.nl). According to the human gene mutation database 
(http://www.hgmd.cf.ac.uk/ac/index.php) and to literature search 
(http://www.ncbi.nlm.nih.gov/sites/entrez) no germline mutations in MSH3 have been 
described so far.  
Here we present a patient carrying a germline missense mutation in MSH3 
and the assessment of the putative pathogenic role of the alteration in adenoma and 
colorectal cancer development. 
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MATERIAL & METHODS 
Subject 
Following colonoscopy because of blood in the stool the 1958 born male patient 
(patient ID: 2341) was diagnosed of two adenomas located in the distal colon. One 
of these adenomas contained a carcinoma in situ at the base. Detailed family history 
indicated a putative cancer predisposition. His father had developed a colon 
carcinoma at the age of 74 years and his grandfather died of oesophageal cancer at 
the age of 42 years. The mother and four sisters of the patient were investigated by 
colonoscopy without any findings (Figure 1). Written informed consent was obtained 
from the patient and the family members tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Pedigree of family 2341  
 
Analysis of microsatellite instability and immunohistochemistry 
A panel of five microsatellite loci (BAT25, BAT26, BAT40, D5S346 and Mycl-1) was 
used to assess microsatellite instability47. In addition three tetra- (MSH2_TAAA, 
MSH2_TTTA and MSH2_TTTG) and three penta-nucleotide markers (4A, D17S2227 
and D17S2230) were applied to assess microsatellite instability. The presence or 
absence of 5 MMR proteins (MLH1, MSH2, PMS2, MSH6 and MSH3) in the tumor 
was examined by standard immunohistochemical techniques168 at the Institute of 
Molecular Cancer Research in Zurich, Switzerland (Dr. G. Marra). 
RNA extraction from leukocytes and first-strand cDNA synthesis 
RNA extraction from blood-derived leukocytes was isolated using a combined 
approach of the TRIZOLReagent (Invitrogen) and RNeasy Mini Kit according to the 
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manufacturer’s protocol (QIAGEN, Basel, Switzerland). First-strand cDNA synthesis 
was carried out applying the Omniscript Reverse Transcriptase protocol (QIAGEN, 
Basel, Switzerland). 
DNA extraction from peripheral blood and tumor tissue 
DNA from peripheral blood was isolated applying the salting-out method described 
by Miller et al.102. DNA from formalin-fixed tumor tissue blocks was extracted using 
the QIAamp tissue kit according to the manufacturer’s protocol (QIAGEN, Basel, 
Switzerland). 
MSH3 gene mutation analysis 
Due to the coding sequence of 3414 base pairs of MSH3 primers for six overlapping 
segments of cDNA were designed to analyze the gene (GenBank accession number 
NM_002439.2). PCR products were directly sequenced using the BigDye Terminator 
Cycle Sequencing Kit and analyzed on an ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems, Rotkreuz, Switzerland).  
Restriction enzyme digest with PfoI 
The minor allele frequency for a single nucleotide polymorphism (SNP) to be 
considered common is usually above 1% (www.hapmap.org). To test if the identified 
missense mutation p.Arg795Trp represents a SNP 100 healthy persons were 
investigated by restriction digest with PfoI. The enzyme cuts the PCR product only if 
the DNA carries the wildtype sequence of MSH3 and produces two bands on a 2% 
agarose gel of 129 and 113 bp length. 
Analysis of loss of heterozygosity 
Loss of heterozygosity (LOH) was investigated using the following MSH3 flanking 
polymorphic microsatellite markers: D5S424, D5S641, D5S428 and D5S346. LOH 
was scored at any informative marker if the area under one allelic peak in the tumor 
was reduced by >50%169. In addition direct sequencing of exon 18 was carried out. 
 
RESULTS 
A 46 years old male patient (patient ID: 2341/01) was diagnosed of a large adenoma 
with a carcinoma in situ at the base. Because of a putative predisposition to 
colorectal cancer tumor tissue was investigated for the presence or absence of five 
MMR proteins (MLH1, MSH2, PMS2, MSH6 and MSH3) by immunohistochemistry. 
This investigation revealed exclusively loss of MSH3 whereas the four other MMR 
MSH3 study 
 
 90 
proteins were present. Therefore the patient’s blood and tumor tissue were referred 
to our research group.  
Firstly, DNA from formalin-fixed colorectal cancer tissue was investigated for 
the presence of MSI using the recommended NCI panel of microsatellite markers54. 
None of the applied markers were found to display novel alleles, corresponding to a 
microsatellite-stable status (MSS). In addition to the recommended markers, MSI 
analysis was carried out using three tetra- and three penta-nucleotide markers, 
which were also found to be MSS.  
Secondly, due the immunohistochemically proven loss of MSH3, leukocyte 
derived cDNA was investigated for mutations in the MSH3 gene. Bidirectional 
sequencing of the MSH3 gene identified a novel missense mutation in exon 18, 
c.2383C>T, which results in an amino acid change from arginine to tryptophan 
(p.Arg795Trp). This missense mutation was then confirmed by sequencing of exon 
18 of leukocyte derived DNA (Figure 2a). Interestingly, the father of the patient who 
had actually developed colorectal cancer at age 74 years, did not carry the 
c.2383C>T missense mutation, whereas his at the age of 75 years still healthy 
mother did. 
   
Figure 2: Sequencing chromatograms displaying the identified missense 
mutation c.2383C>T in leukocyte (a) and tumor derived DNA (b) 
compared to a wildtype control 
 
The missense mutation leads to the change from a basic-polar (arginine) to an 
aromatic-nonpolar (tryptophan) amino acid and suggests therefore modification of 
the protein function. To further investigate the pathogenicity of the missense 
mutations alignment of the respective amino acid from different species was carried 
out. It was found that the missense mutation is located in a conserved region of the 
MSH3 protein comparing different vertebrates (dog, mouse, rat, chicken, and others) 
(Figure 3). In MutS of E. coli and in S. cerevisiae, however, another amino acid is 
located at the respective position (glycine and lysine, respectively). The amino acid 
wildtype control 
 
 
a) 2341/01 leukocyte derived DNA  
 
 
b) 2341/01 tumor DNA 
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change is located in the MutS_III domain of the protein, which is responsible for the 
binding of dsDNA. This suggests that an alteration in this domain impedes mismatch 
repair proficiency. 
 
 
Figure 3:  Vertebrate alignment of p.Arg795Trp 
 
Furthermore, 200 alleles of 100 healthy probands were tested for the presence of 
c.2383C>T using the restriction enzyme PfoI which cuts the DNA in the presence of 
the wildtype sequence. All of the tested DNAs were digested, so the allele frequency 
for p.Arg795Trp is less than 1%. Therefore the criteria for a single nucleotide 
polymorphism (SNP) indicating a minor allele frequency of more than 1% is not met.  
Sequencing and LOH analysis of the patient’s tumor showed that 
p.Arg795Trp is present in a hemizygous state (Figure 2b). The three markers 
surrounding the MSH3 locus as well as marker D5S346 and D5S428 encompassing 
the APC locus on chromosome 5 indicated consistent loss of the wildtype allele 
(Figure 5).  
 
Marker Location Ratio Interpretation 
D5S1981 5p15.33 1,06 no LOH 
D5S406 5p15.32 1,01 no LOH 
D5S407 5q11.2 1,04 no LOH 
D5S424 5q13.3 0,08 LOH 
MSH3 5q14.1     
D5S641 5q14.2 7,55 LOH 
D5S428 5q14.3 2,29 LOH 
APC 5q22.2   
D5S346 5q22.2 5,8 LOH 
D5S400 5q34 5,2 LOH 
 
Figure 5:  Results of LOH analysis with 8 different markers on chromosome 5 
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DISCUSSION 
In this study we present a 46 years old patient whose tumor showed exclusively loss 
of MSH3. Sequencing analysis of leukocyte derived DNA from the patient revealed a 
MSH3 germline missense mutation. With regard to published data the overall 
detection rate for pathogenic germline mutations in MSH3 appears to be very low. 
Ohmiya et. al170 detected a missense variant (c.Pro2043Ser) in a conserved region 
of the mouse MSH3 homologue. But no further investigation with regard to 
pathogenicity of this variant was carried out. Whereas nonsense, frameshift and 
splice site mutations can be easily interpreted as pathogenic, pathogenicity of 
missense mutations is often difficult to determine. To be able to counsel patients with 
a missense mutation regarding the risk of colorectal cancer, it is necessary to 
understand the functional effect of a given missense variant on MMR proficiency171. 
Criteria defining the pathogenic nature of mutations in general and in 
particular of mutations associated with HNPCC have been reported in several 
publications172-174. The identified missense mutation c.2383C>T (p.Arg795Trp) was 
checked for pathogenicity using these criteria: 
Criteria to define the pathogenic nature of MMR gene variants 
1. De novo appearance of a mutation:  
p.Arg795Trp is not a de novo mutation because the mutation was detected 
also in the mother of our index patient. 
2. Segregation of the mutation with pedigrees:  
The mutation was detected in the index patient and in his healthy mother.  
3. Absence of the mutation in control individuals:  
In none of 100 healthy persons tested for p.Arg795Trp the missense variant 
was present. 
4. A change of amino acid polarity charge or size in the encoded peptide: 
Polarity changed because of the replacement of the non-polar wildtype amino 
acid arginine by the polar amino acid tryptophan. 
5. Occurrence of the amino acid change in a domain which is evolutionarily 
conserved between species and/or shared between proteins belonging to the 
same protein family:  
Looking at different species (chimp, dog, mouse, rat, chicken, fugu, zebrafish) 
we found that p.Arg795Trp is located in a conserved region. Furthermore, the 
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alteration is located in the MutS_III domain of the MSH3 protein. This domain 
is responsible for DNA binding in DNA mismatch repair.  
6. Loss of the non-mutated allele in tumor material of the patient (loss of 
heterozygosity, LOH):  
Sequencing and LOH analysis of tumor DNA using markers located around 
the MSH3 locus indicate loss of the wildtype allele.  
7. Absence of immunohistochemical staining for the corresponding protein in 
tumor material:  
The immunohistochemical analysis of the patient’s tumor revealed loss of 
MSH3. 
8. Presence of MSI in tumor material of the patients:  
MSI was not detected in the tumor using 11 different markers. This could be 
explained by the partially redundancy of MSH6 and MSH3175,176.  
9. Effect of the mutation on MMR capacity in functional assays:  
In collaboration with S. Ollila und M. Nystrom, Helsinki, Finland this approach 
is currently investigated. 
10. Previous inclusion of the mutation in disease-specific mutation databases: 
The mutation has not been reported so far. 
 
Taken together, the available data support a pathogenic role of the missense variant 
p.Arg795Trp.  
 
Looking at the patient’s mother, she’s still healthy by the age of 75 years although 
she carries the mutation. This may be explained by a possibly low penetrance of 
MSH3 mutations. The MSH6 and MSH3 proteins are shown to be functionally 
redundant, so that MutSα can partially compensate the function of MutSβ175,177,178. 
This redundancy could explain the lower penetrance of MSH3 mutations. In addition, 
the genetic background179 and the effect of possible modifier genes could also play a 
role.  
LOH-analysis showed that chromosome 5q is completely deleted in the tumor 
of our patient. As mentioned MSH3 is located on 5q but also APC can be found on 
the long arm of chromosome 5. Possibly, the loss of APC is therefore the major 
driving force in tumor formation.  
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Taken together, the alignment of MSH3 from different species, looking at 
allele frequency of the observed missense mutation, the appearance of the mutation 
in a homozygous state in the tumor and the loss of the wildtype allele suggest the 
possible pathogenic meaning of p.Arg795Trp. 
 
To finally determine the functional effect of p.Arg795Trp on MMR proficiency 
of MSH3 functional analysis of this alteration, however, is necessary. 
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7. GENERAL DISCUSSION 
 
This thesis has focused on genotype-phenotype correlations and rare susceptibility 
genes in two hereditary colorectal cancer syndromes, familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC). In 
particular, the aims were to survey predicted genotype-phenotype correlations and to 
establish the contribution of the comparatively rare mutated genes MYH to FAP and 
PMS2 as well as MSH3 to HNPCC.  
All investigations aim ultimately to aid clinicians in selecting colorectal cancer 
patients for optimal genetic testing and to provide them guidelines and an overview 
for the best surveillance and prevention strategies and genetic counselling schemes.  
The most important clinical step regarding the diagnosis of a hereditary 
colorectal cancer syndrome is a compilation of a thorough family cancer history162. 
The focus should be on identifying cancer of all types and sites, the family member’s 
age at onset of cancer, any associations with phenotypic features that may be 
related to cancers such as colonic adenomas, and documentation of pathological 
finding whenever possible. This information will frequently identify a hereditary 
colorectal cancer predisposition in a family. Molecular genetic testing may then 
provide verification of the diagnosis. Once a pathogenic germline alteration has been 
identified, at risk family members should be informed about the possibility of 
predictive genetic testing which has been shown to reduce morbidity and 
mortality180,181.  
Pre- and post-test genetic counselling is of high importance for the patient as 
well as for his/her family members. They should be informed on the details for 
surveillance and management and the necessity for genetic testing182,183. Mutation-
positive subjects can be advised on appropriate prophylactic measures, such as 
endoscopy and surgery in FAP or colonoscopic surveillance in HNPCC. Mutation-
negative subjects and their children need no further increased evaluation. 
 
Familial adenomatous polyposis (FAP) and MYH associated polyposis (MAP): 
In the first study (page 15) of this thesis genotype-phenotype correlations were 
assessed investigating 101 index patients with the clinical diagnosis of FAP. 
Genotype-phenotype correlations, linking the site of the germline mutation with the 
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severity of the disease, have been reported by several research groups: Severe 
polyposis with thousands of colorectal polyps has been associated with APC 
germline mutations between codons 1240 and 146419. In contrast, patients carrying 
mutations at the extreme 5’ end (codons 1-177)20-23, the alternatively spliced exon 9 
(codons 312-412)24-26, and the 3’ end (codons >1580)23,27,28 presented more often 
with attenuated polyposis. In addition, certain extracolonic disease manifestations 
have been correlated with the site of the germline mutation, e.g. alterations between 
codons 1403 and 1578 with desmoid tumours29,30. 
In contrast to reported genotype-phenotype correlations, nearly half of our 
APC mutation carriers with alterations in the classical region actually displayed an 
attenuated polyposis phenotype. In addition, four (57%) out of seven 5’ APC 
mutation carriers in our consecutive series actually presented with severe polyposis 
coli displaying hundreds to thousands of colorectal polyps. Extracolonic disease 
manifestations were evenly distributed among patients with mutations in the 
“classical FAP” or the “AFAP region”. With regard to upper gastrointestinal 
adenomas, desmoids and osteomas, 59% (10 out of 17) of patients actually carried 
mutations outside the regions correlated with these manifestations. 
In our study population of APC mutation carriers, no genotype-phenotype 
correlations with regard to polyp number or extracolonic disease manifestations 
could be established. These data challenge the prevailing view on genotype-
phenotype correlations and advise great caution when basing clinical management 
decisions for an individual patient on the site of the APC germline mutation. These 
findings were confirmed in a second study85.  
 
This second study (page 27) reports phenotypic differences among AFAP families, 
both between and within kindreds with mutations in each of the three AFAP-
associated regions of APC. We have found that patients with germline APC 
mutations in the 5’ and 3’ regions of the gene or the alternatively spliced region of 
exon 9 have a highly variable large-bowel phenotype, in that the number of 
colorectal adenomas varies from almost none to the hundreds or thousands of 
lesions found in classical FAP15.  
We investigated the somatic APC mutation spectrum in AFAP patients with 3’-
mutations and compared them with the other AFAP-associated regions of APC. The 
study had found that ‘three hits’ at APC often occur in AFAP adenomas (Figure 1). In 
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such polyps, the ‘third hit’ appears to be required for the initiation of tumorigenesis. 
In conclusion, the phenotypic and somatic molecular heterogeneity in AFAP means 
that clinical management of patients with AFAP associated mutations must be 
empirical. A more accurate prediction of phenotype may eventually be possible when 
additional genetic and environmental factors, such as modifier genes, that influence 
colorectal cancer susceptibility and disease severity are identified. 
 
Figure 1 A simplified model of the associations between the first hit and the second hit 
at APC in colorectal tumors184. a) In colorectal tumors the “first hit” and 
“second hit” are interdependent. The following patterns are seen: b) “first hits” 
between codons 1284 and 1378 and LOH as “second hit”; c) truncating “first 
hits” before codon 1284 and truncating “second hit” between codons 1378 and 
1580; d) as for c) but in reverse order; e) in AFAP patients sometimes a 
“second hit'”by truncation close to codons 1284–1378 and a 'third hit' by allelic 
loss of the inherited mutant allele occur. 
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This thesis reports in the third study (page 49) on the assessment of frequency of 
MYH mutation carriers in 79 unrelated Swiss patients. Despite extensive genetic 
testing, in about 20-50% of FAP patients worldwide no germline APC mutation can 
be identified. About 50% of these so-called APC-negative patients display a multiple 
colorectal adenoma phenotype with less than 100 colorectal polyps at a later age of 
onset75,99,185. In addition, extracolonic manifestations are less frequently observed. 
There are several reasons for the failure in identifying APC germline mutations in 
FAP patients:  
• A combination of several different screening techniques would result in a 
better detection rate than only one individual method. 
• Other genes may be responsible for the development of FAP or may lead to a 
similar clinical phenotype186,187.  
 
Al Tassan et al. demonstrated that biallelic germline mutations in the human 
homologue of the base excision repair gene MutY (MYH) cause a phenotype of 
multiple colorectal adenomas and carcinomas, thus describing for the first time an 
autosomal recessively inherited CRC predisposition6,7. In this study we assessed the 
frequency of MYH mutation carriers in 79 Swiss polyposis patients and investigated 
them for phenotypic differences between biallelic, monoallelic mutation carriers and 
APC/MYH mutation-negative patients. 9% of patients were found to harbor biallelic 
(n = 7) and 11% monoallelic (n = 9) germline mutations in the base excision repair 
gene MYH. In contrast to initial studies reporting classical disease (>100 adenomas) 
in all biallelic mutation carriers7, the MYH associated-polyposis phenotype in our 
patients is predominantly an attenuated one. Colorectal cancer was significantly 
more frequent in biallelic as compared to monoallelic mutation carriers or those 
without MYH alterations but with regard to other phenotypic properties (age of onset, 
extracolonic disease manifestations), it is virtually impossible to discriminate biallelic 
from monoallelic MYH mutation carriers and MYH mutation-negative polyposis 
patients.  
Based on our results, we suggest that MYH mutation screening should be offered 
to individuals who fulfill all of the following criteria: (i) presence of classical or 
attenuated polyposis, (ii) absence of an APC germline mutation, and (iii) a family 
history compatible with an autosomal recessive mode of inheritance. 
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Hereditary non-polyposis colorectal cancer (HNPCC):  
HNPCC is caused by germline mutations in DNA mismatch repair (MMR) genes. 
The majority of MMR germline mutations have been identified in MLH1 and MSH2 
(ca. 90%) and a small fraction accounts for mutations in MSH6 (ca. 10%). To date, 
heterozygous germline mutations in PMS2 have not been reported in HNPCC 
families as defined by Amsterdam criteria.  
The fourth study (page 59) reports the analysis of PMS2 expression along 
with that of its heterodimeric partner MLH1 in a large series of unselected CRCs. 
This approach, supported by the analysis of the PMS2 gene, allowed us to identify 
patients affected by cancers with a primary defect of PMS2 (i.e. not secondary to an 
MLH1 defect) and to describe their phenotype. The most striking finding of our study 
concerns the unexpectedly high frequency of PMS2-deficient CRCs (1.5%), which 
was similar to that of tumors lacking MSH2 (1.4%). Looking at the phenotype of 
germline PMS2 mutation carriers, many of them were diagnosed the fifth or sixth 
decade of life, some were also affected with extracolonic PMS2-deficient tumors, 
and several relatives were identified with CRCs or cancers in other organs at earlier-
than-average age of onset. It has to be mentioned, that several pseudogenes 
located on chromosome 7 can interfere with the mutation analysis of PMS2 
121,132,145,152-154.  
With regard to clinical management, PMS2 defects should be remembered as 
a reason for colorectal cancer and thus, should be taken into account of genetic 
testing.  
 
The fifth part of this thesis (page 87) deals with apparently rare findings in HNPCC: 
mutations in the MMR gene MSH3. To date, no germline mutation in MSH3 has 
been described. This study reports the case of a 46 years old colorectal cancer 
patient with immunohistochemically proven loss of MSH3 in the adenocarcinoma. 
Screening MSH3 for germline mutations, a missense mutation c.2383C>T was 
identified. The fact that this variant does not occur in 100 healthy persons, that 
alignment of the respective gene in several species showed that the variant is 
located in a conserved region, and that tumor DNA sequencing and LOH analysis 
showed loss of the wildtype allele suggest that the missense mutation c.2383C>T 
may indeed be pathogenic albeit at a low penetrance level as explained by the 
functional redundancy of MutSα and MutSβ.  
General discussion 
 
 100 
In summary, germline mutations in MSH3 appear to be very rare but nevertheless 
geneticists and clinicians should bear this gene in mind when examining familial 
colorectal cancer patients where no apparent defects in the common MMR genes 
have been found. 
 
Taken together, in hereditary colorectal cancer syndromes genetic testing is of great 
importance for the patients and their families. Once the patients’ familial risk is 
determined a complex program of cancer surveillance and management has to be 
undertaken188-190. 
To identify germline mutations in the respective genes well established 
methods like the protein truncation test, sequencing analysis, immunohistochemistry, 
and microsatellite instability analysis are methods of choice. In hereditary cases 
without identified germline alterations the recently introduced MLPA assay may help 
to detect gene copy number changes. And finally, cDNA analysis can be applied for 
large genes or genes where pseudogenes impede mutation analysis. The use of 
these molecular genetic testing methods allows early identification of at-risk family 
members, improves diagnostic certainty and reduces the need for costly screening 
procedures like colonoscopies in those family members not carrying the inherited 
disease-causing mutation. Identification of the responsible germline mutation will 
help to improve prevention and risk assessment in a family with a hereditary cancer 
syndrome.  
Advances in technology in cancer screening, identification of biological 
markers of cancer susceptibility and specific germline testing is necessary to help 
physicians in management of patients with hereditary colorectal cancer syndromes. 
In addition, molecular genetic research has to be intensified in searching for new 
mutations, screening novel, rarely mutated or modifier genes and assessing 
genotype-phenotype correlation where possible in these heterogeneous disorders.  
Looking for target genes Sjöblom et al.3 described in their huge study the 
systematic analysis of 13023 in 11 breast and 11 colorectal cancers. They identified 
189 genes (average 11 per tumor) that were mutated at significant frequency. The 
vast majority of these genes were not known to be genetically altered in tumors. This 
study shows that to date only the tip of the iceberg is known about genes involved in 
cancer. But whole genome microarrays contain a great potential to identify new 
genes responsible for hereditary colorectal cancer syndromes. This technology 
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promises to monitor the whole genome on a single chip, so researchers can 
investigate thousands of potential CRC genes simultaneously. Recently, Albert el al. 
published a highly efficient and cost-effective method for capturing targeted regions 
of the genome via NimbleChip microarrays in preparation for high-throughput 454 
Sequencing. The technology, called "sequence capture", enables fast and accurate 
enrichment of thousands of selected genomic regions, such as segments of 
chromosomes or all genes or exons. The study demonstrates that the sequence 
capture process is simpler, more accurate, more efficient and more cost-effective 
than the multiplex PCR that was previously used to prepare genomic samples for 
sequencing191. 
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8. APPENDIX 
 
GENERAL INTRODUCTION 
Amsterdam criteria I and II 
Amsterdam criteria I 
- three or more relatives with colorectal cancer (CRC) 
- one affected patient should be a first-degree relative of the other two 
- CRC should involve at least two generations; at least one case of CRC should 
be diagnosed before the age of 50 years 
Amsterdam criteria II 
- three or more relatives with HNPCC-associated cancer 
- one affected patient should be a first-degree relative of the other two 
- two or more successive generations should be affected 
- FAP should be excluded; Tumors should be verified by pathological 
examination 
 
Bethesda guidelines 
Bethesda guidelines 
- Individuals with cancer in families that fulfill the Amsterdam Criteria 
- Individuals with two HNPCC-related cancers 
- Individuals with CRC and a firs-degree relative with CRC and/or HNPCC 
related extracolonic cancer and/or colorectal adenoma; one of the cancers 
diagnosed before the age of 45 years and the adenoma before the age of 40 
years 
- Individuals with CRC or endometrial cancer diagnosed before the age of 45 
years 
- Individuals with right-sided CRC with an undifferentiated pattern diagnosed 
before age of 45 years 
Revised Bethesda guidelines 
- Individuals diagnosed with CRC before the age of 50 years 
- CRC or other HNPCC-associated tumors regardless of age 
- CRC with a high-MSI morphology diagnosed before the age of 60 years 
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- CRC with one or more first-degree relatives with CRC or other HNPCC-
related tumors, one cancer diagnosed before the age of 50 years including 
adenoma diagnosed before the age of 40 years 
- CRC with two or more first- or second degree relatives with CRC or other 
HNPCC-related tumor, regardless of age 
 
Stages of Colorectal Cancer 
Colon and rectal cancer are staged according to how far they have spread through 
the walls of the colon and rectum and whether they have spread to other parts of the 
body. This staging process allows doctors to determine the best treatments for the 
particular cancer. It also allows them to determine if the cancer is getting better with 
treatment or not responding. 
Stage 0  
Stage 0 cancer of the colon is very early cancer. The cancer is found only in the 
innermost lining of the colon.  
Dukes A colon cancer  
The cancer has spread beyond the innermost lining of the colon to the second and 
third layers and involves the inside wall of the colon. The cancer has not spread to 
the outer wall of the colon or outside the colon. 
Dukes B colon cancer  
tends through the muscular wall of the colon, but there is no cancer in the lymph 
nodes (small structures that are found throughout the body that produce and store 
cells that fight infection). 
Dukes C colon cancer 
The cancer has spread outside the colon to one or more lymph nodes (small 
structures that are found throughout the body that produce and store cells that fight 
infection). 
Dukes D colon cancer 
The cancer has spread outside the colon to other parts of the body, such as the liver 
or the lungs. The tumor can be any size and may or may not include affected lymph 
nodes (small structures that are found throughout the body that produce and store 
cells that fight infection). 
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AFAP STUDY 
Supplementary Table 1  
Somatic APC mutations and allelic loss in tumours from AFAP patients with 5’ germline 
mutations. All tumours with mutation or LOH are shown.   
Patient ID 
Germline 
mutation 
Somatic 
mutation 
Type of 
somatic 
change 
20 AARs in 
somatic mutant 
allele LOH 
DFAP 48 141FS 1309FS 3927del5bp 1 NL 
AVC.III.2 Q163X 1305FS 3914delC 1 NL 
AVC.III.2 Q163X 1309FS 3927del5bp 1 NL 
554.iii.2 179FS Q1378X 4132C>T 1 NL 
554.iii.2 170FS 1398FS 4192delAG 2 NL 
554.iii.2 170FS 1439FS 4316delC 2 NL 
554.iv.2 170FS 1462FS 4386delGA 2 NL 
AFX MK G125X S1356X 4067C>G 1 LOH mut 
AVC.III.S Q163X 1309FS 3927del5bp 1 LOH mut 
FS = frameshift; LOH = loss of heterozygosity; wt = germline wild-type allele; mut = germline mutant 
allele, where this assignment was possible 
 
Supplementary Table 2  
Somatic APC mutations and allelic loss in 79 tumours from  AFAP patients with germline 
mutations in the alternatively spliced region of exon 9.   
Patient ID Somatic mutation(s) 
Type(s) of somatic 
change(s) 
20AARs in 
somatic 
mutant 
allele(s) LOH 
673.iii.3 K792X 2374A>G 0 NL 
578.iv.4 1335FS 4004del31bp 1 NL 
1571.ii.2 1462FS 4386delGA 2 NL 
578.iv.1 1505FS 4514dup7bp 2 NL 
578.iv.1 K1469X 4405C>T 2 NL 
578.iv.4 1518FSwt 4552delA 3 NL 
578.iv.7 E1265X; 1462FS 3793G>T; 4386del4bp 0 ; 2 NL 
578.FPL 1462FS mut 4386delGA 2 NL 
578.iv.7 1462FS mut 4386delGA 2 NL 
578.iii.9 1372FS ; 1554 FS 4114delG; 4661insA 1 ; 3 NL 
578.iv.4 1372FS ; 1554 FS 4117delC; 4661insA 1 ; 3 NL 
578.AA 1554FS mut 4661insA 3 NL 
578.FPL 1554FS mut 4661insA 3 NL 
578.FPL 1554FS mut 4661insA 3 NL 
578.FPL 1554FS mut 4661insA 3 NL 
578.iii.9 1554FS mut 4661insA 3 NL 
578.iii.9 1554FS mut 4661insA 3 NL 
578.iii.9 1554FS mut 4661insA 3 NL 
578.iii.9 1554FS mut 4661insA 3 NL 
578.iii.9 1554FS mut 4661insA 3 NL 
578.iv.4 1530FS mut 4661insA 3 NL 
578.iv.4 1554FS mut 4661insA 3 NL 
578.iv.4 1530FS mut 4661insA 3 NL 
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Patient ID Somatic mutation(s) 
Type(s) of somatic 
change(s) 
20AARs in 
somatic 
mutant 
allele(s) LOH 
578.iv.4 1554FS mut 4661insA 3 NL 
587.iv.7 1554FS mut 4661insA 3 NL 
587.iv.7 1554FS mut 4661insA 3 NL 
587.iv.7 1554FS mut 4661insA 3 NL 
587.iv.7 1554FS mut 4661insA 3 NL 
1571.ii.2 1554FS 4661insA 3 NL 
1571.ii.2 1537FS 4611delAG 3 NL 
578.iv.1 1554FS 4661insA 3 NL 
578.iv.1 1554FS 4661insA 3 NL 
578.iv.1 1554FS 4661insA 3 NL 
578.iv.1 1554FS 4661insA 3 NL 
578.iv.1 1554FS 4661insA 3 NL 
578.iv.1 1554FS 4661insA 3 NL 
578.iv.4 1554FS 4661insA 3 NL 
DFAP 81 1554FS 4661insA 3 NL 
578.iv.1 none detected     LOH wt 
578.iv.1 none detected     LOH wt 
578.iv.1 none detected     LOH wt 
578.iii.9 1554FS mut 4661insA 3 LOH wt 
578.iii.9 1554FS mut 4661insA 3 LOH wt 
578.iv.7 1554FS mut 4661insA 3 LOH wt 
578.iv.7 1554FS mut 4661insA 3 LOH wt 
578.iv.1 1554FS mut 4661insA 3 LOH wt 
578.iv.7 1554FS mut 4661insA 3 LOH wt 
578.FPL 1394FS 4182delTA 1 LOH mut 
578.iii.9 E1286X 3856G>T 1 LOH mut 
578.iii.9 S1315X 3944C>T 1 LOH mut 
See Supplementary Table 1 for abbreviations. 
Supplementary Table 3  
Somatic APC mutations and allelic loss in 126 adenomas from AFAP patients with 3’ germline 
mutations.  
Patient ID 
Germline 
mutation 
Somatic 
mutation(s) 
Type(s) of somatic 
change(s) 
20AARs in 
somatic 
mutant 
allele(s) LOH 
MD2976 1919FS R283X 847C>T 0 NL 
MD2976 1919FS R283X 847C>T 0 NL 
MD2976 1919FS R283X 847C>T 0 NL 
77-11 1943FS E1374X 4120G>T 1 NL 
DW20284 2078FS Q1338X 4012C>T 1 NL 
J42424 2078FS 1300FS 3902insC 1 NL 
L12562 2078FS Q1338X 4012C>T 1 NL 
110.2.vi 2078FS 1354FS 4061delTT 1 NL 
01/266 1738FS 1441FS 4323delA 2 NL 
01/266 1738FS 1441FS 4323delA 2 NL 
01/266 1738FS 1441FS 4323delA 2 NL 
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Patient ID 
Germline 
mutation 
Somatic 
mutation(s) 
Type(s) of somatic 
change(s) 
20AARs in 
somatic 
mutant 
allele(s) LOH 
01/266 1738FS 1441FS 4323delA 2 NL 
01/266 1738FS 1441FS 4323delA 2 NL 
01/266 1738FS 1441FS 4323delA 2 NL 
2333/3 1919FS 1398FS 4192delAG 2 NL 
2233/3 1919FS 1407FS 4219delAG 2 NL 
2233/3 1919FS R1435X 4303A>T 2 NL 
77-11 1943FS 1490FS 4468insG 2 NL 
77-11 1943FS Q1406X 4216C>T 2 NL 
110.2.vi 2078FS 1403FS 4209insCT 2 NL 
MD2976 1919FS 
1129FS wt; 
1554 FS mut 3387delT; 4661insA 0;3 NL 
344-44 1597FS 1554FS 4661insA 3 NL 
01/266 1738FS 1576FS 4726delG 3 NL 
77-11 1943FS 1579FS 4709del6bp 3 NL 
2233/3 1919FS none detected     LOH wt 
2233/3 1919FS none detected     LOH wt 
2233/3 1919FS none detected     LOH wt 
77-11 1943FS none detected     LOH wt 
77-11 1943FS none detected     LOH wt 
77-11 1943FS none detected     LOH wt 
77-11 1943FS none detected     LOH wt 
77-12 1943FS none detected     LOH wt 
77-12 1943FS none detected     LOH wt 
77-40 1943FS none detected     LOH wt 
1460/6 1982FS none detected     LOH wt 
1460/88 1982FS none detected     LOH wt 
1624/04 1982FS none detected     LOH wt 
77-11 1943FS 1462FS mut 4386delGA 2 LOH wt 
77-11 1943FS 1429FS mut 4286delA 2 LOH wt 
77-11 1943FS 1234FS 37ins8bp 0 LOH mut 
77-11 1943FS none detected     LOH mut 
77-11 1943FS none detected     LOH mut 
1460/6 1982FS none detected     LOH mut 
1460/42 1982FS none detected     LOH mut 
1460/42 1982FS none detected     LOH mut 
1460/42 1982FS none detected     LOH mut 
1624/04 1982FS none detected     LOH mut 
J42424 2078FS none detected     LOH mut 
J42424 2078FS none detected     LOH mut 
1460/42 1982FS 1357FS 4069delGG 1 LOH mut 
1489/10 1982FS 1354FS 4060delAA 1 LOH mut 
1624/04 1982FS E1322X 3964G>T 1 LOH mut 
01/266 1738FS 1431FS 4294delC 2 LOH mut 
MD2976 1919FS 1493FS 4479delG 2 LOH mut 
See Supplementary Table 1 for abbreviations. 
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PMS2 STUDY 
 
Supplementary Table 1  
Primers and Reaction Conditions for Analysis of MSI, LOH, Germline PMS2 Mutations and Promoter Methylation Status 
 
 Primers for analysis of BAT 26*    
 Sense Primer Antisense Primer    
 5'-TGACTACTTTTGACTTCAGCC-3' 5'-AACCATTCAACATTTTTAACCC-3'     
      
 Primers for LOH analysis**    
Marker location Forward Primer Reverse Primer    
d7s531 5'-GTCCTGCCCCTCTGTCAGT-3'  5'-TGGAAGACACCAGCTTTAGGA-3'     
d7s517 5'-TGGAGAAGCCATGTGAGT-3'  5'-AGCTGTAATTAGTTGCTGGTTTGA-3'     
d7s511  5'-ACTTGCTTGAGCCCAGG-3' 5'-AGTGATCTGCCCACCGT-3'    
d7s2478 5'-GTGCTCCGCCATTTCTGTAT-3'  5'-CTGCAGCCAAAATGATCTGC-3'     
d7s2201 5'-AGTTCAACCTGGGCAACATA-3'  5'-TCAAGCCAAGGCATTTTCTA-3'     
d7s481 5'-CACCCCCATATTAATTTTATTCTTGT-3' 5'-TTTTTACCAGACTATTAAATCAGCAA-3'    
d7s2553 5'-TTGAGAGGTGGGGACT-3'  5'-CATGTTTTTATGCTTTAACTACATT-3'     
d7s2514 5'-CATCAGTTGTTAAACTTTGCCAT-3'  5'-CAACCAGCCGTCATCTT-3'     
      
 Primers for PMS2 sequencing***    
Exon Sense Primer Antisense Primer Product size Tm (°C) 
MgCl
2 
(mM) 
1 5'-AGCACAACGTCGAAAGCAG-3' 5'-AGAGGGGACACCGGAAGACT-3' 162 60 1.5 
2 5'-TGTTTCTTGTAACTGATTTCTC-3' 5'-CTTAACTACAACAACATTCACAG-3' 224 54 2.5 
3 5'-CTGATAGCATGGGTCCGTTT-3' 5'-TTGCATTTCCCAAGACAGTG-3' 225 60 2.5 
4 5'-TCTTGGGAAATGCAAAAACA-3' 5'-AAGGGGTCAAGTGAGTGGAT-3' 248 50 1.5 
5 5'-CCCAACATCATGGGTCTCTC-3' 5'-TGCTCATGTGCATTAACCAA-3' 289 60 1.5 
6 5'-ACTTGAGCTGTGTAATTCC-3' 5'-CCCGCTATAATCACTAGAGC-3' 289 60 1.5 
7 5'-GTCCACTCTGTCTTTATTAG-3' 5'-AGCTCTCAGGATAAAATGTTC-3' 204 60 1.5 
8 5'-TCCCTTTCACTCTGGAATCCT-3' 5'-TCCACGTAAACTGCCTATTATCA-3' 236 60 1.5 
9 5'-GGGGCTGGGAACATTTGTC-3' 5'-ATAGCAGAGCTGTAGAATTTC-3' 215 60 1.5 
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10 5'-TGAGACGCTGTCTGAAAATAATAA-3' 5'-AATAAGGAAACACATTAGCTAAAAGC-3' 300 60 2.5 
11_1 5'-CAGGATAGTCCCTGACCCTCT-3' 5'-GGACGCCTTTGTCAGAGATG-3' 300 60 1.5 
11_2 5'-GAAGGAGCCCTCTAGGACAGA-3' 5'-GCGAGATTAGTTGGCTGAGG-3' 388 60 1.5 
11_3 5'-CGACTCTTTTTCAGATGTGGAC-3 5'-CTGCGCAACAGAGCAAGAC-3' 472 65 1.5 
12 5'-AAAAGAAAGCGGGATGGCTA-3' 5'-CTCAAACTCCTGGCCTCTTG-3' 397 60 1.5 
13 5'-TTGTTTTCATTTCATTTCTGCTG-3' 5'-CCACACCCAGCCGCTATAGTT-3' 216 55 1.5 
14 5'-CGTGTTTGTCAAGTCATGGA-3' 5'-CTGAGACCTTCCTCGACTGC-3' 279 62 2.5 
15 5'-CTACTAAAACGTTGAACCATTGTG-3' 5'-GCGCATGCAAACATAGAGAA-3' 384 55 1.5 
      
Primers for the Analysis of the Methylation Status of the MLH1 Promoter by Real-Time PCR§    
 Sense Primer Antisense Primer Amplicon ^   
 5'-GAGTTTTTAAAAAIGAATTAATAGGAAGAG-3’ 5’-TAAATACCAATCAAATTTCTCAACTCTA-3’ from -299 to - 152  
      
Primers for the Analysis of the Methylation Status of the MLH1 Promoter by Methylation-Specific PCR (MSP)§§   
Reaction Sense Primer Antisense Primer Amplicon ^   
Methylated 
Reaction (M) 5’-AACGAATTAATAGGAAGAGCGGATAGCG-3’ 5’-CCTCCCTAAAACGACTACTACCCG-3’  from -288 to - 202  
Unmethylated 
Reaction (U) 5’-TAAAAATGAATTAATAGGAAGAGTGGATAGTG-3' 5’-AATCTCTTCATCCCTCCCTAAAACA-3’ from -292 to - 190  
      
Primers for the Analysis of the Methylation Status of the PMS2 Promoter by Real-Time PCR    
Amplicon Sense Primer Antisense Primer Amplicon ^^   
1st Amplicon 5’-GGTATGGTAGAATTAAAGTAAAAG-3 5'-AAAACCTAAACCAATCAAAACACA-3’  from -349 to - 193  
2nd Amplicon 5’-GTGTGTTTTGATTGGTTTAGG-3’  5'-CTCCTAAACTCCCATTAACTA-3’ from -217 to – 68  
      
Primers for the Analysis of the Methylation Status of the PMS2 Promoter by Methylation-Specific PCR (MSP)     
Reaction Sense Primer Antisense Primer Amplicon ^^   
Methylated 
Reaction (M) 5'-AGAGGCGCGTCGTTTTCGTG-3’  5’-CTCCGTCGTAACCTCTAACG-3' from -391 to – 271  
Unmethylated 
Reaction (U) 5’-GTAGGTGGGAAGTTTTATATGGAG-3’ 5’-CCAATCTCCATCATAACCTCTAACA-3’  from -413 to - 266  
 
*Amplifications were carried out using a reaction mix of 8µl of True Allele PCR Premix (Applied Biosystems), 5pM primers and 30-50 ng DNA. Thermal 
cycling conditions: 95°C for 12 min, 94°C for 15 sec, 55°C for 15 sec and 72°C for 30 sec for 10 cycles followed by 89°C for 15 sec, 55°C for 15 sec and 
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72°C for 30 sec for 20 cycles. Fragment analysis was performed on an ABI 310 (Applied Biosystems) using 1µl PCR product in 20.5µl 
fromamide/GenScan350TAMRA-Mix. Data were analyzed with the Genotyper version 2.5 software. 
 
** PCR was performed in an Eppendorf Mastercycler using a reaction mix of 9µl of True Allele PCR Premix (Applied Biosystems), 5pM primers and 20ng 
(genomic)/10 ng (tumor) DNA. Thermal cycling conditions: 94°C for 15 sec, 55°C for 15 sec and 72°C for 30 sec for 13 cycles followed by 89°C for 15 sec., 
55°C for 15 sec and 72°C for 30 sec for 23 cycles. Fragment analysis was performed on an ABI 310 (Applied Biosystems) using 1µl of PCR product in 24.6µl 
HiDi-formamide/Rox400-Mix. Data were analyzed with the Genotyper version 2.5 software. 
 
*** PCR amplification of genomic DNA was carried out in a 35µl reaction containing 20mM Tris-HCl (pH 8.4), 50mM KCl, 2.5mM each of the four dNTPs, 
1.5/2.5mM MgCl2, 5pM of each primer, 20ng of DNA and 2.5U of Taq Polymerase. Thermal cycling conditions (in an Eppendorf Mastercycler) were as 
follows: 95°C for 30s, 50-65°C for 1.5 min, and 70°C for 1.5 min for 35 cycles. PCR products were sequenced (Big dye terminator kit, Applied Biosystems) 
and analyzed with an ABI 3700. 
 
§ Real Time PCR was performed by the Roche LightCycler System using the QuantiTect SYBR Green Kit (Qiagen) according to the manufacturer’s 
instructions, 0.5µM of each primer and 2µL of the bisulphite-treated DNA in 20µL final volume of reaction. PCR conditions: 95°C for 15 min, then 55 cycles 
(94°C for 15 sec, 51°C for 20 sec, 72°C for 10 sec), followed by a melting curve analysis step (65°C-95°C, 0.1°C/sec slope). The analysis of melting curves 
allowed us to distinguish between methylated and unmethylated alleles (see Supplemental Figure S1). ^From the ATG start site (GenBank accession no. 
U83845): this promoter region has been found to be critical for gene silencing192 
 
§§ Reactions were carried out in a 25µL final volume, using 2µL of bisulfite-treated DNA, 1.25U ampliTaq Gold (Applied Biosystems) with final primer 
concentrations of 0.5µM for the methylated reaction (M) and 1µMf or the unmethylated reaction (U). After an initial step (95°C for 10 min), 37 cycles (95°C 
for 30 sec; 62°C (M) or 60°C  (U) for 30 sec; 72°C for 30 sec) were performed and followed by a final step of elongation for 7 minutes at 72°C. Products 
were loaded on 1.8% agarose gels and stained with ethidium bromide (see Supplemental Figure Sl). From the ATG start site (GenBank accession no. 
U83845). 
 
 Real Time PCR was performed by the Roche LightCycler System using the QuantiTect SYBR Green Kit (Qiagen) according to the manufacturer’s 
instructions, 0.5µM of each primer and 2µL of the bisulphite-treated DNA in 20µL final volume of reaction. PCR conditions: 95°C for 15 min, then 55 cycles 
for the 1st Amplicon (94 °C for 15 sec, 50°C for 20 sec, 72°C for 10 sec) or 45 cycles for the 2nd Amplicon (94 °C for 15 sec, 50°C for 20 sec, 72°C for 10 
sec), followed by a melting curve analysis step (65°C-95°C, 0.1°C/sec slope). The analysis of melting curves allowed us to distinguish between methylated 
and unmethylated alleles (see Supplemental Figure S1). ^^ From the presumptive ATG starting codon (Gene-Bank accession number U24168). 
 
 Reactions were carried out in a 25µL final volume, using 2µL of bisulfite-treated DNA, 1.25U ampliTaq Gold (Applied Biosystems) with final primer 
concentrations of 0.5µM. After an initial step (95°C for 10 min), 37 cycles (95°C for 30 sec; 58°C for 30 sec; 72°C for 30 sec) were performed and followed 
by a final step of elongation for 7 minutes at 72°C. Products were loaded on 1.8% agarose gels stained with ethidium bromide (see Supplemental Figure 
S1). ^^ From the presumptive ATG starting codon (Gene-Bank accession number U24168). 
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Supplementary Table 2        
     Characteristics of Patients with MMR-deficient CRCs 
Tumor no. 
Absent MMR 
protein* BAT26 
Promoter 
Methylation** Age  Sex Tumor site*** 
History of 
cancer  
59255 MSH2 unstable  77 f A n.d. 
69101 MSH2 unstable  64 m R sporadic 
17676 MSH2 stable  81 f R n.d. 
52012 MSH2 unstable  86 m A n.d. 
51470 MSH2 unstable  39 m C BG1 
52285 MSH2 unstable  65 f S BG5 
50633 MSH2 unstable  71 m R AC 
13617 MSH2 unstable  61 f R AC 
4556 MSH2 stable  56 m A BG3 
21269 MSH2 unstable  74 f C sporadic 
11752 MSH2 stable  39 m A BG1 
7429 MSH2 unstable  87 f C n.d. 
6831 MSH2 unstable  50 f D AC 
14685 MSH2 unstable  53 f A AC 
7467 MSH2 unstable  34 m A AC 
        
69770 MSH6 unstable  61 f A BG2&4 
54013 MSH6 stable  69 f S BG5 
21532 MSH6 stable  57 f A BG5 
22577 MSH6 stable  57 m R n.d. 
13894 MSH6 stable  58 m R sporadic 
        
1081 MLH1 unstable met 81 f A BG5 
55121 MLH1 unstable unmet 39 m A AC 
53430 MLH1 unstable met 81 m C sporadic 
65453 MLH1 unstable unmet 60 f R BG4 
63887 MLH1 unstable met 48 m R BG1 
58560 MLH1 unstable met 81 f A BG5 
56727 MLH1 unstable met 57 f D AC 
55998 MLH1 unstable unmet 27 m T BG1&5 
63850 MLH1 unstable unmet 55 f C BG4&5 
69999 MLH1 unstable met 72 f HF sporadic 
67543 MLH1 unstable met 76 m A sporadic 
50005 MLH1 unstable met 77 f C sporadic 
53460 MLH1 unstable met 88 f A sporadic 
307 MLH1 unstable met 73 m A sporadic 
61282 MLH1 unstable met 74 f S BG5 
9549 MLH1 unstable met 78 f HF sporadic 
63585 MLH1 unstable unmet 59 m S AC 
60661 MLH1 unstable met 94 f S sporadic 
67255 MLH1 unstable met 91 f HF AC 
70511 MLH1 unstable met 74 f A sporadic 
23348 MLH1 unstable met 85 f A sporadic 
52458 MLH1 unstable unmet 36 f D AC 
50263 MLH1 unstable met 79 f A sporadic 
52201 MLH1 unstable met 76 f A sporadic 
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Tumor no. 
Absent MMR 
protein* BAT26 
Promoter 
Methylation** Age  Sex Tumor site*** 
History of 
cancer  
55843 MLH1 unstable met 87 f C sporadic 
54631 MLH1 unstable met 83 m C sporadic 
60404 MLH1 unstable met 69 m A BG5 
61104 MLH1 unstable met 71 f A sporadic 
64041 MLH1 unstable met 69 f A BG5 
65509 MLH1 unstable unmet 52 f C AC 
66221 MLH1 unstable unmet 69 m R AC 
51385 MLH1 unstable unmet 69 m R sporadic 
52187 MLH1 unstable met 83 f T sporadic 
9251 MLH1 unstable met 87 m A sporadic 
2421 MLH1 unstable met 70 f C sporadic 
6534 MLH1 unstable unmet 60 f R BG5 
5941 MLH1 unstable met 88 f T sporadic 
6459 MLH1 unstable met 86 m A sporadic 
655 MLH1 unstable met 84 f A sporadic 
20140 MLH1 unstable met 81 f A sporadic 
12167 MLH1 stable met 49 m S BG1 
13458 MLH1 unstable met 76 f C sporadic 
11628 MLH1 unstable unmet 42 m S AC 
13297 MLH1 unstable met 71 f HF sporadic 
20719 MLH1 stable met 69 f C sporadic 
20079 MLH1 unstable met 76 m A sporadic 
19372 MLH1 unstable met 78 m S sporadic 
17325 MLH1 unstable met 47 f C BG1 
16165 MLH1 unstable unmet 57 m C BG3 
14895 MLH1 unstable met 71 f A sporadic 
14230 MLH1 unstable met 77 f A sporadic 
22857 MLH1 unstable met 73 m A BG4&5 
22643 MLH1 unstable met 68 m A sporadic 
12287 MLH1 unstable unmet 56 m C sporadic 
11656 MLH1 unstable unmet 36 f S BG1 
11779 MLH1 unstable met 94 f C sporadic 
14124 MLH1 unstable met 78 m C AC 
15600 MLH1 unstable met 90 f A sporadic 
17291 MLH1 unstable met 80 m R sporadic 
19604 MLH1 unstable met 52 f X sporadic 
4734 MLH1 unstable met 67 m T sporadic 
22752 MLH1 unstable met 76 m C sporadic 
22666 MLH1 unstable met 84 f C sporadic 
23697 MLH1 stable met 79 f D n.d. 
700 MLH1 unstable met 49 f D AC 
9658 MLH1 unstable met 79 f A sporadic 
22529 MLH1 unstable met 78 f C sporadic 
20758 MLH1 unstable unmet 89 f C n.d. 
6579 MLH1 unstable met 76 f HF sporadic 
9465 MLH1 unstable met 74 m T sporadic 
10570 MLH1 unstable met 81 m A sporadic 
15659 MLH1 unstable met 79 f A sporadic 
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Tumor no. 
Absent MMR 
protein* BAT26 
Promoter 
Methylation** Age  Sex Tumor site*** 
History of 
cancer  
25013 MLH1 unstable met 67 f C sporadic 
6110 MLH1 unstable met 78 f A sporadic 
10335 MLH1 unstable met 75 f A  sporadic 
15581 MLH1 unstable met 64 f S n.d. 
1398 MLH1 unstable met 85 m C sporadic 
5160 MLH1 unstable met 91 m A sporadic 
218 MLH1 unstable met 76 f A sporadic 
2019 MLH1 unstable met 68 f C sporadic 
2503 MLH1 unstable met 80 m HF sporadic 
7366 MLH1 unstable met 72 m HF sporadic 
12306 MLH1 unstable met 86 f C sporadic 
17296 MLH1 unstable met 85 f A sporadic 
17520 MLH1 unstable met 88 f C sporadic 
18573 MLH1 unstable met 76 m T sporadic 
19353 MLH1 unstable met 68 f A sporadic 
21492 MLH1 unstable unmet 82 f C n.d. 
18102 MLH1 unstable unmet 79 m S sporadic 
22391 MLH1 unstable met 62 f S n.d. 
27489 MLH1 unstable unmet 48 m HF BG1 
27300 MLH1 stable met 83 f C sporadic 
34746 MLH1 unstable met 60 m A n.d. 
32757 MLH1 unstable met 93 f C sporadic 
35096 MLH1 unstable met 73 m T sporadic 
37919 MLH1 unstable met 84 f A sporadic 
19698 MLH1 unstable met 88 f C sporadic 
1648 MLH1 unstable met 78 m C sporadic 
11768 MLH1 unstable met 82 m A sporadic 
13452 MLH1 unstable met 67 m C BG5 
13674 MLH1 unstable met 89 f C sporadic 
20938 MLH1 unstable unmet 48 m R AC 
        
64501 PMS2 unstable unmet 79 m D BG2 
53072 PMS2 unstable unmet 57 m A BG4 
61263 PMS2 unstable unmet 73 m A sporadic 
66543 PMS2 unstable unmet 77 f T BG4 
66732 PMS2 unstable unmet 46 m D BG1 
52557 PMS2 stable# unmet 77 m A sporadic 
54882 PMS2 unstable unmet 42 m A BG1 
53989 PMS2 unstable unmet 57 m SF BG4 
61162 PMS2 unstable unmet 82 m C BG4 
65950 PMS2 unstable unmet 43 m R BG1 
59519 PMS2 unstable unmet 78 m SF BG2 
11318 PMS2 Stable# unmet 46 f S BG1 
20498 PMS2 unstable unmet 76 m A sporadic 
16655 PMS2 unstable unmet 66 m A sporadic 
5194 PMS2 unstable unmet 57 m HF BG3 
27499 PMS2 (partial) § § 49 m A BG1&4 
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*Lack of expression as detected by immunohistochemistry 
**Data from the analysis of the MLH1 promoter region -299 to -152 and from 2 regions of the PMS2 
promoter (see Methods and Supplemental Table S1 for details) 
***C cecum; A ascending; HF hepatic flexure; T transversum; SF splenic flexure; D descending colon;  
S sigmoid colon; R rectum 
 AC: revised Amsterdam Criteria, BG: revised Bethesda Guidelines; n.d.=not determined (5 patients 
died; 2 patients: parents unknown; 5 patients: questionnaire not returned) 
# unstable in other markers 
§ DNA extracted from microdissection not suitable for molecular analysis 
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Supplementary Figure 1 
Methylation analysis of MLH1 (a and b) and PMS2 (c and d) gene promoters in colorectal           
cancers (CRCs) (see Methods in Supplemental Table S1) 
 
a) Fluorescence melting peaks for the MLH1-promoter fragment –299 to –152. The melting 
temperature of PCR products obtained from the bisulfite-treated DNA of the CRC cell lines 
GP5D and Co115 are shown as unmethylated and methylated controls, respectively. 
b) Unmethylated (U) and Methylated (M) alleles as detected by Methylation Specific PCR 
(MSP). The presence of both alleles In 2 CRCs is due to contamination with DNA from 
stromal cells. 
c) Fluorescence melting peaks for two overlapping fragments amplified in the PMS2 gene 
promoter. Human genomic DNA treated with SSS1 methyltransferase (New England 
Biolabs) was used as positive control for methylated alleles. 
d) All CRCs tested by MSP showed only PMS2 unmethylated alleles (U).  
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ADDENDUM  
PMS2 cDNA Primers 
  FWD REV 
Product 
size 
MgCl2-
Konz. 
Segment 1 
(S1) ATCGGGTGTTGCATC CAAAATTTGCCTTTTATCTGGA 1048 bp 1,5 
nested 
Segment 1 
(S1n) ATTTGCTCTGGGCAGGTG CAAAATTTGCCTTTTATCTGGA 957 bp 1,5 
Segment 1A 
(S1A) ATTTGCTCTGGGCAGGTG CCATTTTGGCATACTCCTTCTT 478 bp 1,5 
Segment 1B 
(S1B)  
AGGAATTTCAAAGGAATATTAAG
AAGG CAAAATTTGCCTTTTATCTGGA 521 bp 1,5 
confirmation 
fs Ex4 
(fsEx4) 
GGTGCCACTAATATTGATCTAAA
GC GAGGCTTTGCAACTGCTTCT 570 bp 1,5 
Segment 2 
(S2) TGTTACTCCAGATAAAAGGAAA TTCCATACAGTGACTACGGTCAG 1604 bp 1,5 
Segment2A 
(S2A) TGTTACTCCAGATAAAAGGAAA GGAGCTGGCCCGCATACTC 565 bp 1,5 
Segment 2B 
(S2B) ACGGACCCAGTGACCCTAC GAGGTGCTATGAGCCTCTGC 744 bp 3,5 
Segment 2C 
(S2C) 
AAAAGAGATAAGTAAAACGATGT
TTGC TTCCATACAGTGACTACGGTCAG 614 bp 1,5 
 
PCR conditions: 
S1 + fsEx4: S1n + S1A + S1B: S2 + S2A + S2C: S2B:  
94°C - 5 min 94°C - 5 min 94°C - 5 min 94°C - 5 min 
94°C - 1 min 94°C - 1 min 94°C - 1 min 94°C - 1 min 
60°C - 1 min      30x 55°C - 1 min      36x 58°C - 1 min      36x 60°C - 1 min      35x 
68°C - 3 min 68°C - 3 min 68°C - 3 min 68°C - 3 min 
68°C - 10 min 68°C - 10 min 68°C - 10 min 68°C - 10 min 
Hold 4°C Hold 4°C Hold 4°C Hold 4°C  
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SALSA MLPA P008 MSH6 / PMS2 probemix 
Length  (nt) SALSA MLPA probe Gene Chromosomal position 
64-70-76-82* DQ-control fragments   
88-92-96** DD-control fragments   
    
130 0797-L0463 
Control 
probe Chr. 5q31 
136 4249-L3604 TACSTD1 
27 Kb before MSH2 
exon 1 
142 4243-L3598 MSH6 Exon 7 
148 1685-L1265 MLH1 Exon 1 
154 4661-L4043 PMS2 Exon 1 
160 4244-L3599 MSH6 Exon 8 
166 1686-L1266 MLH1 Exon 1 
172 4245-L4021 MSH6 Exon 9 
180 1176-L4022 PMS2 Exon 2 
190 4248-L3603 TACSTD1 
15 Kb before MSH2 
exon 1 
196 4246-L3601 MSH6 Exon 10 
202 1245-L0793 MLH3 Exon 3 
211 4676-L3352 MUTYH Exon 14 
220 2107-L0794 MLH3 Exon 10 
229 1179-L0740 PMS2 Exon 5 
238 1247-L0795 MSH3 Exon 1 
247 1180-L0741 PMS2 Exon 6 
256 1248-L0899 MSH3 Exon 8 
265 1181-L0742 PMS2 Exon 7 
274 1249-L0797 MSH3 Exon 20 
283 1182-L0743 PMS2 Exon 8 
292 4677-L3353 MUTYH Exon 16 
301 1183-L0744 PMS2 Exon 9 
310 4322-L4024 MUTYH Exon 1 
319 1184-L0745 PMS2 Exon 10 
328 1250-L0798 MSH6 Exon 1 
337 1185-L0900 PMS2 Exon 11 
346 4247-L3602 MSH6 Exon 2 
355 2735-L2162 MSH2 Exon 1 
364 1252-L0902 MSH6 Exon 4 
373 4663-L6248 PMS2 Exon 13 
382 1253-L0801 MSH6 Exon 6 
391 1188-L0749 PMS2 Exon 14 
401 4323-L1368 MUTYH Exon 2 
409 4664-L4046 PMS2 Exon 15 
418 3964-L3351 MUTYH Exon 3 
427 1439-L0908 MSH6 Exon 3 
436 4662-L4044 PMS2 Exon 12 
445 1440-L0909 MSH6 Exon 5 
454 1810-L0984 APC Exon 7 
463 4675-L0792 MLH3 Exon 2 
* Not ligation-dependent, this indicates the amount of DNA used. 
** Ligation-dependent, these fragments give a warning for incomplete DNA denaturation. 
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MSH3 study 
PCR conditions for MSH3 analysis 
cDNA 
Product 
size 
MgCl2
-Conc. 
(mM) 
Tm 
(°C) 
Q-
Solution FWD-Primer 5'-3' REV-Primer 5'-3' 
S1 953 bp 1,5 60 + CTTGCCCTGCCATGTCTC TGCTGCAGTTTCAGTTTGCT 
S1/S2 347 bp 1,5 60 - CAGCAGCACAAAGATGCAGT TCAACATTTACAGCATCATCCA 
S2 999 bp 1,5 60 - 
CAGACTGTTTGTTCATGTACG
C TCTATGTCGGGCAATTTACG 
S3 910 bp 1,5 60 + CTTCATTTGGGAGACGGAAG CCCAGCAACACATCAATCAC 
S3/S4 271 bp 1,5 60 - GTCCTTGACTGCAGTGCTGA TCTCTGAGTCCTCTGATAAATCTGT 
S4 956 bp 1,5 60 + CAAGGTCGCTAAGCAAGGAG TGTACAGTTGGTATTTTTAATTCTCCA 
genomic DNA       
Ex 18 241 bp 1,5 60 - GTGATGGCATTTCGGATTTT TTTTTCCAGTCTGTTTCTGATAGC 
tumor DNA DNA       
Ex 18 193 bp 1,5 55 - GTGATGGCATTTCGGATTTT TTGTAAACTCACTCTAGAAAATCAAGC 
 
95°C - 3 min  
93°C - 30 sec  
55°/60°C - 45 sec      35 Zyklen 
72°C - 45 sec  
72°C - 5 min  
Hold 4°C  
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